<SEC-DOCUMENT>0001129928-20-000062.txt : 20201112
<SEC-HEADER>0001129928-20-000062.hdr.sgml : 20201112
<ACCEPTANCE-DATETIME>20201112061509
ACCESSION NUMBER:		0001129928-20-000062
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201112
DATE AS OF CHANGE:		20201112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		201303068

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>q32020form6-k.htm
<DESCRIPTION>2020 THIRD QUARTER 6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i59c158b535f2401daa84450520f4cbc1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form 6-K</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Foreign Private Issuer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Rule&#160;13a-16 or 15d-16</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the month of&#160;November 2020 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number 001-38512</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite&#160;210, 1167 Kensington Crescent NW</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Calgary, Alberta, Canada T2N 1X7</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;20-F&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#254;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;40-F&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1)&#58;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7)&#58;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div id="i59c158b535f2401daa84450520f4cbc1_4"></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">INCORPORATION BY REFERENCE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant&#8217;s Management&#8217;s Discussion and Analysis of Operations and Financial Condition for the Three and Six Months Ended September&#160;30, 2020, included as Exhibit&#160;99.2 of this Form&#160;6-K and the Interim Financial Statements as of and for the Three and Nine Months Ended September&#160;30, 2020, included as Exhibit&#160;99.1 of this Form&#160;6-K (Commission File No.&#160;001-38512), furnished to the Commission on&#160;November 12, 2020, are incorporated by reference into the Registrant&#8217;s Registration Statement on Form&#160;F-10 (Commission File No. 333-239025).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:16.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT<br>NUMBER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION</font></td></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex991-interimfsseptemb.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Oncolytics Biotech&#174; Inc. September 30, 2020 Interim Financial Statements</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex992-q32020mda.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Oncolytics Biotech&#174; Inc. September 30, 2020 Management Discussion &#38; Analysis</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex993-q32020certificat.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certification of September 30, 2020 interim filings - CEO</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex994-q32020certificat.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certification of September 30, 2020 interim filings - CFO</a></font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncolytics Biotech Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 12, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Kirk Look</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-interimfsseptemb.htm
<DESCRIPTION>2020 THIRD QUARTER INTERIM FINANCIAL STATEMENTS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i4b8850f753c3453c86a2c83d5341afff_4"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interim Consolidated Financial Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">September&#160;30, 2020 and 2019</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i4b8850f753c3453c86a2c83d5341afff_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:402.00pt"><tr><td style="width:1.0pt"></td><td style="width:226.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at </font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,710,802</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,148,021&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,475</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068,772&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,735,622</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,713,591&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,516,899</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,930,384&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">260,591</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,768&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">464,117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,713&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">724,708</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,481&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,241,607</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,657,865&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities And Shareholders&#8217; Equity (Deficit)</font></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,278,508</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173,218&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">412,373</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847,215&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">332,411</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,846&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333,224</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,508,764&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,356,516</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,869,043&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184,108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,429&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current liabilities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,914,395</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,896,716&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,270,911</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,765,759&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity (deficit)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:45pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Authorized&#58; unlimited</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Issued&#58; September 30, 2020 &#8211; 42,334,269 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;December 31, 2019 &#8211; 32,198,453</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344,816,470</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,077,859&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617,570</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,774,656</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,338,849&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">544,658</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,101&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(357,782,658)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344,606,273)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total shareholders&#8217; equity (deficit)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,970,696</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,894)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total liabilities and shareholder's equity (deficit)</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,241,607</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,657,865&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i4b8850f753c3453c86a2c83d5341afff_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:183.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:63pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2019<br>$</font></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6, 13, 14, 16</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,854,272</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659,744&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,883,046</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,121,554&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Operating</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6, 13, 14</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,461,642</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834,021&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,503,602</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,426,093&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Loss before the following</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,315,914)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,493,765)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,386,648)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,547,647)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Change in fair value of warrant derivative</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,264</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,498)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,705,096</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,498)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (loss) gain</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13, 16</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(506,349)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,618&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393,358</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,440)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest income, net</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,367</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,001&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111,809</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,339&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Loss before income taxes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,748,632)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,528,644)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,176,385)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,721,246)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,748,632)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,528,644)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,176,385)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,721,246)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other comprehensive (loss) income items that may be reclassified to net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Translation adjustment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(68,212)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,557</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,649)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Net comprehensive loss</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,816,844)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,490,338)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,095,828)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,807,895)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Basic and diluted loss per common share</font></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.34)</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.67)</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted)</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,720,230</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,642,016&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,072,900</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,431,792&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i4b8850f753c3453c86a2c83d5341afff_22"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:666.00pt"><tr><td style="width:1.0pt"></td><td style="width:193.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share Capital<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contributed Surplus<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,193,061&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,260,613&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,504&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311,483,385)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,195,363&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,649)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,721,246)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,807,895)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,437&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,437)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562,608&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562,608&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; Agreement</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,034,933&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,034,933&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,429&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,429&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based compensation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811,491&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811,491&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659,776)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659,776)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at September 30, 2019</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,555,692&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,961,667&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,855&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325,204,631)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451,153&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,077,859&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,338,849&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,101&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344,606,273)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,894)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,557&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,176,385)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,095,828)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,812&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,024)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,788&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,690&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358,690)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; Agreement</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,147,501&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,147,501&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4, 5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332,778&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332,778&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based compensation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,521&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,521&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263,170)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263,170)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at September 30, 2020</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344,816,470</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617,570</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,774,656</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">544,658</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(357,782,658)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,970,696</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i4b8850f753c3453c86a2c83d5341afff_25"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:63pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss for the period</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,748,632)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,528,644)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,176,385)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,721,246)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,891</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,483&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,520</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,190&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use-assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87,878</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,522&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271,034</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,201&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based compensation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6, 13, 14</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">201,076</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,384&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">854,521</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811,491&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,970</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,822&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,064</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,399&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss (gain)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360,258</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,865)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(368,419)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,425&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60,264)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,498&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,705,096)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,498&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-cash working capital</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,293)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491,146)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(331,243)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412,173)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in operating activities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,123,116)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,516,946)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,337,004)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,651,215)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,556)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29,305)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,660)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in investing activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,556)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29,305)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,660)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,788</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrant derivative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,696,460</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from Common Stock Purchase Agreement</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529,672&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from &#34;At the Market&#34; equity distribution agreement</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,597,300</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,015&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,884,331</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,874,377&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,505,359&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,505,359&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(114,838)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,070)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(347,946)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,872)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by financing activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,482,462</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,448,304&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,335,633</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,574,536&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Decrease) increase in cash</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,656,210)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,642)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,969,324</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086,339)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,911,351</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,275,766&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,148,021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,699,881&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(544,339)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,554&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">593,457</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314,864)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,710,802</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,298,678&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,710,802</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,298,678&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i4b8850f753c3453c86a2c83d5341afff_31"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div id="i4b8850f753c3453c86a2c83d5341afff_34"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 1&#58; Incorporation and Nature of Operations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interim consolidated financial statements for the period ended September&#160;30, 2020, were authorized for issue in accordance with a resolution of the Board of Directors (the &#34;Board&#34;) on November&#160;3, 2020. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep emphasizes three programs&#58; chemotherapy combinations to assist the escape of the virus from the vasculature and enhance its distribution in the tumor&#59; immuno-therapy combinations to create an inflamed phenotype promoting synergies with immune checkpoint inhibitors&#59; and immune modulator&#47;targeted combinations to upregulate natural killer cells promoting synergies with targeted therapies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2020, the global outbreak of COVID-19 caused significant fluctuations in stock markets and global economic activity. The scale and duration of these developments remain uncertain and could affect our ability to finance our operations.</font></div><div style="text-align:justify"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_37"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 2&#58; Basis of Financial Statement Presentation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries as at September&#160;30, 2020 and are presented in Canadian dollars, our functional currency.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts are prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) issued by the International Accounting Standards Board (&#34;IASB&#34;). The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim consolidated financial statements have been prepared in compliance with International Accounting Standard 34 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes presented in these interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements.  Accordingly, these interim consolidated financial statements should be read in conjunction with our most recent annual audited consolidated financial statements, for the year ended December&#160;31, 2019. We have consistently applied the same accounting policies for all periods presented in these interim consolidated financial statements as those used in our audited consolidated financial statements for the year ended December&#160;31, 2019.</font></div><div style="text-align:justify"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_43"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 3&#58; Cash Equivalents </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of interest bearing deposits with our bank totaling $25,044,807 (December&#160;31, 2019 &#8211; $13,058,092).&#160;&#160;The current annual interest rate earned on these deposits is 0.50%  (December&#160;31, 2019 &#8211; 1.17%).</font></div><div style="text-align:justify"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_46"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 4&#58; Warrant Derivative</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share and one common share purchase warrant (see Note 5). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IAS 32 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#58; Presentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of US$0.90 meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in fair value of the warrant derivative is as follows&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:391.50pt"><tr><td style="width:1.0pt"></td><td style="width:199.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued, August 16, 2019</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619,773&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657,214&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,935,647)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,687,003)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,608,808&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,255)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684,126&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,508,764&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418,369)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,636,317)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,705,096)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,873&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at September 30, 2020</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">265,757</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333,224</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine month period ending September&#160;30, 2020, we received cash proceeds of US$1,276,532 with respect to warrants exercised.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative was determined using the following assumptions&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:341.25pt"><tr><td style="width:1.0pt"></td><td style="width:202.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$0.94</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$3.89</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$1.69</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$4.76</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i4b8850f753c3453c86a2c83d5341afff_49"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 5&#58; Share Capital</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:504.75pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,399,749&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,193,061&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,301&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,917&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494,943&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403,385&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; (ATM) equity distribution agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,425,040&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476,454&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619,773&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,429&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935,647&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,152,869&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854,256)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,198,453&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,077,859&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,812&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,931&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,690&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; (ATM) equity distribution agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,549,396&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,147,501&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418,369&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332,778&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263,170)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, September 30, 2020</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42,334,269</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344,816,470</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the &#34;Agreement&#34;) with Lincoln Park Capital Fund, LLC (&#34;LPC&#34;). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US$1.00 per common share&#59; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the five immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to 19.99% of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. We reached that limit in the fourth quarter of 2019, and have not sought shareholder approval to increase the limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period ending September&#160;30, 2020, we sold nil (September&#160;30, 2019 - 1,379,024) common shares for gross proceeds of nil (September&#160;30, 2019 - US$2,663,768) and issued nil commitment shares (September&#160;30, 2019 - 11,348). The commitment shares have been valued at fair value of nil (September&#160;30, 2019 - US$21,998) and have been recorded as share issue costs in addition to cash share issue costs of nil (September&#160;30, 2019 - $3,757). </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability. Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. During the period ending September&#160;30, 2020, our share capital included fair value of $4,636,317 (September&#160;30, 2019 - nil) in addition to gross proceeds of </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US$1,276,532 (September&#160;30, 2019 - nil) for the 1,418,369 (September&#160;30, 2019 - nil) warrants that were exercised (see Note 4).  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. During the period ending September&#160;30, 2020, we sold 6,741,518 common shares (September&#160;30, 2019 - 1,572,745) for gross proceeds of US$17,538,342 (September&#160;30, 2019 - US$3,030,892). We incurred share issue costs of $856,754 (September&#160;30, 2019 - $160,556). This sales agreement expired on June 4, 2020.  </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value up of up to US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the period ending September&#160;30, 2020, we sold 1,807,878 common shares (September&#160;30, 2019 - nil) for gross proceeds of US$3,479,212 (September&#160;30, 2019 - nil). We incurred share issue costs of $406,416 (September&#160;30, 2019 - nil). </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant. Following the 2018 share consolidation, 9.5 common share purchase warrants entitled the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. These warrants were classified as equity. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:391.50pt"><tr><td style="width:1.0pt"></td><td style="width:199.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant <br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at September 30, 2020</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">                               (1) Exercisable into 1,730,894 common shares.</font></div><div><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_55"></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 6&#58; Share Based Payments</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Option Plan</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at September&#160;30&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:492.00pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:76.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br>$</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,246,947</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.31</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249,361&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.40</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(131,418)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.54</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,787)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.64</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised during the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45,120)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.28</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,275,409</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.30</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259,574&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.58</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 4.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable, end of the period</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,366,248</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.21</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,129&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at September&#160;30, 2020&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:135.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:51pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.42</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,667&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.43 - $1.79</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786,667&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,675&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.80 - $3.39</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,887&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.59</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,888&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.71</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.40 - $7.13</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451,849&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,787&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.14 - $63.84</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,006&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.47</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,231&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.82</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275,409&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.39</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.30</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366,248&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.21</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-exercisable options vest annually over periods ranging from one to three years.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the period was determined using the Black-Scholes valuation model using the following weighted average assumptions&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:336.75pt"><tr><td style="width:1.0pt"></td><td style="width:202.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.66%</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.52%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.58%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.02%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected forfeiture rate</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.67%</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$2.27</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.04</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incentive Share Award Plan</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Units</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued restricted share units (&#34;RSUs&#34;) to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three year period. The following RSUs are outstanding at September&#160;30&#58;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"><tr><td style="width:1.0%"></td><td style="width:62.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the period</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,657</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,755&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43,501</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,963&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released during the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(118,721)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,176)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the period</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,437</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,542&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">                                (1) The weighted average fair value of the RSUs granted was $2.73 in 2020 (2019 - $1.42).</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Share Units</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also issued performance share units (&#34;PSUs&#34;) to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after 3 years or vest over a three year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at September&#160;30&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:383.25pt"><tr><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the period</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,051</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,156&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released during the period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,210)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,105)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the period</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,841</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,051&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reserved 4,048,468 common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs was $201,076 and $854,521 for the three and nine month periods ending September&#160;30, 2020, respectively (September&#160;30, 2019 - $250,384 and $811,491, respectively).  </font></div><div style="text-align:justify"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_61"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 7&#58; Loss Per Common Share</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated using net loss for the period and the weighted average number of common shares outstanding for the three and nine month periods ended September&#160;30, 2020 of 41,720,230 and 39,072,900, respectively (September&#160;30, 2019 - 22,642,016 and 20,431,792, respectively). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="text-align:justify"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_67"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 8&#58; Contract Liability</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regional licensing agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the &#34;Licensing Agreement&#34;) with Adlai Nortye Biopharma Co., Ltd. (&#34;Adlai&#34;) in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant purchase agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also entered into a warrant purchase agreement with Adlai. As at September&#160;30, 2020, we were entitled to the following&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One common share purchase warrant of US$6 million whereby, upon exercise, Adlai may purchase our common shares priced at a 20% premium to the five-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the 50th patient in the phase 3 metastatic breast cancer study. This common share purchase warrant expires on November 14, 2020. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract liability</font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance, which w</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:333.00pt"><tr><td style="width:1.0pt"></td><td style="width:175.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:78.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the period</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regional licensing agreement</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_73"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 9&#58; Commitments</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments totaling $10,181,986 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include one-half of the committed payments related to our collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc (&#34;Pfizer&#34;), known as BRACELET-1, as the cost of this phase 2 clinical trial will be shared equally between Oncolytics and Pfizer. As at September&#160;30, 2020, we recorded nil (December&#160;31, 2019 - US$1,500,000) in other receivables related to an upfront payment of BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and US$309,148 (December&#160;31, 2019 - US$652,306) in other liabilities representing future trial costs to be incurred.    </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product.&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of&#58; (a) 5% of gross sales of a specified product&#59; or (b) $100,000 per annum once sales of a specified product commence.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with initial lease terms generally between 3 to 5 years. We currently do not have leases with variable lease payments, residual value guarantees, or leases not yet commenced to which we are committed. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, we entered into a lease for our Barbados office space. We recognized a $297,737 right-of-use asset and a lease liability of the same amount. The incremental borrowing rate applied to the lease liability was 15%.    </font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:11.842%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at September&#160;30, 2020 is as follows&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.947%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity analysis - contractual undiscounted cash flows</font></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,311&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,470&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability as at September&#160;30, 2020</font></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593,781&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_76"></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 10&#58; Capital Disclosures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&#160;We include shareholders&#8217; equity (deficit) and cash and cash equivalents in the definition of capital.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:70.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,710,802</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,148,021&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity (deficit)</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,970,696</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,894)</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any debt other than trade accounts payable and lease liabilities, and we have potential contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 12, 2020, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf  provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreement in June 2020 (see Note 5). We will use this equity arrangement to assist us in achieving our capital objective. This arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2020.</font></div><div style="text-align:justify"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_79"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 11&#58; Financial Instruments</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, other liabilities, accounts payable and warrant derivative.&#160;As at September&#160;30, 2020, the carrying amount of our cash and cash equivalents,&#160;other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these warrants have not been listed on an exchange and therefore do not trade on an active market. As at September&#160;30, 2020, the fair value of our warrant derivative was $333,224 (December&#160;31, 2019 - $8,508,764). &#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, British pound and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2020 by approximately $153,000.&#160;The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $27,500. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $3,000.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balances in foreign currencies at September&#160;30, 2020 are as follows&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:457.50pt"><tr><td style="width:1.0pt"></td><td style="width:156.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US dollars <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">British pounds<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro<br>&#8364;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,551,370</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,766</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,795</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,346)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,295)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,812)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,851,212</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,529)</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,795</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 10. Accounts payable are all due within the current operating period.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="i4b8850f753c3453c86a2c83d5341afff_82"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 12&#58; Additional Cash Flow Disclosures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.75pt"><tr><td style="width:1.0pt"></td><td style="width:274.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:74pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14,290)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413,908)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,998,297</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406,536)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">375,085</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657,069)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,022,031)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,980,288)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(408,710)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368,715)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(894,710)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899,616&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(58,134)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(434,842)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,338)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,756</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,454)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,043</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,373&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,293)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491,146)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(331,243)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412,173)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:494.25pt"><tr><td style="width:1.0pt"></td><td style="width:255.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:74pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,337</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,823&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">162,873</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,738&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,836</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,047</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,461&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="i4b8850f753c3453c86a2c83d5341afff_88"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</font></div></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 13&#58;  Other Expenses and Adjustments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details highlight certain components of the research and development and operating expenses classified by nature. The foreign exchange (loss) gain as presented separately on the face of the consolidated statement of loss and comprehensive loss is also classified as a research and development expense. Remaining research and development and operating expenses include personnel costs and expenses paid to third parties.   </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:219.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,863</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,401&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">225,772</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,891</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,483&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,520</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,190&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use-assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87,878</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,522&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271,034</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,201&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172,213</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,983&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">628,749</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,491&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs, warrant derivative</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,143&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,143&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_94"></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 14&#58;  Related Party Transactions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Key Management Personnel</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain employees of the Company.    </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:483.00pt"><tr><td style="width:1.0pt"></td><td style="width:202.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Month Period Ending September 30, 2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Month Period Ending September 30, 2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">667,730</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615,207&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,240,429</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993,227&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">278,160</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">495,175</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based payments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115,593</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,055&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">559,347</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,856&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061,483</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835,262&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,294,951</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717,083&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_100"></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 15&#58;  Subsequent Events</font></div><div><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between October 1, 2020 and October 30, 2020, we issued 835,556 common shares for gross proceeds of US$1,837,353 through our June 2020 ATM equity distribution agreement. </font></div><div style="text-align:justify"><font><br></font></div><div id="i4b8850f753c3453c86a2c83d5341afff_103"></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 16&#58;  Comparative Figures</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification was made to prior period's figure to conform to the current period's presentation. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992-q32020mda.htm
<DESCRIPTION>2020 THIRD QUARTER MD&A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib6dd1406b5774958a5a4a4a34be8305e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img alt="oncolyticslogotaglinebluea.jpg" src="oncolyticslogotaglinebluea.jpg" style="height:297px;width:682px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT DISCUSSION &#38; ANALYSIS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">September&#160;30, 2020 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">November&#160;3, 2020 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with the unaudited interim consolidated financial statements of Oncolytics Biotech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inc. as at and for the nine months ended September&#160;30, 2020 and 2019, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&#38;A&#8221;) contained in our annual report for the year ended December&#160;31, 2019. The financial statements have been prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;). </font></div><div style="text-align:justify"><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_7"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and under applicable Canadian provincial securities legislation. Forward-looking statements, including&#58; our belief as to the potential of pelareorep, an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic&#59; our expectation that we will not generate significant revenues until and unless pelareorep becomes commercially viable&#59; our business strategy, goals and objectives for the development of pelareorep&#59; our plan to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep supply&#59; our plans respecting regulatory approval for pelareorep&#59; our planned clinical development program, including the timing thereof&#59; our expectations regarding enrollment under our various clinical trials and the intended and anticipated results, benefits and opportunities therefrom&#59; our planned 2020 development activity for pelareorep, our 2020 manufacturing program&#59; our anticipated 2020 expenses relating to clinical trials, manufacturing, intellectual property, research collaborations and other research and development and operating expenses&#59; our plans respecting the maintenance of adequate cash reserves to support our planned activities&#59; our plans for funding our capital expenditure requirements&#59; our approach to foreign exchange risk mitigation&#59; and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements. We may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the forward-looking statements made within this MD&#38;A, we have made numerous assumptions regarding among other things&#58; our ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and&#47;or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake to update these forward-looking statements except as required by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pelareorep Development Update For 2020</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncolytics Biotech Inc. is a Development Stage Company</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company. We have focused our research and development efforts on the development of pelareorep, an intravenously delivered immuno-oncolytic virus (IOV) with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal each year is to advance pelareorep through the various steps and stages of development required for potential pharmaceutical products.  In order to achieve this goal, we proactively manage all aspects of the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supply, and our intellectual property.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Potential Impact of COVID-19</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2020, there was a global outbreak of a novel coronavirus identified as the SARS-coronavirus-2 (SARS-CoV-2) leading to the associated coronavirus infectious disease 2019 (COVID-19).&#160;In order to combat the spread of COVID-19, governments worldwide have enacted emergency measures including travel bans, legally enforced or self-imposed quarantine periods, social distancing and business and organization closures.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have developed a robust business continuity plan to ensure the safety of patients, employees, and investigators, as well as the productivity of our clinical programs. We expect that the continued execution of this plan will allow us to build on the positive momentum of the past two quarters, despite any COVID-19-related challenges that may arise. Moving forward, we plan to remain in contact with relevant stakeholders and keep the market apprised of any new information that may impact clinical timelines.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of COVID-19 has also caused significant fluctuations in stock markets and global economic activity. The scale and duration of these developments remain uncertain and could affect our ability to finance our operations.</font></div><div style="text-align:justify"><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_13"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ultimate objective of our clinical development plan is to obtain regulatory approval for pelareorep as quickly as possible and is based on the compelling efficacy data from previous studies in breast, multiple myeloma, and selected gastrointestinal cancers. Our clinical development program centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and&#47;or targeted therapies. Our focus is to deliver a demonstration of enhanced antitumor efficacy with high profile checkpoint inhibitors as we believe this is the most immediately impactful clinical data and the most expeditious path to approval.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%">Third Quarter 2020 Developments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Clinical studies aiding registration program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Pfizer Inc. and Merck KGaA, Darmstadt, Germany&#58; BRACELET-1 study </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into an agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody, for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative (HR+ &#47; HER2-) metastatic breast cancer (mBC). The cost of this phase 2 clinical trial will be shared equally between Oncolytics and Pfizer. The study, known as BRACELET-1 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">east c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r with the Oncolytic Reovirus Pe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">areor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">p in Combina</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion with anti-PD-L1&#160;and Paclitaxel), is an open-label study planned to enroll 48 patients into three cohorts&#58; paclitaxel alone, paclitaxel in combination with pelareorep, and paclitaxel in combination with both pelareorep and avelumab (Bavencio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). PrECOG LLC, a leading cancer research network, is managing the BRACELET-1 study.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study will examine the expression of immune-related biomarkers to identify changes in T cell population between pre-treatment and on-therapy biopsies and seek to confirm our previously identified biomarker and is designed to assess efficacy in terms of overall response rate at week 16 per RECIST 1.1 and iRECIST. The safety of the combination will also be </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluated.&#160;Similar to the AWARE-1 study (see below), the results of this study may provide an opportunity to add an arm to our proposed phase 3 study that includes a checkpoint inhibitor in addition to the chemotherapy-virus combination. Furthermore, the results of the BRACELET-1 study may provide important confirmatory data in the same patient population where we presented compelling mBC survival data at the 2017 AACR Annual Meeting. These endpoints, including the biomarker data, are expected to further de-risk our planned phase 3 registration study, permitting for a smaller study with a higher likelihood of clinical success. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first patient was dosed in the second quarter of 2020. In the third quarter of 2020, we continued patient enrollment and treatment and study initiating activities including selecting and readying additional clinical trial sites. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with SOLTI&#58; AWARE-1 study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received approval for our AWARE-1 study, which was announced in September 2018, from the Spanish Agency for Medicine and Health Products. This clinical collaboration with SOLTI, an academic research group dedicated to breast cancer research, is a window of opportunity study in the neoadjuvant setting for breast cancer using pelareorep in combination with F. Hoffmann-La Roche (Roche)'s anti-PD-L1 checkpoint inhibitor, atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), which we are utilizing under our Master Clinical Supply Agreement with Roche. In 2019, we announced preliminary trial data demonstrating viral replication and promotion of inflammation following systemic administration of pelareorep when combined with Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2020, we published an electronic-poster with clinical data demonstrating that pelareorep induced an adaptive immune response in the tumor microenvironment (TME) and highlighted the potential of a predictive biomarker (T cell clonality) to identify patients with breast cancer most likely to respond to pelareorep.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study plans to enroll 38 patients. Data generated from this study is intended to confirm that the virus is acting as a novel immunotherapy in breast cancer and to confirm biomarker data for breast cancer. The primary objective of this study is to supplement the existing randomized phase 2 results by providing key biomarker data points to enhance our probability of success in the phase 3 registration study. The results of this study may also provide an opportunity to add an arm to our proposed phase 3 study that includes a checkpoint inhibitor in addition to the chemotherapy-virus combination. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020, we continued patient enrollment and treatment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Additional checkpoint inhibitor combinations </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Triple-negative breast cancer study combining pelareorep and retifanlimab </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, we dosed the first patient in our investigator-sponsored trial (IST) managed by Rutgers Cancer Institute of New Jersey. The phase 2 trial, known as IRENE (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NCMGA00012 and the oncolytic virus pela</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep in metastatic triple-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gative breast cancer), will investigate the use of pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). This single-arm, open-label, phase 2 study plans to enroll 25 patients and will be conducted at the Rutgers Cancer Institute of New Jersey and the Ohio State University Comprehensive Cancer Center. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRENE study represents an expansion of our lead breast cancer program into a new disease subtype (TNBC). In addition to investigating the safety and efficacy of pelareorep-anti-PD-1 combination treatment in TNBC patients, the study will also evaluate changes in PD-L1 expression and correlations between treatment outcomes and peripheral T cell clonality, a previously identified biomarker of pelareorep response that may enable the success of future pivotal studies by facilitating the patient selection process. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pancreatic cancer study combining pelareorep and Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, we continued patient treatment in our IST supported by Merck Inc. (Merck), Northwestern University and Oncolytics. This study, an extension of our phase 1 study (REO 024), will investigate pelareorep in combination with Merck&#8217;s anti-PD1 checkpoint inhibitor Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to treat second-line pancreatic cancer patients. The study plans to enroll approximately 40 patients. Preliminary data indicate that the combination of pelareorep and pembrolizumab resulted in tumor-specific replication, a high degree of T cell repertoire turnover, and the creation of new T cell clones in the peripheral blood during treatment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple myeloma study combining pelareorep and Opdivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, we continued patient enrollment in the safety cohort of our IST with Emory University and the University of Utah investigating the combination of pelareorep and Bristol-Myers Squibb's anti-PD1 checkpoint inhibitor Opdivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 40 - 50 relapsed or refractory myeloma patients. The safety cohort will investigate the combination of a proteasome inhibitor with the checkpoint inhibitor prior to the addition of pelareorep. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Post Q3 2020 Developments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we entered into a collaboration with Roche and AIO-Studien-gGmbH, a leading academic cooperative medical oncology group based in Germany. The phase 1&#47;2 trial, known as GOBLET (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">astrointestinal tum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rs exploring the treatment com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inations with the oncolytic reovirus pe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep and an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i-PD-L1), will investigate the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers. The study will be conducted at 25 centers in Germany. The primary endpoint of the study is safety, with overall response rate and blood-based biomarkers (T cell clonality and CEACAM6) as exploratory endpoints. Approximately 55 patients are planned for enrollment across four separate cohorts&#58; pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line metastatic pancreatic cancer patients, pelareorep in combination with atezolizumab in 2nd and 3rd line metastatic colorectal cancer patients that are diagnosed as MSI high (microsatellite instability), pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients, and pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients. </font></div><div><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_16"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Manufacturing and Process Development </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the third quarter of 2020, we completed a current good manufacturing practices (cGMP) production run and the associated release testing, continued distribution activities with the product supply and initiated activities for a product fill. As well, we continued our activities to maintain clinical and commercial production capabilities to manufacture pelareorep at the 100-liter scale. Ongoing bulk manufacture and expanded filling capabilities are both part of the process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of our submission to regulators, including the FDA, for product approval.</font></div><div style="text-align:justify"><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_19"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the third quarter of 2020, we had been issued over 394 patents including 49 US and 18 Canadian patents as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028. Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><div style="text-align:justify"><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_22"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financing Activity</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three month period ending September&#160;30, 2020, we sold 1,493,769 common shares for gross proceeds of US$2,829,208. We incurred share issue costs of $191,051. </font></div><div style="text-align:justify"><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_25"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financial Impact</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We estimated at the beginning of the third quarter of 2020 that our cash requirements to fund our operations for the year will be between $23 - $25 million. Our actual cash usage for the nine month period ending September&#160;30, 2020 was $16,337,004 for operating activities, $29,305 for the acquisition of property and equipment and $347,946 for the payment of office leases. Our net loss for the period was $13,176,385, which included a non-cash change in fair value of warrant derivative gain of $3,705,096 and a foreign exchange gain of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$393,358</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> primarily due to unrealized translation gain on U.S. dollar denominated cash balances.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_28"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Cash Resources </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ended the third quarter of 2020 with cash and cash equivalents totaling $26,710,802 (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_31"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Subsequent Events</font></div><div><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between October 1, 2020 and October 30, 2020, we issued 835,556 common shares for gross proceeds of US$1,837,353 through our June 2020 ATM equity distribution agreement. </font></div><div style="margin-bottom:3pt;text-align:justify"><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_34"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pelareorep Development for the Remainder of 2020</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our planned 2020 development activity for pelareorep focuses on our clinical development plan along with our manufacturing and intellectual property programs. Our 2020 clinical objective is to incorporate our immuno-oncology combination strategy that includes checkpoint inhibitors, prove the usefulness of biomarkers across various indications, and combine with other anti-cancer agents as we develop our registration strategy and clinical protocol in preparation for a phase 3 clinical study in mBC. While we are making every effort to maintain the timing of our future milestones, the full impact of the COVID-19 pandemic on these milestones is not known. Patient safety is our foremost concern and we will provide updates as they become known. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 manufacturing program includes completing production of 100-liter cGMP batches along with the related analytical testing and product filling, as well as labeling, packaging and shipping of pelareorep to our various clinical sites for ongoing and upcoming activities. These activities are consistent with our process validation master plan. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently estimate the cash requirements to fund our operations for 2020 will be approximately $23 - $25 million but will depend on our ultimate clinical program.  (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_37"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Third Quarter Results of Operations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(for the three months ended September&#160;30, 2020 and 2019)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three month period ended September&#160;30, 2020 was $6,748,632 compared to $3,528,644 for the three month period ended September&#160;30, 2019. Net loss for the three month period ended September&#160;30, 2020 included a non-cash change in fair value of warrant derivative gain of $60,264 (September&#160;30, 2019 - loss of $122,498) and a foreign exchange loss of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$506,349</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (September&#160;30, 2019 - gain of $41,618).  </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:408.00pt"><tr><td style="width:1.0pt"></td><td style="width:286.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">768,230</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,134&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,602,554</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,476&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212,132</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,507&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaboration expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,466</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,742&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,201,027</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674,484&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based payments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,863</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,401&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,854,272</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659,744&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:68.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">768,230</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,134&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial expenses for the third quarter of 2020 were $768,230 compared to $337,134 for the third quarter of 2019. In the third quarters of 2020 and 2019, our clinical trial program activities related primarily to the preparation and development of our breast cancer registration study. In the third quarter of 2020, these costs included continued patient enrollment and treatment as well as data analysis for our AWARE-1 study and our portion (net of Pfizer's contribution) of trial initiation activities and patient enrollment and treatment related to our BRACELET-1 study. In the third quarter of 2019, these costs included patient enrollment and treatment for our AWARE-1 study and study initiation activities for our BRACELET-1 study. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020, in addition to activities related to our breast cancer program, we also incurred costs related to data management consultants and our IRENE study. In the third quarter of 2019, our other clinical activities included close out costs related to our fully enrolled legacy clinical trials and costs related to patient enrollment and&#47;or treatment in our checkpoint inhibitor pancreatic cancer study investigating Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with pelareorep.  </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &#38; Related Process Development Expenses (&#8220;M&#38;P&#8221;)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:68.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product manufacturing expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,566,257</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,489&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36,297</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,987&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,602,554</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,476&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our M&#38;P expenses for the third quarter of 2020 were $1,602,554 compared to $361,476 for the third quarter of 2019. During the third quarter of 2020, our product manufacturing costs primarily related to the completion of a cGMP production run and the associated testing, as well as shipping and storage costs of our bulk and vialed product. During the third quarter of 2019, our product manufacturing costs primarily related to shipping and storage costs of our bulk and vialed product and production run testing. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our process development expenses for the third quarter of 2020 focused on stability studies and analytical development, and for the third quarter of 2019 focused on analytical development. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212,132</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,507&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property expenses for the third quarter of 2020 were $212,132 compared to $153,507 for the third quarter of 2019. The change in intellectual property expenditures reflects the timing of filing costs associated with our patent base. At the end of the third quarter of 2020, we had been issued over 394 patents including 49 US and 18 Canadian patents, as well as issuances in other jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaboration Expenses </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaboration expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,466</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,742&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaboration expenses were $41,466 for the third quarter of 2020 compared to $31,742 for the third quarter of 2019. Our research collaborations in the third quarters of 2020 and 2019 included studies investigating the interaction of the immune system and pelareorep. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Research and Development Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D personnel related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,188,460</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,671&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,567</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,813&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Research and Development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,201,027</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674,484&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Other Research and Development expenses were $1,201,027 for the third quarter of 2020 compared to $674,484 for the third quarter of 2019. The change in R&#38;D personnel related expenses in the third quarter of 2020 compared to the third quarter of 2019 was primarily as a result of costs associated with changes in personnel and recruitment related costs incurred as we look to expand our U.S. office to support our clinical program.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in Other R&#38;D expenses in the third quarter of 2020 compared to the third quarter of 2019 was primarily due to decreased travel expenses as a result of COVID-19.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Based Payments</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based payments</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,863</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,401&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash share based payment expenses for the third quarter of</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 were $28,863 compared to $101,401 for the third quarter of 2019. We incurred share based payment expenses associated with the vesting of options and share awards to officers and employees. In the third quarter of 2020, we also recognized a recovery of share based payment expenses as a result of changes in personnel and the forfeiture of unvested options.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:402.75pt"><tr><td style="width:1.0pt"></td><td style="width:280.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,597,314</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933,858&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">582,346</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,175&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,891</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,483&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87,878</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,522&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based payments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172,213</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,983&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,461,642</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834,021&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses for the third quarter of 2020 were $2,461,642 compared to $1,834,021 for the third quarter of 2019. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. Our public company related expenses were $1,597,314 for the third quarter of 2020 compared to $933,858 for the third quarter of 2019. The change in our public company related expenses in the third quarter of 2020 was primarily due to increased investor relations activities and an increase in insurance premiums. This is partly offset by transaction costs of $233,143 incurred in the third quarter of 2019 related to our August 2019 public offering (see note 5 of our interim consolidated financial statements).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office expenses include compensation costs (excluding share based payments), rent related to short term leases and other office related costs. During the third quarter of 2020, our office expenses were $582,346 compared to $636,175 for the third quarter of 2019. The change was primarily related to changes in personnel.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash share based payment expenses in the third quarter of 2020 were $172,213 compared to $148,983 in the third quarter of 2019. We incurred share based payment expenses associated with the vesting of granted options and share awards to officers, employees, consultants and independent board members.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued warrants in connection with our August 2019 underwritten public offering. Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until they are exercised or expire. These warrants are adjusted to fair value at each exercise date and at each reporting period and any change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,264</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(122,498)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020, we recognized a gain of $60,264 on the change in fair value of our warrant derivative compared to a loss of $122,498 in the third quarter of 2019. The change in fair value in the third quarter of 2020 was as a result of several factors including changes in the market price of our shares to US$1.69 on September 30, 2020 from US$1.88 on June 30, 2020. The change in fair value in the third quarter of 2019 was as a result of several factors including changes in the market price of our shares to US$0.57 on September 30, 2019 from US$0.54 on August 16, 2019.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange (Loss) Gain</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (loss) gain</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(506,349)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,618</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange loss was $506,349 for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared to a gain of $41,618 for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The foreign exchange loss incurred in the third quarter of 2020 was primarily due to unrealized translation loss on U.S. dollar denominated cash balances. The foreign exchange loss incurred in the third quarter of 2019 was primarily due to unrealized translation gain on U.S dollar denominated cash balances, partly offset by unrealized translation loss on U.S. denominated accounts payable.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_40"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(for the nine month period ending September&#160;30, 2020 and 2019)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the nine month period ending September&#160;30, 2020 was $13,176,385 compared to $13,721,246 for the nine month period ending September&#160;30, 2019. Net loss for the nine month period ended September&#160;30, 2020 included a non-cash change in fair value of warrant derivative gain of $3,705,096 (September&#160;30, 2019 - loss of $122,498) and a foreign exchange gain of $393,358 (September&#160;30, 2019 - loss of $202,440).      </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:408.00pt"><tr><td style="width:1.0pt"></td><td style="width:286.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,853,871</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,186&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,949,229</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302,211&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenditures</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">799,717</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,339&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaboration expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246,942</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,575&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,807,515</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,024,243&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based payments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">225,772</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,883,046</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,121,554&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:396.75pt"><tr><td style="width:1.0pt"></td><td style="width:280.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,853,871</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,186&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial expenses were $1,853,871 for the nine month period ending September&#160;30, 2020 compared to $1,608,186 for the nine month period ending September&#160;30, 2019. Our clinical trial activities related primarily to the preparation and development of our breast cancer registration program. During the nine month period ending September&#160;30, 2020, these costs included continued patient enrollment and treatment as well as data analysis for our AWARE-1 study and our portion (net of Pfizer's contribution) of trial initiation activities and patient enrollment and treatment related to our BRACELET-1 study. During the nine month period ending September&#160;30, 2019, these costs included startup activities and patient enrollment and treatment for our AWARE-1 study as well as costs to complete our supporting regulatory documents and key opinion leader activities. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine month period ending September&#160;30, 2020, in addition to activities related to our breast cancer program, we also incurred consulting costs related to data management, close out costs related to our fully enrolled legacy clinical trials and costs related to our Opdivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combination and IRENE studies. During the nine month period ending September&#160;30, 2019, our other clinical activities included close out costs related to our fully enrolled legacy clinical trials, patient enrollment and&#47;or treatment in our checkpoint inhibitor pancreatic cancer study investigating Keytruda&#174; in combination with pelareorep, and expenses related to updating our supporting regulatory documents.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We still expect our clinical trial expenses to increase in 2020 compared to 2019. During 2020, we expect to make significant progress in the development of our registration program, generate clinical data with checkpoint inhibitors and prove the effectiveness of biomarkers across various indications. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &#38; Related Process Development (&#8220;M&#38;P&#8221;)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:69.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product manufacturing expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,838,438</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,142,323&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,791</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,888&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,949,229</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302,211&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our M&#38;P expenses for the nine month period ending September&#160;30, 2020 were $2,949,229 compared to $3,302,211 for the nine month period ending September&#160;30, 2019. During the nine month period ending September&#160;30, 2020, our product manufacturing costs primarily related to a cGMP production run, a product fill and the associated consulting and testing expenses, as well as shipping and storage costs of our bulk and vialed product. During the nine month period ending September&#160;30, 2019, our product manufacturing costs primarily related to the completion of training and engineering production runs as well as shipping and storage costs of our bulk and vialed product. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our process development expenses for the nine month period ending September&#160;30, 2020 were $110,791 compared to $159,888 for the nine month period ending September&#160;30, 2019. During the nine month period ending September&#160;30, 2020, our process development activities focused on stability studies and analytical development. During the nine month period ending September&#160;30, 2019, our process development activities focused on analytical development studies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We now expect our M&#38;P expenses for 2020 to remain consistent with 2019. For the remainder of 2020, we expect to complete our product fill, label and store sufficient product as well as continue to perform analytical development and other non-clinical projects to support our clinical development program and other collaborative requirements. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:73.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">799,717</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,339&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property expenses for the nine month period ending September&#160;30, 2020 were $799,717 compared to $759,339 for the nine month period ending September&#160;30, 2019. The change in intellectual property expenditures reflects the timing of filing costs associated with our patent base. At the end of the nine month period ending September&#160;30, 2020, we had been issued over 394 patents including 49 U.S. and 18 Canadian patents, as well as issuances in other jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We still expect our intellectual property expenses will remain consistent in 2020 compared to 2019.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.339%"><tr><td style="width:1.0%"></td><td style="width:75.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaborations</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246,942</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,575&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaboration expenses for the nine month period ending September&#160;30, 2020 were $246,942 compared to $102,575 for the nine month period ending September&#160;30, 2019. During the nine month periods ending September&#160;30, 2020 and 2019, our research collaborations included studies investigating the interaction of the immune system and pelareorep. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We still expect that our research collaborations in 2020 will increase compared to 2019. We expect to complete our ongoing collaborative program carried over from 2019 and will continue to be selective in the types of new collaborations we enter into in 2020.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Research and Development Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:69.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D personnel related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,729,058</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876,695&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78,457</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,548&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Research and Development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,807,515</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,024,243&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Other Research and Development expenses for the nine month period ending September&#160;30, 2020 were $2,807,515 compared to $2,024,243 for the nine month period ending September&#160;30, 2019. The change in R&#38;D personnel related expenses for the nine month period ending September&#160;30, 2020 compared to the nine month period ending September&#160;30, 2019 was due to costs related to changes in personnel, recruitment related costs and an increase in headcount as we look to expand our U.S. office, partly offset by personnel cost recovery from Pfizer related to BRACELET-1.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in Other R&#38;D expenses for the nine month period ending September&#160;30, 2020 compared to the nine month period ending September&#160;30, 2019 was primarily due to decreased travel expenses as a result of COVID-19.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We still expect our Other Research and Development expenses in 2020 to increase compared to 2019 as a result of our need for additional U.S. personnel to implement our clinical program. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Based Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:389.25pt"><tr><td style="width:1.0pt"></td><td style="width:282.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based payments</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">225,772</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine month period ending September&#160;30, 2020, our non-cash share based payment expenses were $225,772 compared to $325,000 for the nine month period ending September&#160;30, 2019. We incurred share based payment expenses associated with the vesting of options and share awards to officers and employees. In the third quarter of 2020, we also recognized a recovery of share based payment expenses as a result of changes in personnel and the forfeiture of unvested options. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:69.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,394,493</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499,783&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,141,806</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,428&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,520</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,190&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271,034</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,201&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based payments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">628,749</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,491&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,503,602</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,426,093&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses for the nine month period ending September&#160;30, 2020 were $8,503,602 compared to $5,426,093 for the nine month period ending September&#160;30, 2019. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. During the nine month period ending September&#160;30, 2020, our public company related expenses were $5,394,493 compared to $2,499,783 for the nine month period ending September&#160;30, 2019. The change was due to increased investor relations and business development activities and the associated professional expenses, as well as an increase in insurance premiums. This is partly offset by decreased travel expenses as a result of COVID-19 and transaction costs of $233,143 incurred in the third quarter of 2019 related to our August 2019 public offering (see note 5 of our interim consolidated financial statements). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office expenses include compensation costs (excluding share based payments), rent related to short term leases and other office related costs. During the nine month period ending September&#160;30, 2020, we incurred office expenses of $2,141,806 compared to $2,069,428 during the nine month period ending September&#160;30, 2019. The change was primarily related to costs associated with changes in personnel.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine month period ending September&#160;30, 2020, our non-cash share based payment expenses were $628,749 compared to $486,491 for the nine month period ending September&#160;30, 2019. We incurred share based payment expenses associated with the vesting of granted options and share awards to officers, employees, consultants and independent board members.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We still expect our operating expenses in 2020 to increase compared to 2019 primarily as a result of our continued investment in business development activities, increased insurance premiums, and increased investor relations activities. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued warrants in connection with our August 2019 underwritten public offering. Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until they are exercised or expire. These warrants are adjusted to fair value at each exercise date and at each reporting period and any change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,705,096</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(122,498)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine month period ending September&#160;30, 2020, we recognized a gain of $3,705,096 on the change in fair value of our warrant derivative compared to a loss of $122,498 for the nine month period ending September&#160;30, 2019. The change in fair value during the nine month period ending September&#160;30, 2020 was as a result of several factors including changes in the market price of our shares to US$1.69 on September 30, 2020 from US$4.76 on December 31, 2019, and the revaluation on warrants exercised. The change in fair value in the nine month period ending September&#160;30, 2019 was as a result of several factors including changes in the market price of our shares to US$0.57 on September 30, 2019 from US$0.54 on August 16, 2019.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Gain (Loss)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gain (loss)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393,358</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(202,440)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange gain for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month period ending </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2020</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $393,358 compared to a loss of $202,440 for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month period ending </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2019</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign exchange gain incurred during the nine month period ending September&#160;30, 2020 was primarily due to unrealized translation gain on U.S dollar denominated cash balances. The foreign exchange loss incurred during the nine month period ending September&#160;30, 2019 was primarily due to unrealized translation loss on U.S dollar denominated cash balances, partly offset by unrealized translation gain on U.S. denominated accounts payable.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_43"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Commitments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at September&#160;30, 2020, we were committed to payments totaling approximately $10,181,986 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. All of these committed payments are considered to be part of our normal course of business. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include one-half of the committed payments related to our collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc (&#34;Pfizer&#34;), known as BRACELET-1, as the cost of this phase 2 clinical trial will be shared equally between Oncolytics and Pfizer. As at September&#160;30, 2020, we recorded nil (December&#160;31, 2019 - US$1,500,000) in other receivables related to an upfront payment of BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and US$309,148 (December&#160;31, 2019 - US$652,306) in other liabilities representing future trial costs to be incurred.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with initial lease terms generally between 3 to 5 years. We currently do not have leases with variable lease payments, residual value guarantees, extension or termination options, or leases not yet commenced to which we are committed. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, we entered into a lease for our Barbados office space. We recognized a $297,737 right-of-use asset and a lease liability of the same amount. The incremental borrowing rate applied to the lease liability was 15%.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at September&#160;30, 2020 is as follows&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.947%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity analysis - contractual undiscounted cash flows</font></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,311&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,470&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability as at September&#160;30, 2020</font></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593,781&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_46"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Summary of Quarterly Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:505.50pt"><tr><td style="width:1.0pt"></td><td style="width:187.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:39.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sept</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mar</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sept</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mar</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,749)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,827)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,402)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,529)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,254)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,939)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,819)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic (loss) earnings per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted loss per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,242</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,604&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,553&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,658&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,302&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,461&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,865&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,711&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,911&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,299&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,276&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,214&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,700&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net (loss) income and (loss) earnings per common share between September 2020 and July 2019 are non-cash change in fair value of warrant derivative gain (loss) of $60,264, $(507,150), $4,151,982, $(12,486,310) and $(122,498), respectively. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There was no change in fair value of warrant derivative gain (loss) between June 2019 and October 2018.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in net (loss) income and (loss) earnings per common share between September 2020 and October 2018 are quarterly share based payment expenses of $201,076, $260,640, $392,805, $658,662, $250,384, $260,184, $300,923, and $483,016, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Q1 2020 included the effect of dilutive warrant derivative, stock options and share awards. For all other periods presented, the effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We issued 10,135,816 common shares for net cash proceeds of $28.7 million in 2020 (2019 - 14,798,704 common shares for net cash proceeds of $21.5 million).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have not declared or paid any dividends since incorporation.</font></div><div style="padding-left:36pt"><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_49"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_52"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">2020 Financing Activities </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public offering</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine month period ending September&#160;30, 2020, 1,418,369 warrants in connection with our August 2019 underwritten public offering were exercised for gross proceeds of US$1,276,532. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine month period ending September&#160;30, 2020, we sold 6,741,518 common shares for gross proceeds of US$17,538,342. We incurred share issue costs of $856,754.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine month period ending September&#160;30, 2020, we sold 1,807,878 common shares for gross proceeds of US$3,479,212. We incurred share issue costs of $406,416. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_55"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">2019 Financing Activities </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Purchase Agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine month period ending September&#160;30, 2019, we sold 1,379,024 common shares for gross proceeds of US$2,663,768 and issued 11,348 commitment shares. The commitment shares have been valued at fair value of US$21,998 and have been recorded as share issue costs in addition to cash share issue costs of $3,757.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine month period ending September&#160;30, 2019, we sold 1,572,745 common shares for gross proceeds of US $3,030,892. We incurred share issue costs of $160,556.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public offering</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share purchase warrant with a fair value of US$0.27 (see Notes 4 and 5 of our interim consolidated financial statements). Each</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common share purchase warrant entitles the holder to purchase one common share at an exercise price of US$0.90 until August</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocated to operating expenses, based on their relative fair values. </font></div><div><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_58"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Liquidity</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at September&#160;30, 2020, we had cash and cash equivalents and working capital positions as follows&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.093%"><tr><td style="width:1.0%"></td><td style="width:65.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,710,802</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,148,021&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital position</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,493,607</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,570,105&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any debt other than trade accounts payable and lease liabilities, and we have potential contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 12, 2020, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf  provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity offering sales agreement in June 2020 (see Note 5 of our interim consolidated financial statements). We will use this equity arrangement to assist us in achieving our capital objective. This </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that the expected cash usage from our operations in 2020 will be between $23 - $25 million. We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources. Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources to fund our presently planned operations to the end of 2020. Factors that will affect our anticipated cash usage in 2020, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&#38;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2020.</font></div><div style="text-align:justify"><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_61"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financial Instruments and Other Instruments</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, other liabilities, accounts payable and warrant derivative. As at September&#160;30, 2020, the carrying amount of our cash and cash equivalents,&#160;other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at September&#160;30, 2020, the fair value of our warrant derivative was $333,224 (December&#160;31, 2019 - $8,508,764). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, British pound and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2020 by approximately $153,000.&#160;The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $27,500. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $3,000.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balances in foreign currencies at September&#160;30, 2020 are as follows&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:33.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US dollars </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">British pounds</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro<br>&#8364;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,551,370</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,766</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,795</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,346)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,295)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,812)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,851,212</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,529)</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,795</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 10 of our interim consolidated financial statements. Accounts payable are all due within the current operating period.</font></div><div style="text-align:justify"><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_64"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other MD&#38;A Requirements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 43,298,907 common shares outstanding at October 30, 2020. If all of our options, restricted share units and performance share units (2,447,503), common share purchase warrants with a $9.025 exercise price (1,730,894) and common share purchase warrants with a US$0.90 exercise price (265,757), were exercised or were to vest, we would have 47,743,061 common shares outstanding.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2019 annual report on Form 20-F is available on www.sedar.com.</font></div><div style="text-align:justify"><font><br></font></div><div id="ib6dd1406b5774958a5a4a4a34be8305e_67"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal controls over financial reporting during the quarter ended September&#160;30, 2020 that materially affected or are reasonably likely to materially affect, our internal controls over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993-q32020certificat.htm
<DESCRIPTION>Q3 2020 CERTIFICATION CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="id1bc38cbecf24bfcbb99f029879a0b50_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM&#160;52&#8209;109F2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Matthew Coffey, President and CEO of Oncolytics Biotech Inc., certify the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Review&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  I have reviewed the interim financial report and interim MD&#38;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended September&#160;30, 2020.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">No misrepresentations&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fair presentation&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Responsibility&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&#38;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, for the issuer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed DC&#38;P, or caused it to be designed under our supervision, to provide reasonable assurance that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Control framework&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ICFR &#8209; material weakness relating to design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Limitation on scope of design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reporting changes in ICFR&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer has disclosed in its interim MD&#38;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on January 1, 2020 and ended on September&#160;30, 2020 that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; &#160;&#160;&#160;&#160;November&#160;11, 2020&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Matthew Coffey</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Matthew Coffey, PhD, MBA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">President and CEO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ex994-q32020certificat.htm
<DESCRIPTION>Q3 2020 CERTIFICATION CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2c0e2be2efcd49bd9f190e536f7d3394_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM&#160;52&#8209;109F2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Kirk Look, CFO of Oncolytics Biotech Inc., certify the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Review&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  I have reviewed the interim financial report and interim MD&#38;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended September&#160;30, 2020.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">No misrepresentations&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fair presentation&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Responsibility&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&#38;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, for the issuer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed DC&#38;P, or caused it to be designed under our supervision, to provide reasonable assurance that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Control framework&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ICFR &#8209; material weakness relating to design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Limitation on scope of design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reporting changes in ICFR&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer has disclosed in its interim MD&#38;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on January 1, 2020 and ended on September&#160;30, 2020 that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; &#160;&#160;&#160;&#160;November&#160;11, 2020&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Kirk Look</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Kirk Look, CA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CFO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>oncolyticslogotaglinebluea.jpg
<TEXT>
begin 644 oncolyticslogotaglinebluea.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
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M$0,1 #\ S^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                   -0  8WD
M F  #(     ,-@  ;R   U  !D
M
M
M
M
M
M
M
M
M
M
M                                                '57(=>< J I*
M]3KS*8X_]K_]@K;CF0H R"KSH<=9["F<;@%3G4XYE*?,AQSH8T7@-"KS*<<R
ME+K/8.=?0AD%7=3@I\R^KYAS+ZOF *@*?,OJ.=W>H [@Z;N]1QNOJ *ASN4N
M9?5\PYE]7S %7F4YYE*/,OJ'6>P K<RG/.I1YSGG0QIZC.A6ZSV'/.A1W0Y,
MF"MS(<[H4  2 4-SE'J8!6!3ZSV'9'H9!V!QN<@
M
M
M
M
M
M
M
M
M
M
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MN=T> 50=4>AV,@
M
M
M
M
M
M
M
M
M
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M>=0"9UGM'/[2)UGL.>= "8CD]2?$<[I[4(B*=N90"5OZE_"<HJ^Q2-SJ<H\
ME<WK11S(44D]ISS>Q/B )&YSS>M$(^_JW.R*OP@%?WOP'*;_  E#G.Z* 5.?
MUH=T4I<_QCL^#\ !6&Y33?X3GG0 K(\[HY"B!H"0"BCE0[H\ [@
M
M
M
M
M
M
M
M
M
M
M                     ZJY"FKE,?U [J_8Z*[<ZG"N1#(.3A5V.G,J]W<<
M=GI[0#MS^I#JOM7XCCF^(Z*H!4YMNY#JJE)7>HXW3T]OL0 [\R?"<*J_ 4]R
MFKT *GX3A7;>SQ\I1YU.BN *RR?&=5>4%?ZCJK_B *RN]9TYT*"O0Z<X!)ZS
MV'57J15D]I360 E*]#CG(BR>/&YU5Z^OY]@"6LAT5_M(BR)Z_'QG59 "6KT.
M.=/:0UD]GX3KS^Q/F )G6IX4XZSQLI#61?6GCX#A9/6OCXU )O6+X_.=>L7Q
ML0NL3U_@"R)X5 ";UOCL.>L]OX"#S^.S\AQUGM^=/R :D_K/;^ XZWQV$'K/
M;\Z?D.>?QV?D U)O6+XV.R2+X_,6_K/&Z?D.>L3U_@ )_6>-E.>M3PI 23V^
M/B4[)(OK_" 3^= CT(/6+[%^0Y1_L\?$ 3^L]IW23X%("2'/6)Z_'Q %PZSV
M'/.A!1_M.Z/7Q^8 GH_U*=T?["W)(=T?[=OF )_.AV1WJ(2/4[\X!-1ZG=)"
M&C_:=D> 34=OX_*<]GZ"(CT.Z.7U@$M%7T=OL])SS_$1D>5$< 2$4[\_K0C)
MM\"G;F7X0"O\'9[#GF5.]"DCD4[(X JHY%.Q2W1?8<]J %5%*B/(Z/13N 2
M4$4J(\P#N #(
M
M
M
M
M
M
M
M
M
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MVQ41Z%%'(<@$@%%'%5%W, Y !D
M
M
M
M
M
M
M
M
M
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MH"L#JCMSL-0  9
M
M
M
M
M
M
M
M
M
M          *;G^HQKX [*[8I*IP<*[8): Y*:N]07M[5[$.JN]7<9,G.^WP^
MGU'55W.BNV.B^WL]2 P=E=ZCIV?#^ ZN=\2%)7@'=7E-7;E-7(47/]8!55_J
M*+G%)S_B*#G^A "NZ3XB@LA2<[QX[B@Y_P 7CY0"NYWM**R>/':1W2)\/CY"
M@Z3V@$A9$]/;X]2%%TA&=*47R^/S $E9"@Z4BND_2I1=( 2G2^$*+I/B(RR>
MTHNE0 E+(4G2?H(;IO'YD**R^.X FND1"FZ8@.E]OR%%TWCO )[IBDLOA5(*
MR_#^ IK* 35E\(=%E\;D!9D]J_@*:S $]9O'Z3HLJEO=-[?D\)^,Z=;\*^/9
MM^$ N/6? =%F]I;^L\=GXU.G/OZD\>P GK.GK.J3;^@@K(O_ %O'QG7G3U_@
M +@LOL^?]!QUOCL_*6[K$]OR_F'6IXW +BLOP''7?!\_Y"W<Z>SYQUB>SYP"
MX]=\'S_D'7?!\_Y"W=8GL^13CG;ZD^< N?6_!X^-!UOCL_*6[K$\;A9$]ORK
M^0 N?6^SQ\ARDWPIX^(MB2)ZU\?"<H_U+^  NJ3>T[I+\!:N=?8<I)[$^;\P
M!=DD4[I,6GK/A3Q\9W;-[?E\?B +NDIW24M"3>/'Y"JDR>U/@[?P %W;,5$F
M+0V7VE5LJ_H +PV;QWE5)2S-F*J2^.\ O+9/B*J2%G27QN5VS>.X NK9?"E9
MLI:FRE9)/: 79LOC\Q7;)X0LZ2%9L@!=VR%=LOR_(6ALOM)#90"ZM?[?'CU%
M9)$4M;7^KY"LDB>H NB2>/SE9LA;6O\ 5V^/D*S7I\'CY@"XH\K(_P!9;FO*
M[7^H GHOJ*K7_$06O*R/]8!-W_2AV1=O:GK(B.V*S7@$E%]1WWW[%(Z>SL7U
M'='>CT@%;=4]J'=%**+\AV3V?( 52HU_K**..QAK4$@%%KMBJBC4'( ,@
M
M
M
M
M
M
M
M
M
M                                             '"KL%78HJNYA?U
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M[<J(OH7N!DK'*+L4>[N[4*B*#!71VYV(^Y6:[<P#L #.H
M
M
M
M
M
M
M
M
M
M                          &H!U<[8X<XI;F-/$'*J=54*NQ3[^U>XR#E
M>WX$.JKZ$[@J_(4G.]"?H .57U=YT7UKW^KU'&_RE%S_ % '=S_E*"N]9U<[
M8HN=ZP#NY_R%!7G1S_61G2 %1TGZ2.Y^WC\/YCJYY&<_X_'S %1S_;X_$1G2
M%)S_ %D=\@!5=)X\=Y'?*4'R$99 "LZ3QZ2@Z3])1=(A%?* 2'RD9\I'?(17
M2^$ )+Y2.Z4CND]9'?-MX_$ 25D^(H.E1/RJ1'2D=S_6 2GS?'\WX"BLGCQV
M?A(ZR>H^4^D7TW.%/"B'K->ZXP."M.B6:##R78[.?ML1$5'5<'46?)R1NW1J
M6%K,JM<YC7SMYF[_ +8^-9=-5U5SLG+E"N,IR?LC%-O\A^&1E54P=EMD*JX^
M=.R<807ME)I+ZV?5RR>/SG19%V5?0U%55]#41-U5?4B(G:O<B=JF*=TE?.7<
M;72Q1X2Z(ER4V[V09_6;Y*5!.QW)/'@L?,V_93]KO#/?QR[*NTBJFR^!G2'\
MI]QUXGOG;J?B%F(L;.[=N TZL>FL'!'NJMA;3Q#:\MEK.96I-DK-^X]OO9K,
MB$B;(ZK-I9*4KE7B0?X9[UNGJJAJT_59*MD:;9ZW-E8K<:79FV+A[PDJD_7=
M/1->NN-BXF>9T@/*+\%.&+)/U8\0\!1MQIS?4JC._-9N1.U$6/#X:.]D'IS)
MR.=U"1QN5$D>Q%W/$KCCYS3I2JL];AQPZSN;>WF;%E=7VZ>"HO<U5;UD>+Q<
M^5OS5WK[YCK%O'6.7]TJQN7E3#Q>JN>^1RJZ21RODD<JNDD>Y=W/D>[=SWN5
M55SG*JN555555.-O'CY"2]F=4VSJ4G>[<N??O2=5?U0J>_[=;)+U=Y%>U^N/
M:ES:Q84X<.*6[%7V\?&=J[/@N6E4=./%\-/8/C?Y=#I$:RZV&KJBIHRA(KT2
MKI/'5ZECJG;HD4F3N)<N*K=^R:NZK-NB>_39=_*;76N\[JG(.RVI\WF-295Z
M<KLEG\G=S%Y6^AONO(SV)T8G<UC7HQJ(C6M1J(B?RP) V?L7$Q5IC8U-'#36
MNN,9/Y4DMZ7UMD<[2VYF9CURLJ^_CJE99*4$_P 6&NY'^;%'5&[=W8GL.40Y
M!LMU&J2T  ,F0                           <;'(,;J!4H325;$-NK))
M5MUWI)7MUI'U[,$K>ULD%B%630R-_P 5\;VN3T*>CW _RN72%T%U,>-XC9;-
M48.Q,;J]6ZGK/3_%1]G)*_+<K$]ZQC<DV-C=FHS9K43S=!XLW9F/DQW<BBJ^
M/<K81L2]F\GH_6M&>[ VGDXLM_&ONQY>--DZ]?4U%I27J::]1E5<#O.:\C!U
M%?B/PVBOL3D9/E-&Y)M6WRJ[W\R8C,+[DFD1O[2!F3HQN5&HLS=W*GM-T>?+
M*='SB.L%?'ZVCTYE9^5&X36M;]3>125^W+"R>::QAKLO;VMQF6O-39WOMD-=
M=L<*Q%39414]2HBHOPG!;3ZJ]F7ZNJ-F+-\G3-RAKZZ[=]:>J$H>I]Q(>R>M
MW:^.TKI59D%P:N@H6:>JRK=X^N<9^M<M-L=C,O7N01VJ=F"W5F3>*S6FCL5Y
M4W[5CFB<^.3;M3=KE3T=BEQ23])J\N!G3"XI<-)HYM":]U)IQL:M5*=2^ZQB
MWHQW,V.;#WVV\3/#S?MH)J4D+_\ '8X]V.C7YREK7%=11XJ:1QFJZS5:V3/:
M81F S75HU$62SB9%DPMR=[]W.?3?AH6MV:RHKNU8VVOU2Y]"<L:=67!?!3[*
M[3Y$WV;^JUM]R9*6QNN39M^['*A;A3?PI+MJ=?#M*UOKVRIC%=\C,Z1_J7\?
MYRLV7;\W=X]FQYF=&?RM' GBDM2IA=;X_#YVWR,CTYJJ2/3V5DL.9S.K4_=\
MD=/(RHY'MCCHVIIY48LC848J'I*V3Y/1^9?T]WL4C;,P+\>?9WTV4S^+9"4'
MIXI22U7K6J)1P=HX^3!68]U5];^'59&R/L;BWH_4]&79DV_CM^0DMD]OQ%F2
M1/@*S9%\>/P'D/87ELI(;*69D_A?1\9);)Z@"\ME)+92R-E\>@DMD +TQY7;
M(6ALQ);( 7=DI*;)N6=K_C*[) "\->2F/\>.XM#)"2V0 NK7$AKRUMD^+QX_
M226O^/Q\WX "Y-?\:%=KRVM?X_+^8D-> 7!JE9KR"U_Q%9KMP":G;[#NCO61
M6NV*R+\@!(1=COMZ4(Z+M\'H*J* 5D4Y*7?VIW^H[H[< K-?ZRH1RHUWH,:
MJ  )@  R
M
M
M
M
M
M
M
M
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M9(:_UEL:\DM?\@!<FO\ 656N(#'_ "$AKOD )S7?(5$7;VI^ AM=Z4*['_H
M)*+Z4._?\)&1>WL^0JHNX!6:[T+WG<I)LO9W'=%]"@%9KO65".=VN]!AKP!5
M  3  !D
M
M
M
M
M
M
M
M
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M1%W *Z.]"G8I(N_9\BG9J^A0"LUWH*I'*C7&'^K_ +T!4 !G4
M
M
M
M
M
M
M
M
M
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MX2/[?5WH5$4 KM=Z%.Q2[_A3YSNUWR@%=KCN1T4K-=N8?B#L #(
M
M
M
M
M
M
M
M
M
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MP3=9V<Y7*YSE5SG.<]SG*KG.<Y5<YSG*JN<YSE5SG.57.5555W4X ):2T(=
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MB@$A%W.2@U=BN?/+V   ^@
M
M
M
M
M
M
M
M
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MN#!(!T8[<[GRO   'T
M
M
M
M
M
M
M
M
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MJ+Z4^, D]_PG=J_*444[KZP"JBE=%(Z*=VJ8!6 !D
M
M
M
M
M
M
M
M
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M_NC%<(1T2[VZ==).D>3M3*EDY+T^#55%ZPHKUX5P_7*7.<M6]."0 &^-"
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MD?Q(26Q^/'Z?85(XE]7XO'PDUD7LW7YOS&#)19#X\=Q+9%Z.Y"JR(ELB\>L
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MU#NUVX!78IW*"*5D4PP<@ R
M
M
M
M
M
M
M
M
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M2QWYP"0BG=?7Z"@U?1\A6;ZO6 5CNQWH*+/4=P"0#AJ[H<F$  #(
M
M
M
M
M
M
M
M
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M^ K(I&8XK)V+[% *^_I]7>5$4I-7Y#LWL78 K-=M\!6(Y6:[<^7X^ .P /H
M
M
M
M
M
M
M
M
M                                                       X53YE
MX IO4Z Z/7T'T$<;]Z_$A253NY?1ZBBY?1Z@#JOM[_Q$=R[E5[B,Y=@#H]WS
M$-[O257J1'N^0 I2.\>/6O9\!"E?Z/'CT%:1WI\>/007N]/R %&5Y D?X]I5
MD<07N *4C_SEND>5Y7^/'J+;*_\ , 4I';^/'Q$":3U%:5^Q;GO]/CQZ0"G(
M[QX]9B9^<#>4@Y62<!M&7MGRI%8XCY*M,N[8%1DM'243XUW3KT5+F<153F@]
MR4.7JYK:.]H/*D=/*EP&X:9#-5YJTNL\VR?$:*QLW)*LF6EB5%RL]9W[KC\*
MQR7;+7HD4\C8:BN1;!KI=0Z@OY?(7LME;EC(Y3)V[%_(Y"W(LUJ]>MRNFLVK
M,KMUDFGE>Z1[E]*JB(C=D28.J[HC[HM_=&^.M-,],>,EPLNCIK9H^<*?@^-O
MR&G"G6WTS]STO9F-+2_(@GDSBUK5CRU79I]T[M-)=ZJUX:V1DK.B>/C.0"PZ
M6A6I(  R  <*NR;KV(@!*HT)[=B"I5@FLVK4T=:M6KQNEGL6)GMCAAAB8BOD
MEED<UD;&HKG.5$1.TSI_(T^2MBX.X.+7>MZE>;B=J&HCF5U1)FZ,P]EC7,Q,
M$CF[.S-EFS\W:B7JHW.;C:KY8:\ERY\8^0K\E<VE'CN.'$;%.]WS1^Z>'FG\
MC K6TZ\S4ZK5UVK*U%=;L1*Y<#',WDKUY4RK6+9?1FK95C47T]Y7[K*Z<=K*
M>SL2?O47NY5L7]\DGQIBU_%Q:]\?PY+=7DQ>_8WJMZ =BH;4S8>_26]B4S7W
MJ#7"Z<6M5;--]FGYD'O/RY)0Y:WU$N-AUC9X_$3&,W^ A@G,,9N3HHMOA$46
MWP^@G1Q@".,FQQG,<1/C9L &,V)3(SED?C\A-CC]@!U9'["8R,Y8S])+9'MX
M_, =61I\)*;'ZSEC-O026L^, Z-85VL^)"HC"NUGI .C6%9K=CLB;E9K/4 4
MT9ZRLC?B.S?9\JG9&^L ZHGJ3XU._+Z^T[HFYV[$]J_, =4;[#MLB>WX#MLJ
M]_8AV1$0 Z=OJV')ZU*@V .$:B')W1AV1B#4%([(U2L#"?J_*"ER';D0[@,'
M7D3U#D3U'8#0'&R>H;)ZCD#3_O5@XV3U#9/4<@:?]ZL'7E3U#D3U'8&0=%8A
MUY"J "BK%.NQ(!@$<XV*ZM0Z]7[3.H*"L^(X7?T]I55-C@ I=GP'56J5E1#I
MRJG< 458AT5%]/;[20NWI[%.%;L 1^7?N^0HJSU$I6G1?;\H!#<WUE)S?D)S
MF_(47-V (#F%!S/47%S?E*#F[@%M='N171^OQX^0NCF$=S?'J_*@!:7Q_I(D
MD9>',\?@(CV %F?&17L+Q)'X_$0I(_'J +-)$0)(_'J+Z]A"EB\>/0 6-[/E
M_$6^1FV^R?#[/'CM+X^/QZB%)'O\/X0"RO81'L+J]FWP?@4B2, /.KRC70 T
M_P ?]#V,%=6#':IQ<=BWH[4CXN9V*RCH]VU[:L:Z63#9![(H,G!&CGI%M8KM
M6S!%OKP^,'!_4>@=2Y?2&K,;-B<]@[;ZEZG,BJG,WMCL5Y-D;8IVH^6>K9C]
MY/"YKD1%YFIM1G-^4\4O+"^3"J<;M,)J?2]2*#BAI>I,N,DB8QBZIQ;4ZV33
MF05.7K9VO:LV#LN57UK+YJOOH+CD9*/5YTV]PV+$R9?O.V7DR?'W/9)^=KW5
M3?GKE%OM%IY>]$O69T"6T*GFXL/W]3'RHKA[IJC\#UVP7WM_"7O;>FYNX#H)
M>0Q]BG8L4[=>:K;J3S5;56Q&Z&Q6LUY'0V*\\+T1\4T$K'Q2QO1',>U6N1%0
MB%ED]>15G_\ P  R <*<@ ]O?(G>4<?P=UPFC]477-X<:WLQ5[3I7;QZ:U%(
MZ.&AGHU<Y$CI6=DH9F)J;.BD@O-3K*CV39[5>PUS6O8YKV/:US'M5'-<UR(K
M7-5%V5KFJBHY-T5-E3L-3,YJ*FR]R]BI[%[/P&;GY!#RB3]?:37A1J_)K9UG
MHNFKL%<N2M6YJ#2,;T978]RJC[5[3O618Z:5&K++C?J?-9?):Z^Q/!O6GT1U
M3VGCQXK2.7&*YKE&_AWKA"SQ6[+NDR?>J'IDTULG(EJGK+"G)\GSECZON?&=
M7\^'Q$9&T,G;M^$N+'_G+)&[Y4+A!)^<@DL&7N)Y<8GECC>7&)_CV %XC<7"
M)_CUEHC>38W?E0 O$;O03HU\>/66F-WYB;&_N_%X^, N<;OS$QCNY2W,>2XW
M?. 3VKL26]O9\GCVD%BDEB_, 26K\I5[T^ CHOI]?S%9J@%9J[G9J[%).Q=B
MH 2 =6=QV/E/N  !]
M
M
M
M
M
M
M
M
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M5OJ^0ZJW?X?45]O5^<Z*FX!%<PHJWUDQ?4ORG1S/T@$![",YGK+BYNQ0<WY
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M6>-_CVEPC> 7:-WR>/'QDQB^@MD3_036* 7%CB2B^D@L=\Y*8OH )K5W^/\
M"56K\W81F*5D7M3V]_P@$A.U/@*C5W0I-78[-7T %9B]I6(Y7:NZ&&#D &0
M
M
M
M
M
M
M
M
M                                                  ='KV%([.7<
MIN7L"!T1?2OH.BKZ3LO8B?.4G>A #IOV?#^(CN7M*SW?F(KE[ "D]WS$-[OG
M*[U]!#>NX!1>I!D?N5WO[R#(O8 1Y7%OD<2)'D"1WS@$>5Y;97DF5Q;I' %"
M1W>6Y[^]?'M_(5YWD![N[Q\2 'RWTR^E)A^#?#G4FO\ ,I',W#TW)C<<^3JU
MRV:L;Q8K%M5%1[4MVUC;,]GOXJR32M[6)OK/N)?$K-ZRU#FM5ZDNOR.>U#D;
M.5RMQ^Z==;M/YG)&W=4BKPMY*]6!J\E>M%#!'LR-J'N1Y?\ Z<"Z_P"(T7#7
M W>MTEPY>Z/(.A>JU\KK2=CFY"=?\62'!UGLQ-5R;M6V[*2M=)%) YO@ A9S
MJQZ->XL/W39'3(S%&?%>571SJAZM[7M)<N<$UK JGUK=*?=V=[EJEKC83E#@
M_)LR.5L^'/<T[*//32;7"8 !)A%8   +EA<+<R5VGC<=5GO9'(VJ]&A2K,66
MS<NVYF5ZM6O&G;)-8GD9%$Q/VSW(A;%4RH?-[O)[K=LR\==78_\ P2E--C^'
M56U%O[IM,:Z+*:I8QR*B5ZRN=B\5(OOI;+<E.C6PQ5Y;&AZ2;>JV=B6Y-FC<
M5I7#71V6RU4(+VOC)K7=A&4M.!T'1CH_;M3-JQ*M4I/>MLTU55,=-^Q\O%1@
MOA3<8\-=5[:^2NZ -+@-PZJ8ZVR"?6^HF5LMK3(QHCN2^^%'182K-MN^AA&/
M=48]-FV;26+:-1)FH>GC&_(=&-^529&PJ#M#/MRK[<BZ6_;;)SF_6^22[HQ6
MD8KNBDEP1=/9NSZL2BK&H@H54P4(1]2[V^^4GK*3YRDVWQ94C83(H]_QG2./
M?N^+VEPCC_2>,]I4C83XHSI%&7&./Q^( [1,)L;/E.L;/S$V./QZP#O%'X_&
M36,.K&$R-FWCQ\8!RQGH3Q^;V^DEL9Z$^7Q\QPQGJ^,E,9\@!RQGR$AK=_@#
M6[_ 5T3< X:GH0D,9^D-9V%1$W^  )ZD^-3NB'9$.W=W=J@#9$[^_P!1SMOV
MK\AV1IV !RB;G9K=RHB&-0=4:=P!I_WX   R
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M!6.[%*+5]'J.^X!(!PBG(0
M
M
M
M
M
M
M
M
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M8[(@!P548<HW8[&.8  ,H
M            '56[E)4V*YPJ;F 4"GW=_<5G-V.ID%%6_(4E;Z4*W<OL4X5/
M5W $=4W3\*$=S=B6K?2GZ3HYO9[/P $!S?D(SV_(I/<W8H/;\@!;'L(KV>OQ
M^0N;V>@BO;ZP"T/9^DA2,\>HO$C=_'SD&1GYP"SR-_.098_'CU%XD807M_,
M625A D9\WX/SE[E86V5GC\0!99&;?'^?Q["$]A=YF?/^$@2-^5 "U31HJ*BH
MCD5%:YKD16N:J;*CD7L5%3L5/2FZ+NBF ;Y;#H&)P=XF+G<#4='H3B"^UEL.
MYC?V#$9QK^LS>GG*QC61-8^2/)8UKNV:E9EC8LCJ%E69_3T/C?IV=$C%<;.&
MNH-"Y#J8;=R!;>GLE,W_ *)U#4:Y^,NH]$5[(EF_P>WR=KZ<T[%:]%Y'=AT(
MZ2O9F;"R3?N>W2O(CQ^]MZJQ+XU3\M=[6]'AO-G%=/.BRVK@3JBDLFK6W%D]
M/OD4]:V^Z-L=8/N3<9M/<T-9H#^DUGH[*Z=S&4T_G*4V.S.$R%O%96A.B)-4
MOT9WU[,+]E5J\DL;N5[%<R1BMDC<Z-S7+_-EMH34DI1:::337%-/BFGR::XI
M]Z*:RBTW&2<91;C*,DTTT]&FGQ33X-/D^  !]& <.3=-O6<@!F;UYO=TV7:X
MX?W>&&=N.FU+PY9"[%OF<KILEHRY(K*+D<J[OEP5U78N=&M3DIS8F1[I)9Y7
M-R)8W;_"GCQ[?FUC/04Z5%W@QQ1TMKVMUSZ6.MI4U!4A]\^]IR_M7R]=L?\
MZ65E=5M5HMV\]FO$Q'LYE<FS$TKJBAFL;CLSB[4-[%Y:A3R>.NUWME@N4+]:
M.W3M0R,W;)%/7FCEC>U=G,<BIV%7^LSH[[BSNWKCI1F;UL4EPC:M.VAPY:MJ
MQ+1+2>D>$66PZJNDWN[9RHMEKDX6[3/5ZRG3I[Q9QXOR4ZY/GK7O2XRX_P!G
M"_<N$3BRQ.V5"YL<1N2@7J%Y<(W%FB=X]I<HG %VB=X]I/C=W%HC=X]I<8G
M%UC=Z/'L^0F1J6V-_9X^/U_"3F.[E +@QWI)35[2!&I+:O8 3.]/@_ 544H,
M=Z2JWTH 5]^U%]94*3>U-OC.[5[ "NQ3N46KVH5C'_\ @  ,@
M
M
M
M
M
M
M
M
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M/:5-@B;'9$!G4(FY61-@B;')@P  9
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M9KHKV(MC&QL>Y(GR([C^G.P?W0V==7%:W5+MZ/%VUJ3W%\Y%RK\-91;Y':=
M.D3V;M.BV3THN:Q\A=RKMDDK'\U/=L??NQDES-E4QW87*%^_CQ^DL5.U'+''
M-#(R6&9C)8I8W(Z.6.1J/CDC<G8YCV.1S7)V.:Y%3L4ND3ORIX^8J.7,+S$X
MN<+O'X2S1J7&)_C\(!>(U+A$_N\?"6F-WCV$^)P!=XW$Z-?'L_1VEJC=V%PC
M=W>/@ +C&OS$UB_.6V->WQ\1-8O9\ !-8OH)"+W+\2D1J]RDIOJ *Z*=T[%V
M*+5["KOW+\0!5*Z+V% J,4P^0*@ ,I@
M
M
M
M
M
M
M
M
M               ,%)ZE-5[#LJE-Z^CUA Z>CX2D]?1ZRJ[U>HHKW_ @!T>[
MYNPB.7L*S_01GJ 4'J0I%\?,2)'=_P Q#D4 C2N\?-^<@2N)4KNWV%NE=^4
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M[?D .R)M\*_,=FIL<-3TG< Y1"LU-CAK=CL8Y@  R
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MO:J'< D X:O8<F$  #(
M
M
M
M
M
M
M
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M!V1#NB;_  ''L0J(FP!R5&-])U:G:5C#\/\ O0  &4
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M#N4F+VE4Q_W_ -_D  !D
M
M
M
M
M
M
M
M
MHO7M*Q051J#H_N*:]R)\9W?^,Z.7M *2]Z?*4'K\Y55>_P"0CO4 H/4AR+W^
M/82GKWD*10"+(I"E<2WK^ MTB]X!$E=X^ MSU)DSOR%OD=W@$*9WC\!;)7?D
M)TKBVR+^4 @SN^;\9;Y%]!*E7?Y57\?XD+?8F1B.>]=F,:KGKZFM3F<OMV1-
M]O9\0!AO^<P=(5<CJ[07#&E9<M;3.,NZKSE9C_V-^8SJQTL,V9FW[MC\34NS
M0N3_ -'G9&][5VQASZ[Z>_'MW$WC%Q UDD[;%/(ZANUL1(QW-$N&Q;UQN,=
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M0#NU/3\A5:GI.J)Z#NO?LG< =F)Z3N"HQ/2&P=VIL<@&$  #(
M
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MH+7DK)$:=:^Q/=>R;+(KWW"DLF'BX13C='7P[.3GPYRKB87B X0Y+2E2D
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MN1RNB@'(
M
M
M
M
M
M
M
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MX>PJH@!W;Z_45&=WPG1?0GJ*H!RB;E9#JQ#N8  !D
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M^JI09ZBKZ/@4 K%5B]A11>PJQ^D J  )@
M                                                          '&
MX!R#CQX[SD  X.0
M     <*H!R#A#D  X&X!R
M
M
M
M                                 #C<* <@'"@'(.-SD
M                                 '" '(!P <@Z[J=@
M                                             "F_T%)3N[O*3^X
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MQ.Q/'>2V)\P!W3O3V%9J>GU%-O<5/1\(!W9Z_6=T"%1B>D J( #"  !D
M
M             !@H.393HY.PKO3L*0!27M3?XBB[LV4K(G>A35-T (ST[",]
M"8OYB,Y.] ""]OSD%Z>CQ[2XO0B2)X^8 MDK2WRH761/'S?D+?(G8 6B1/F(
M$S>_QWEUD0M\K>SQ\0!9I4W+=,WYTV+O,GY2V3-[/@4 M4B=GCT?F(+T^<N3
MT[T^/Q\1 D ,4GSFW@FLF.X8<1Z\:K[CNY;1&6D1-TZN_#]7<$JJB>]:R6CG
MF.<[L<Z>!K=EV1^) ;%;RQ'!7]7/1XXAX^*%9;N(Q\&J<:C&<TWNS3EJ/)<D
M&W:C[%>*Q4>OIAL2M[.;=-=0UR*B*G:BHBI\"]REF^JC:7;;+53?E8MUE7KW
M)OMH/V:SG%>J!5/K@V7V&UG<EY.917;KW=I6NPFEQ[HUUR?!<9Z\6V<@ DTB
ML   ^LN@?QD3A]QGX9ZODD2&KB=7XEF1E541(L1E9OJ-F)5W]Z[J<9D+4R-<
MJ(YT;??,79[=G7RJURM7O153XT7\6QJ7+#.:-[?^LQS?E14-HKT1>+'ZN>%W
M#[5ZR==-G](X*_;EW3]DR#J$,63=NB(BHN0BLHFR)V;=B=R01URX/E8.2ES5
MM$WZDXV5+_>N+!]1VT/)S\1OE*G)@O7)2JM?^Y2N"]O<?3,2_,OZ/PETB=^)
M2SQKV_-^(N<2]Q!Q/I=X5\?"7.->XM$2^/@+G&O8GCV@%TB4N,2]J%JB7\1<
MHU[@"XQKX^?\&Z$Z->[V$"-W=X]9,B7\0!<(U[23&I$8O<2F=X!):O;\*%9O
MI0H)Z/'I*[5[0#NQ>SY?PG@5YPMTK^(O"+A;I/.\-=5WM)9>]K./&W+M&KB[
M4EBB[&6Y5K/CRM#(0(SK6,D1S(F2(YB(C^57-7WU9Z?A4QA?.H_K+Z(^^!#]
M$WCI^A=,+-J85=D(60E<E*$XQG"2W9<)1DG%KU-')]/,FRK9&T+:ISJLA0Y0
MLKDX3C)2CHXRBTT_8S&%_OWG2O\ MUZA_F;1G_+(_OWG2O\ MUZA_F;1G_+)
MY7 M/_X;V=_H_!_HF/\ Y94O_P 6;4_TCG?TJ_\ QGN=T8O."^D)H_6N&S>N
MM993B-I&";JL]I6Y0TW1EN8^;9D\V-MT,3C7PY:JS>>@EBRE.:9O46NKBD6:
M+85<$>-NF>(VE,)K71V4@S.G-0T8<AC+\*.;SQ2MW=#8@>C9JERL_F@N4[#(
M[%6Q')!-&R1CFIJ!SW4\B=Y6F_P U:W2NK+DMGA%JNXQN7ADYI':1RTW+'%J
M?&[(KVTW;,AS]!%ZJ:MR9"!([521EV/^GG5_5D4>Z,"BNK(IB]:::XUQOK6K
M:4()1[6/%P:2<UK!ZO<W9$ZO>LB['R/<^T<BR[&R)+=NNG.R>/:](QUG)M]C
M+E-/A6_?."W]=CX"TX+/4LI2J9+&VZ]['WZT-RE=J2LGK6ZMB-LL%BO-&KHY
M89HG-?'(QRM<U45%V+L5R:TX-:-<&O LVGKQ7%/DT  8,@
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M7--/BFO D6,E))IIII--/5-/DTUP:?<P #Y/H
M  'SQTBNECPWX38CZM\1M98'25!W/[F3*WHHKN1DC1%?!B<8Q7Y'*V6HY'+7
MQ]6S*UB]8YK6(KD_2FF=DHPKA*<Y/2,(1<I2?@HI-M^Q'Y7WPJ@YV3A7"*UE
M.<E"$5XN4FDE[6?0Y2GG9&Q\DCVQQQM<]\CW(QC&-17.>]SE1K6M:BN<Y51$
M1%5>Q##VZ7OG3]&O[IQG!'17U2F]]''JO7+9ZV/8NZ<LU33E&>&_<14WY?=F
M1QJ-=RO5DS>:-<:+I'^4OX\<69I7:XXFZDOTY'N<S"XV>+3N!@8N[6Q1X? 0
MXZD]L<:]5UUJ.S;FC3>U9L2*^1\D;'ZJ]HY*4[]S#@^ZW65VGS4.7LLG"7J(
MOVWUO;+Q6X8_:9UB_ Z1I7_O3X2]3KA9'\9&Q>Z0GE7.CWPO6:'5W%'3<%^%
M-WX?$3RZCS7=[U/J5@(LC=1'.]ZCWPMB1VZ.>U&O5OB_Q@\ZVX7X]TT&AN&V
MN-3OCZQC+N>LX72F.E<BJV.>NR&UJ#)R5W)ROY;=#&V%[8W1Q+[],%AC$3?9
M$3==U[-MU7?=5]:KZ57M5>U=^]:A).SNJ39M23OE?DR[]Z?95_5&K2:^NV1%
M^T>N7:ES?N>&/BQ[M(.ZQ<>^=OD/AIRJCWOO6F3IQ+\Z?XT9+G;IG1>A=,L]
M\D<EEN4SLZ(NZ-61)K%.!SF[IV,C8URHJ=RGQ#K;R_\ TJ\T]SX^(T."YG*O
M+@=-X&NQN[D=RL3(4LGLU-N5$57+RJJ*J]Z>-(.KQNA>RJO,P,;^?6K7^6US
M9QV5TYVQ=Y^T<KN^]S['EZJ56O;PX]YZ"ZB\J]TE,JKUN<:]>JKV.C=[CRK,
M9[U[G/=RIBZ])&.YG+M(Q&R-39K7-:UK4_@$\HAQ]^W7Q4_TZU%_;SXY!MX;
M'Q(K2.+C17A&BI+\BBC3V[9S)O6>7E2?C+(M;_KF?9U3RC72 AE9-'QKXH\\
M;D<WK-:YV=FZ=W-%/<DBD3_W9&.:OI0_6]->6-Z4.'V]Q<:M7JB(J<MY,-E4
M5KGMD<B_53%7'*JN8B(Y')(UBN8QS&.<B^:P/FW8N'-:3Q,:7RL>J2_K@?56
MW,ZOC7FY<'XPR+H_JFCW3T%YQMTHL*C&6=2:;U%&G5]9]6]+TW32(Q$:O[-C
MI:"1NDVW<YL2IS*JM8B;(GWYPM\Z^UK4=#'K+A1IW,PM3:6?3V=O86W(O9[_
M )+]7*UD5%W7E:UK51&M]ZJJ\Q, :7*Z"[)NUWL&A:]]<94OC\U*'U>!N\3I
M]MFC3<VC>TDEI;N7)Z?/1F_:]=7XFP;X&><[]'G4SXJNJJFMN'5MR1H^QF\+
M%FL(LKUVY(,CI>UE[J1M7;GL9##8V%J*CWN:Q'JWVJX'=+GACQ*K):T%KS2V
MJHUY45F(S%.S9C>YJOZN6HDGNJ*5&HO/%)"U[.54<U%134=%RPF;O8RW'?QE
MVYC;T/;#=Q]F>E;B7=%_8[-9\4S.UJ+[UZ=J-7T'';3ZH,*:;Q;[L>7=&6EU
M?U)[EBU\79+V';[+ZZLZK19>/1DQ[Y0UHMT]JWZWIPX*N/K?AN/@:T;HM>7K
MZ2/#&:I!+K#^Z!IZOU;'Z>U[79EE6!J<BLJ:AA2MJ2I*V+9E?K<G=H5U8Q78
MV9B.C?E#]#KSE#@KKWW-C>(#+/"C/2\C'39F7W=I2694]\L>H:\3/<4/,J-2
M3+5*3$3F?+)'&WF6,]M=6^T\-.:K654N._C:SDE^-4U&S7QW8SBN^1*NP>M'
M96<U!VRQ+7II#*481;\(VJ4JGX)2E"3[HF1D"QZ;U)CLQ0J93$7Z64QE^".U
M1R.-M07J%RM,U'Q6*ERM)+7L02L5'1S0R/8]JHYKE1=R^'!--/1K1K@T^:?@
M2(FFDUQ3XIKBFGR:  ,&0                          #A3'(Z6?G'FA.
M$O$G5_#;)<-M9Y>_H_*-Q=K)X^_@(J5R1U*I=ZVM':MQV&1HRVUFTK&NYF.7
M;E5%,C@U<OEF_LI^-WW7Q?0.&)#ZN.CV+M'*OJRH.<*\=V12G*&DNUKCKK!I
MOA)\'P(WZS>DF7LS#HNQ)QA.>0JY.4(S6[V=DM-))I/6*XF2W^NQ>&WVI-?_
M ,YZ8_MP_78O#;[4FO\ ^<],?VXP;@3%]R[8_P" G^GN_P 9"/W6MM_AZOZ/
M3_A,Y']=B\-OM2:__G/3']N'Z[%X;?:EU_\ SGIG^W&#<##ZK]CK^(L_3W?X
MS#ZV]MI??ZOZ/3_A-KWY/_IK8GI \-<=Q+PN$R>GJ&2R69QL>,R\U2>[&_#9
M";'RR/DHR25U9-)"LD2->KD8J(_9>P^U3P6\VR^Q4TO]U.N_ZS7CWI*Y](,2
MO'SLRBI-5TY-U<$VY-0A9*,4V^+X+F^)9WHYFV9&!AY%K3LNQJ;;&DHISG7&
M4FDN"6KY+@@ #3FZ                        .%4QUNE]YPWI[@KQ#U#P
MYU=PAUS]5<#8;U5VID]/KC\QB[+5EQV8QKY[$,CZ=ZOL]$>QLE>=D]69$FKR
M(9%1CD><3^3D?Q3X<-XF:5QZSZ[X:UI[5FO5B?+:U#HU567+8YD42*^:]B%1
M<QCFM8^26.*_18U\MNNL73]$:\&S-KIVA!RHN][4U9.OL[6_>Y-QDM8M^1+7
M@MY2U2BSE.F=FT*\&V_9LU'(H]\<'7"SM:H_?(Q4D])QCY<-/.W7#1N2:^=_
MUV+PV^U)K_\ G/3']N'Z[%X;?:DU_P#SGIC^W&#8UR*B*BHJ*B*BIW+OW?*=
MB?ON7;'_  $_T]W^,KI]UK;?\HJ_H]/^$SD?UV+PV^U)K_\ G/3']N'Z[%X;
M?:DU_P#SGIC^W&#<!]R[8_X"?Z>[_&/NM;;_  ]7]'I_PF<C^NQ>&WVI-?\
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M/5_1Z?\ "9R/Z[%X;?:DU_\ SGIC^W#]=B\-OM2:_P#YSTQ_;C!N ^Y=L?\
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MB^<FV^+[RR'0[:=V9LS#RKVI775;\VHJ*;WI+A%:)+1)<  #GCI@
M 6+4^<;C,;D,E(QTL>/HV[SXF;(^1E2O)8=&Q7>]1STC5K57L1515[$4OI_
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MT(=IAY%=R2UE&+TLA\NN6ED/YT5ZC^F !J#<@
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M$A$[?@3YP"HB=R%7T_ =&_@[3NP [E9J=A2;WE<P  #(
M
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M<M]JP755T^U4-EYL^*TCAW3EJY<7ICSD^]<.Q;?%>]<U!/*;!QN<D'D_
M                    &*EYV#]:GA7]\J?^J><,%PSH_.P?K4\*_OE3_P!4
M\X8+A:+JL]$5?.W_ &DBIO6[Z:L^CX_[+  )&(Q!DS^:Q?7TUC][BU].XDQF
M#)G\UB^OIK'[W%KZ=Q)R'3ST1G?,_P!^!V75YZ;V=\]+[*9GT@ J,7.
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M\4Y*+X;VJ>EM>C.W/W1PJ<SL;*.V3?9V::^3)Q<HOAO0DTW"3C%RCH]W1IL
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MO6F#>=&/26S_ *=B?VBLY[I=Z)VG_P"GYO\ 9K369@ N84@
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M*^-;G')KCI&<8):N^*\FN6KT4XZ0G)J.Y%Z;WO2 ")29
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M .["J=6)V'8QW@  R
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M)C,&3/YK%]?36/WN+7T[B3D.GGHC.^9_OP.RZO/3>SOGI?93,^D %1BYP
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MJ==_UFO'O24ZZ6^E-H?3,G[61=[H=Z)V;]"QOLH@ '/'2
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MB]'IXI\T^36C7!EV<#.JR::LBF2G5="-D)+OC):KV-<FN:::?%  'E/6
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MFVL%Y6'EXT9*$LC&OHC)IM1=U4ZU)I<6DY:M+CHC3Q]OL';[#:\?WM'HX_\
ML_\ !+_53H3_ ("/[VCT<?\ V?\ @E_JIT)_P$G+[LF+_(\C\^K_ )$!_<-R
M?](4_H;/\PU0_;[!V^PVO'][1Z./_L_\$O\ 53H3_@(_O:/1Q_\ 9_X)?ZJ=
M"?\  1]V3%_D>1^?5_R'W#<G_2%/Z&S_ ##5#]OL';[#:\?WM'HX_P#L_P#!
M+_53H3_@(_O:/1Q_]G_@E_JIT)_P$?=DQ?Y'D?GU?\A]PW)_TA3^AL_S#5#]
MOL';[#:\?WM'HX_^S_P2_P!5.A/^ C^]H]''_P!G_@E_JIT)_P !'W9,7^1Y
M'Y]7_(?<-R?](4_H;/\ ,-4/V^P=OL-KQ_>T>CC_ .S_ ,$O]5.A/^ C^]H]
M''_V?^"7^JG0G_ 1]V3%_D>1^?5_R'W#<G_2%/Z&S_,-4/V^PY[?8;7?^]H]
M''_V?^"7^JG0G_ 3'&\Y5Z)O"OA]PIT/DM!<,^'VB,C<UXRG;R&D=%Z;TW>M
M4_J'DY?<EBWAL;2L35>M8R5:\DCH5D8QZLYF-5-IL7K0Q\W*IQ88UT)73W%.
M4ZW&/!O5I+7N[C3](.J6_9^'D9DLRJR./#?<(U61<EO*.B;FTN>O(PP@ 2BB
M)4]0 #)DX5=CCM]AZQ^1&X::;U?TDM"X#5NGL'JG W8<][LPFH\1C\YB+:Q8
MFQ)$MG&Y2O:IS+%(B21.DA<L<B(]BM<B*FP4_O:'1P_]G[@E_JIT)_P$C[I3
MT_IV7D1Q[,>VV4JHV[T)022E*<=-)<=?(;^LD?HCU;W;7QIY->571&%TJ=R=
M<IMN,82WM8RCP\O33U>LU1';[!V^PVO'][1Z./\ [/\ P2_U4Z$_X"/[VCT<
M?_9_X)?ZJ="?\!.:^[)B_P CR/SZO^1U7W#<G_2%/Z&S_,-4/V^P=OL-KQ_>
MT>CC_P"S_P $O]5.A/\ @(_O:/1Q_P#9_P""7^JG0G_ 1]V3%_D>1^?5_P A
M]PW)_P!(4_H;/\PU0_;[!V^PVO'][1Z./_L_\$O]5.A/^ C^]H]''_V?^"7^
MJG0G_ 1]V3%_D>1^?5_R'W#<G_2%/Z&S_,-4/V^P=OL-KQ_>T>CC_P"S_P $
MO]5.A/\ @(_O:/1Q_P#9_P""7^JG0G_ 1]V3%_D>1^?5_P A]PW)_P!(4_H;
M/\PU0_;[!V^PVO'][1Z./_L_\$O]5.A/^ C^]H]''_V?^"7^JG0G_ 1]V3%_
MD>1^?5_R'W#<G_2%/Z&S_,/%/S5-?_,KKS[Y5K^K^$,H8_*.$? ;0W#^C8Q>
M@]&:4T3C+=I;UO':1T[B--T;5UT4<"W+%3#4Z5>:TL,44*V)(W2K%''&K^1C
M43]7(7Z1;4CFYN1E1C*$;I[ZC)IRCY*6C:X=Q.71C9$L# QL.4U9+'KW'.*<
M5+RI/5)ZM<'RU  -*;T         '\!Q7_@MJ7^0,S]'63^_/X#BO_!;4O\
M(&9^CK)^E/GQ^5']:/SM\R7R9?J9I\Y_W23^,D_IN*15G_=)/XR3^FXI%Y"@
M,.2]B_4  #Z(M[]PF_BI/Z"FX X!?P$T5]R6G/H>F:?^]^X3?Q4G]!3< < O
MX":*^Y+3GT/3(1ZZ/O>SOEY7[..3YU&>?M/Y.)^O)/UH $"EA
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MZ(_N9A=I='3+RU&RY/G5#3WJCU.*>]8OPDG'5J$6  1Z22
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M2M_5-$UB=WQ?,A<84_)^(@QIW>/47&+N3VJ<F=B7")/'P%TB_$6V$ND2=GS
M$Z)"XQ=WR$"/\A<HT^=0";'W)X]"$YG?\I#C\>/B)T?X@"6SN)C4[2)&G<3&
M=X!73N^'8K(A1_ZOCTDAG> =D[_'P%0Z,]*^TJ(G: 5D.0#$?^(  ,@
M
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M/GJ]7&,-*@]8/32>ULIQKE)85$G&B')626J>1-=\I_ 3\R&BT4G/4 #O"/P
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MREST:U+,]'>A6S]F17N:A.WX61;I9?+Q\MKR$_BUJ$>_37B  <P=6
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M4G]!3< < OX":*^Y+3GT/3(1ZZ/O>SOEY7[..3YU&>?M/Y.)^O)/UH $"EA
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MA)#/3\!13O\ B_(54[E\=X".[.XJL[RFSN*K "J #"  !D
M
M          %)Y37N*KRF87) I+W(4'=Z%;?L^,IN]'PF01G]Q&D]!+D]/P_C
M(KP"#)Z2%)X^4GR>GQZ"#)W+\/XD_( 6^3O+;,G>7.7O+=.G?\?S %ND3O\
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MIIR@VFE-*3BW%Z:22DG%M:I--,[  _0^#KMV[F2MY!3RO\G"?-U^$O$;*_\
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M'[W%KZ=Q)C,&3/YK%]?36/WN+7T[B3D.GGHC.^9_OP.RZO/3>SOGI?93,^D
M%1BYP                 !PJF$1YS7Y0^7,YRCT?]+WML1@9:V;XB/@<N]_
M.*R.Q@L!*YJ]E7$P2?5:[ ]')/?L8UZMB7'-=-E4^4%Z6]'@=PBUGQ&MMCGM
M8;&218&C*J(S):EOI[DP5%_:U>HDOR12W%9O(RC#9DB;)(QL;M5!K'5^4U%F
M,KJ#-W),AF<YDKN8RUZ;EZRWDLE9DN7+#D:B-;UEB61S6,1K(V*D<;6L:UJ2
M]U4=&^WOEM"V.M>-+=I37G9#2;EQX>\Q::_'E!KC%D*]</2AT8\-FTRTMRX[
M][7..,FUN_\ O3BXM=]<)Q:TFC^= !8HK2   #TN\F/Y,G6'25UB[$XETN%T
M=A9:\FL=9/KI-!B:\RJYF/Q['JV*[G[T3)%I4W.ZN&-%N6U;7:U)?P?H/]#;
M5?'CB-A>'FDH=I[SUMYG*RHON+3VGZKX_JEF;KT:]&L@8]D-2'E5]S(3U:<;
M5?+V;0CHF=%?1_!C0V'T!HC'1T</BHU?--RM]V9;)3-8E[,92=$Y[>1O/C:L
ML\KGN;%'!6C5M>O#&R-^G_3=;-K5%#4LRZ+W==&J(/AVLHOG)\57%\&TY2UB
MMV4F]770-[5M]T9&]'!IGI+36+R)KCV4)=T%P[647JDU".DI;T)_1CZ+FB>#
M^D,9HC0.%APV"QD:(B(Y9KN0M.1%L9+*W9-YK^1MR\TMBQ*J)S.ZN!D-=D4,
M?T$AR"L=UT[)RLLE*<YR<ISDW*4I-ZMMOBVWS;+7440JA&NN$85PBHPA!*,8
MQBM%&,5HDDN"2X(  _,_4
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M&E%Q;36C3::?--<&G[&7/C)22DFFFDTUQ33XII^#0 !@^@
M :N7RS?V4_&[[KXOH'#&T:-7+Y9O[*?C=]U\7T#AB7NIO^'Y7T-_;TD,]=GH
M[%^F+[&T\R0 6**R@ 'S/D?,^1L9_-L?L5-+_=3KO^LUX]Z3P6\VQ^Q4TO\
M=3KO^LUX]Z2G72WTIM#Z9D_:R+O=#O1.S?H6-]E$  YXZ0
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MIB0><W^4+?A<%C^ .E[ZQ9'4T4&9X@35G[30:;CD<_&:><]OOHOJY>B9<O\
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MOG9+G5%KWN.DVM]Q[,AR 0J3N
M       >3GER=;+@NBMQ?E9*D4V1P-7!1>^:WK&YK+X['6HDYE17+)0GMIRM
M1SE3?9-MU36(IX\>/@-C?YR%DI*_19U,V/EVM:DTC5DYDW_8Y,LQ[N7U.WC;
MV]NR;]AKD$+(=4%6FSK9_'R[/]VJE?\ '^LJ[UU7Z[5HK^)A5O\ /NO?]TY
M!+!$(/TO@MPS?K76>C]&1O?&[5VJ].:726/]O F?S%+%/L(J-?R^YV6W3.>K
M'-C;&KW(K6J?FA]L>38FJ,Z0?!9UYO-7_NE:3;LJ.=_A#\I RFNS51?>W'5W
M(O<U4YG>]13R;0N==%]D?.A39..G%ZQA*2T7M1[-G51LR,>N6F[9?5"6KT6[
M.R,7Q7+@^?<;63"8>KCJ=3'T8(ZM*C6@ITZT+4;%7JU8FP5X(F)V-CBB8R-C
M>Y&M1$[BZ'5/2=BD;>O%\R^:6G!<$@ #!D
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M/XR;'Z/'I(4?X_RD^/T $QA(9W$=G<2H_0 5T[U^([^A?B_&4V]ZE7T?'^(
MJM[D*L?I*2=R%6/T@%0
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ME6'CTXM$=VJF"A%=[TYREISE.6LIOODV^\  \)L
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MVA],R?M9%WNAWHG9OT+&^RB  <\=(
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M.&"*.&&&-D4,,3&QQ111M1D<<<;$1D<<;$1K&-1&M:B(U$1-B0 58+=
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M8OBFB\G1W;5>T,*C+K:TM@G.*_B[5PLK??K"::]:TDN#3.0 :<W0
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M ! %5.Y"K'Z2DG<A5C](!4
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MZ>/2 3HN[Y"='Z/'H(,7=\A.C]'CT $IG>2/^KX])'9WDA/0 5V=YC"^=/\
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MM":U<=,6EZ<FU&RYKUZ.J/BDY+E([@ @DL(
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M*4FY2D^+E*3U;;[VV]67@JJC",80BHPA%1C%+11C%:1BEW))))>  !\'V
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MLB[W0[T3LWZ%C?91  .>.D                                    ,
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M^^K&^?OB791]BJ4.'QG)][  .")#
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M5145%0JG%G<@
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M0
M                             -0=7]Q1*KRD$P4$[E.COPJ5/1\?XBF[
MT?" 4I/3X]!$?W$F3TD5_< 17]Y;Y.Y?'K)TB]Y">OX?Q $"7T>/0A;Y5_&7
M"5>TMTWY0"W/[RVS+V>/67*3O+9, 6Z;\?XBU2]R_$7.9?QEKE]'P_B0 A2]
MY$;WM_[S?QDJ;T_!^4M\LO(BO]#$5Z[]G[1-^_T?#Z #6)]-S).M\9.*<[^7
MG=K[5$:\G8W]@RUFNW;M7MY8DYNW]MS;(G:A\P'Z]TA<LV_Q"U]?9R\E[7&K
M[K.1W.SEMZBR5A.1^R<S$21.5VR;MV543?9/R$NYLZ&[CT1TTW::HZ>&D(HH
M9M*6]DY,M==[(NEKX[ULGK]>H ![#Q X4Y.%,,P^1L&?(-461=%CAQ(W?FMW
M=?6)=U[Y&<1M65&JU-DY4ZBK"FW<KD<[?WVR>QD79R^/5^0\L_(OXE:71AX2
M0JYCNLPV7N;L3E1$R&J<]?1JI_UV)91DB]SI&N=Z3U,9WM\>LIITGGO;2V@U
MQ3S<IKV=O9I_47CZ*Q:V7LY-:-8&'JN>C]SUZK7VEPA]'Q%TB]'QEL@3N^+Y
MBZ0FC-\7*+N^0N,/H^(M\:=A<8N_Y "X,[BXQIVIX]);X_QEQB7YD_* 3(N[
MY"='Z/'H(4:=A.C]'P $EG>2&^CXR.PDIZ/C_  54_+^ QAO.G_K+:(^^##]
M$73)Y3\OX#&'\Z?^LOHC[X,/T1>.MZ">E\#Y[^Y(XSK#]";2^C2_:B8&P +=
ME,@  #*,\U2^N_Q$^X*M]-0F>(8'?FJ7UW^(GW!5OIJ$SQ"K/6AZ8N^:Q_LH
MEMNJ7T)C_.Y/V\P<*AR"/22C'W\N5Y(N#CIIF77>A\?"WBWI7'N]RQ1=37=K
M7#54?,[3EN:1\42Y&)'2OP%JT]L<=A[J,TL-:TLT&O!R%"Q3L6*=RO/3MU)Y
M:MNI:ADKVJMJO(Z*>M9KS-9+!8@E8Z.:&5C)(WM<Q[4<BHFY%V,0_P X+\CL
M[.19'CWPNQBKF:==\_$?2]"!'.S%.!O-^J[%P1-YOJK2@1S,Y5:CTR-*.&[
MR*Y4MKDIEZM>F_8RAL[+GI3*6F-;)\*I-_>9-\JYOS'PW)O1^3+R(-ZT^@/;
MQGM/"A[]!:Y=,%QNA%??H)<[*UY\4M;(+5>7'2>% #JUR*B*BHJ+VHJ>E%.Q
M8),K@F#A4.09,GO?Y#WRMUK@-JE-%ZUR$TW"/5-MJ64G<^1NBLY.^-C-0TMU
M7J,39;S1Z@J-:D2_L65B6*6M;;=V*.*RM:]6KW:4\-JI;ABLU;5>1DU>S7GC
M;+#/!+&KF2Q2QN:^.1CE:]KD<U50TWVR&6[YOCY8-NG9\5P"XFY3EPEVRVGP
MWU%D)WJW$W;4G+#H^]8E5R1XZW.[EP$LCF1U+,OU,W2"6DR&%^LKH/VT9;1Q
M(>_16N35%??8I<;HI+[Y%+RTM=^/E>=%[\X=5G3[L)0V9FS2ID],6Z<OO4VT
MECR;X*N3?O;;2A+R--V2W,W0'"')7\L@         8J7G8/UJ>%?WRI_ZIYP
MP7#.C\[!^M3PK^^5/_5/.&"X6BZK/1%7SM_VDBIO6[Z:L^CX_P"RP "1B,09
M,_FL7U]-8_>XM?3N),9@R9_-8OKZ:Q^]Q:^G<2<AT\]$9WS/]^!V75YZ;V=\
M]+[*9GT@ J,7.               .KO1\)K2/+]\4':FZ4W$)G.DD.F8,!I6
M!S58K.6AB*]^9&JSL566LI/%(KO?I+&]KNQK39<&I1Z;VNEU-QHXMY_G62/)
M\2M;3UGKWK09J+(5\<BKSO3=N/AK-7E<K-VKR;,Y6I+W4[BJ6;DW-?>L907J
M=MD?^%<E]9"_79E[N!BTK^-RMY\><:JI]W>MZR+]6B\3Y> !8HK.  -094/F
MJG!9F2XH<0]>6(>9FE](U<!CY7LYF)=U/D6V+KH7*BHRS!2PD4:O39Z5\A)&
MB\DTB+G7(8Q7FL/#9,=P2U?J5S6\VIM?7(FN_P =(\%C:-)&=VZ,YY7N3;L5
MZO7X,G8J=UBYO;[7RWKK&J4*(^KLH1C)?I-]^ULN'U9X*HV+A<-';&>1+Q?;
M3E*+?%_Q>XEZDN"  .(.]
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MLS\K):_@^.H1]4[Y\]/D537AY7+EI]+  KJ69
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M?7IK^]K+$OQJ5VT?]ZM:>O0ZGH3F^Y]K[.L_^ZJJ?JC>^PD_8HV/7U:HV:8
M*>EUP               :N7RS?V4_&[[KXOH'#&T:-7+Y9O[*?C=]U\7T#AB
M7NIO^'Y7T-_;TD,]=GH[%^F+[&T\R0 6**R@ 'S/D?,^1L9_-L?L5-+_ '4Z
M[_K->/>D\%O-L?L5-+_=3KO^LUX]Z2G72WTIM#Z9D_:R+O=#O1.S?H6-]E$
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M3D/:5\/>,66[CIKA9D<W/CSC0M&FN#LE'1ZURBO[38Y *[%F@
M                         8MOG67UG.'WWQ6_U?RIE)&+;YUE]9SA]]\5
MO]7\J==T#],8'SW]R9Q/6/Z#VC\POM(&"" "W*Y(IG#D  9/H]E_(!?94\._
MXG4/T-9-ER:T;R 7V5/#O^)U#]#639<E;.M[TG5]$K^UN+0]2WHN[Z99]E2
M 142^                           #^ XK_P6U+_(&9^CK)_?G\!Q7_@M
MJ7^0,S]'63]*?/C\J/ZT?G;YDODR_4S3YS_NDG\9)_3<4BK/^Z2?QDG]-Q2+
MR% 8<E[%^H  'T1;W[A-_%2?T%-P!P"_@)HK[DM.?0],T_\ >_<)OXJ3^@IN
M . 7\!-%?<EISZ'ID(]='WO9WR\K]G')\ZC//VG\G$_7DGZT "!2P@
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M-_6V7SQZ8U5PK@M(5PC"*\(PBHQ7U)(  _(_8
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M1G"2UC*$E*+7BI)M->QG( /S/T
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M!(9W@)G=G<5&=Y285$7M *X ,+D  #(
M                                                       *<GH*
M9W?WE)_<$#HO<A1=WH5G>CX"@[O^+\H!0?W$:3T$EY%?W@$.1>\A2^CX?QHG
MXB9(OX2%)X_" 0I.\MDWCY2X2+W_  %NE7O (,B_@+9,I<9%[RV2K^, MLOX
MBVR+W?#O^'\A<)%[_@+;(OCXE7\8!!D]/CT'\WJ2Y'7Q]ZQ*]L44%*W-)*]R
M-9&R*O)(^1SG=C6L:U7.<O8B)NO8?TDGI/E_IGZR73O"#BIGFN1K\-PXUODH
ME5RMWGJ:;R4U=C51S%YY9V1QQHU[7.>]K6JCE0_?&J=EE=:YSG""]LI**_6?
MCDW*NNRQ\H0G-^R$7)_JT-8?=RK[]BQ?EYNMO3SW9%=R\W66Y7V'\W*UC>;F
MD7FY6M;OOLUJ=A&*,,?*UK?^JUJ>SL3;QMM\!6+P122T7+N__10777CQU;;>
MO-M^( !D X<NR;KV(G:OP')'MKM%(J=OO']B;JJ^]7;9$[57V(89AFS#\FEA
M%Q_1\X+57<R/3AMI*:5KU:KF37,16N31[LW:K8Y9WL:J*N[6INJKVK]TL]'P
M?C/Q/H\:6^HF@]%8=$V^IFE=/T=D5J[)6Q56+;WC6,[$;_BM:GJ1.X_;8T[?
M'PE)-H7=ID7V?A+K9_G3E+_B7UV?2Z\>BM\ZZ:H/3@M8PC'U^'BRY0^/D+G%
M^(MT/CY2YP^CXCQGL+C'W?&7"+\:$&/T>/27"'Q\@!<(_07!B=_P?B_.0(O0
M7&->_P"3\" $QG<3H^_XB"SN)S$[?@ ),?I)*=Z? 1V$GT_$ 5&^GX%,83SJ
M#ZR^B/O@P_1%XR>V^GX#&$\Z@^LOH?[X,/T1>.MZ">E\#Y[^Y(XWK#]";2^C
MO]I&!P "W93$   RC/-4OKO\1/N"K?34)GB&!WYJE]=_B)]P5;Z:A,\0JSUH
M>F+OFL?[*);;JE]"8_SN3]O,  CTDH'22-KFN:YK7-<BM<UR(K7-5-E:Y%[%
M14[%1>Q4[#N # >\O?Y'E>&&5N\9.&N+1O#K.7WS:IPM*/:/1.:R%A7+;JUH
MV(ROI?)VI5;%'%RU\+<>VFUD-&:HV/&0-Q7K+1^*U#B<E@LYCZN5PV8I6<=E
M,;>A98IWJ-R)T%FK9A>BMDBFB>YCVJG<NZ;*B*:VKRR?DJ\AT<-:,NX2.[>X
M5ZKLS.TGE9U=/)B+NTD\VDLI9[5=<J0L?-B[,VS\IC8WR;OLTKRI8GJVZ<>Z
M8QP,N?[X@O>+)/[_ %Q7F2;YVP2X/X<%J_*BW*L_6CT"]R3EM'#A^];):Y-<
M>6/9)K2<8Z<*;)/BE][L>B6Y)*/C2 "7R%P<+^#94V7945%W145.U%1>U%39
M47MW3O.0 9ZOD#/+#-XG8RMP;XDY)&\1,#CV_J8S5R1&KK;"4F-C=7EFD79^
MI\5"D;K$2KUN5H\U^!KY*>1ZO)Y0TZFD-89;3V5QN=P60MXG,X>Y!D,7DZ,S
MH+=&[6>DD%B"5O[5['HG8Y',>W=DC7,<YJ[)#R-?E4\=TC-#MIYM]/'\4M*U
MH*^KL5!M%#E(DVAKZIQ$#WN>VAD51JW*R*_ZF9!TM7G= ZK++7/K(Z#^Y9RS
M\2'[VLE[_7%<*+)/SHKNIF^[E7-Z<(RBE9GJNZ>^ZX1V?F3URJX^\6R?'(JB
MO-D^^ZM?79!;W&49M^SH (C)G      ,5+SL'ZU/"O[Y4_\ 5/.&"X9T?G8/
MUJ>%?WRI_P"J><,%PM%U6>B*OG;_ +214WK=]-6?1\?]E@ $C$8@R9_-8OKZ
M:Q^]Q:^G<28S!DS^:Q?7TUC][BU].XDY#IYZ(SOF?[\#LNKSTWL[YZ7V4S/I
M !48N<               4;%B.*-\LKVQQ1,=))(]R,9'&QJN>][W*C6L:U%
M<YSE1$1%55V0TV[\O-D'/R%C?W1?DDO3[N>]>NMO6Q+N^172/7K)';ND<KW+
M[YZJY54W"7%/*,HZ8U'=D:YT=/ Y>U(UFW.YE?'V)7-9NJ)S*UBHW=43?;==
MC3NXQ-JT"+WI#$B_%&TG;J7APVC+UXB_(LE_\5_45^Z\Y+79B[U[K??RE[F7
ML^#[?RLG  G(@ '"G)PIA\C#Y&R6\W>TJF,Z*>@YD8K?JQD-59955KF\ZR:B
MR%/G3F<[F14HHB.;RM[-D;NBJOMV>3OD,L>VMT3^#,;7*Y'X#)V55VVZ.N:G
MSMMS4V_Q6.G5C=^U6M17=NYZQ%,^DMCEM'/D^+>9D_;31>+HK4H;,V=&*T2P
ML71>VF#_ .( !I#?@                                          \
M1/.)L][BZ)?$:-O.DF1R6@\?&K6M<U$EUYIR>PDBN<BL8^I7L1M<U'.25\:;
M(BJ]GMV8^GG,T[V=&"\UKW-;+KS1D<C479LC&V[4K6/1/VS4EBCE1%_])&QW
M^*AT/1*&]M39R_\ O,=_FVQE_P #FNF5F[LG:3TU_>63%KU2JE%\_4S7=  N
M.4D   /TW@CI]V6UMH[%-:KUR6J].4$:B([F]UYBG#R\JJF^Z/[E5$]J&WZJ
MUHX(XX8FHR**-D4;$[F,C:C&-1/4UK41.TU,701J1S\<.#L,T;)8I>)^AF21
MO:CF/8[4F.16N:O8J.WV5%[%-M,0!URV-W8$?"J^7URG!?W2Q/497[QM&?C=
M1#U^3"<O#\?^H  A8G<                                 QGO.G](>
M[> &D\JR/>3!<5\'-))V;LIY'36K<9*Q=W)[V2Y8Q[O>M>[FB9V(Q7N;@(&Q
M<\Y4JQR=%G/ODC8]\&L-#RP.<U%=%([.0P.?&J_M7+!--$JIVK'(]O<Y371E
MF^J:URV3I\3*NBO8U7/]<V55ZXZMW:ZE^$Q*)>S25L/#PBO'_@  2:12#[M\
MEYFUQW2-X)7$YE2/B3IACD8C5>L5B^RM*UJ/][[Z.5R=JIV*NRHJ(J?"1]/=
M"-[F\9N%+FN5KDX@Z45'-54<FV9J=RHJ*G9ZE0UVUX;V+DQ^-CW1?L=4T>_9
M,W',PY+X.5CR_)=!]YML@ 4H+X@               U<OEF_LI^-WW7Q?0.&
M-HT:N7RS?V4_&[[KXOH'#$O=3?\ #\KZ&_MZ2&>NST=B_3%]C:>9( +%%90
M#YGR/F?(V,_FV/V*FE_NIUW_ %FO'O2>"WFV/V*FE_NIUW_6:\>])3KI;Z4V
MA],R?M9%WNAWHG9OT+&^RB  <\=(
M       >8OE:^@%2Z0W"'+Z7BCKQ:OPO/J#0F2F3D]RZAJ02(VC-,V.21N.S
ME99,9?8UKT1)H+B1OGI5U;K -0:>OXC(7L5E*<^/R>,N6*&1H66\EBE>J2N@
MM59V;JC98)HWQOV56[MW:JHJ*NXX4P9/.6_)Q+IC4L/'S2E+EP6K)Z^.U[5A
M;^QXW5/+U-#/-:UO+'6U!79%4NIV<N6K-LJLC\I*L,Q]5/2GL;7LZZ7O=S<\
M9OX-WPJ]>Y6I:Q7X1:):V$']</1/MJ5M2B&ME"4,I17G4?!M:2U;I;TD_P &
MVWPK,4L'"')81,K>  9!ZM>34\JSJWHX8_B1BL- _)T-;8&5<94DE;[GP.MJ
MT#ZN*U-'!+S1JGN65U;)Q1M1]YE3%]:DK<?"Q/++*92S?M6K]ZQ-<O7K-B[=
MMV'NEL6[EN9]BU:L2O5SY9[$\DDTTCW.<^1[G.5555(0/#1LVFJZ_(A7&-N1
MV?;37.?91W8:]W"/#@EKS>KXGOR-IWVT48]EDI4XW:=A6^5?:R4YZ>.LEPUU
MTY+1<  #W'@!RUCG.:QC7/>]R,8QC7/>][E1K61L8BN>]ZJC6M:BN<Y6HB;J
MAP9$'F\?DYO[K/$IW$C4U%)M!<-+4%F&.>-KX,]K5.KL8K'<CT5DM/#1+]5\
MCNBHL_U+K;/;8G6'5;;VM5@XMV3<](51;TX:SD^$(1_&G+2*\-=7P3-KL/8]
MNT,JG$I7EW34=[NA!<9V2_%A!.3\=$EQ:1DT^0C\G0[@7PG@RVI*,<'$?B"V
M#-ZF1R-?/A\:O._ :9ZWD:Y)*-*1EK+1M58DS-NW#')8@JUYW^XYPAR4\VKM
M.W,R+<FYZV73<WX17P81UY1A'2,5W12+L[(V55@XU.+0M*Z(*$==-9/G*<M$
MDYSDW.;22<I-I+D  :\V0                                    ,6W
MSK+ZSG#[[XK?ZOY4RDC%M\ZR^LYP^^^*W^K^5.NZ!^F,#Y[^Y,XGK']![1^8
M7VD#!! !;E<D4SAR  ,GT>R_D OLJ>'?\3J'Z&LFRY-:-Y +[*GAW_$ZA^AK
M)LN2MG6]Z3J^B5_:W%H>I;T7=],L^RI  (J)?
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MVKLZ/_WF/+GIYED9K^N)L>P<(<E-R[@
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M)*4)1?)QDM4UZTSD 'Y'[
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MG#^,M,:]GP?E+E"IQ9W9=H5+I$O86B)?Q%TA4 N<2_@+C&O86N%>[XRY1+^
M N4:DZ/\Q;HU[O'L+A&O;X]7Y0";&O<3&+VD)G<2T7N )2=WP*5T792@GI\=
MQ510"JU>U4]JE0I[]J+X\(5 "0B@X:O8<@
M
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ME9%>;-\$HRB5(ZPN@\MDW]K2I2P;I>\R?%U3T;=%CYZI)NN3\Z"XMRC(_"0
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M?^J><,%PSH_.P?K4\*_OE3_U3SA@N%HNJST15\[?]I(J;UN^FK/H^/\ LL
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M.&C  ),(J!]2]!FI+8XT\)X86.DEDXA:4:QC>USG?5BJNR)Z^Q3Y:/OKR5>
M^JG22X(TEC61K^(VGK$C$5Z*L-&RMV==X_?MVAK/55141J(KG.:U'*FMVQ/=
MQ,F7Q<>]_DJD_P#@;#9%6_F8<.6]E8\?SKH+U_J-JL "E)?
M   &KE\LW]E/QN^Z^+Z!PQM&C5R^6;^RGXW?=?%] X8E[J;_ (?E?0W]O20S
MUV>CL7Z8OL;3S) !8HK*  ?,^1\SY&QG\VQ^Q4TO]U.N_P"LUX]Z3P6\VQ^Q
M4TO]U.N_ZS7CWI*==+?2FT/IF3]K(N]T.]$[-^A8WV40 #GCI
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M[NNC^^<R*W$UHZL;76"7@[=%9+\7LUS3.0 162\
M                  #%M\ZR^LYP^^^*W^K^5,I(Q;?.LOK.</OOBM_J_E3K
MN@?IC ^>_N3.)ZQ_0>T?F%]I P00 6Y7)%,X<@ #)]'LOY +[*GAW_$ZA^AK
M)LN36C>0"^RIX=_Q.H?H:R;+DK9UO>DZOHE?VMQ:'J6]%W?3+/LJ0 "*B7P
M                          ?P'%?^"VI?Y S/T=9/[\_@.*_\%M2_R!F?
MHZR?I3Y\?E1_6C\[?,E\F7ZF:?.?]TD_C)/Z;BD59_W23^,D_IN*1>0H##DO
M8OU   ^B+>_<)OXJ3^@IN . 7\!-%?<EISZ'IFG_ +W[A-_%2?T%-P!P"_@)
MHK[DM.?0],A'KH^][.^7E?LXY/G49Y^T_DXGZ\D_6@ 0*6$
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MIENL#.JR::\BB:LJM@IPFN3B_P!37*47QBTTTFF<@ \IZP
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M&+W>/856>KU$>-20U-E4 K>A/8I512BWTH5&+V %9BE0HM7M*Q@  &0
M
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M^OIK'[W%KZ=Q)R'3ST1G?,_WX'9=7GIO9WSTOLIF?2 "HQ<X
M   X4U-?E -!/TQQUXQ8-S.K;3XEZREKL5-E91R.=NY3'M7M=ORT+M9.;?W^
MW/LWFY6[9136T><,\+'::Z4>L[:,VAU;C-.ZHC>B.Y'R38R/$SHBJB)SL=B6
MK*C=TYGHY55SU)<ZGLO=S\BE_P ;C;R^559'3_=G-_40UUUXN]L_&N7\5E*+
MY<(VUS7M\Z,5HOKY</$< %C"L@.%4Y ,-&=!YJ;Q-;<X9\1M)R2IUV"UE7R<
M$/9NE/-8N'FE7L141UJG,Q-U7]IV;=J)E8&O^\U[XZ1Z?X[Y[15F9D4'$/1M
MME-CW;.LYO24KLS5KQ-7]LY<+/J*T_EW<C*:]BMW5NP!*I]96"Z-KY#TTC>J
M[X^M3@HR?Z2$UW\O$M_U6[05^Q<5:^5CNS'DM=='7-N"YM_>I5O3AIKP6F@
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MCMZ>Z<=2CZYT2U2Y?$LL?-+R3(7 !7,LT
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MVWKL8Z>O6Q'5=!L/M]L;.KX\,JNUZ:<L?W]II]S5?'U:Z<3.Q !3\NL
M          #5R^6;^RGXW?=?%] X8VC1JY?+-_93\;ONOB^@<,2]U-_P_*^A
MO[>DAGKL]'8OTQ?8VGF2 "Q164  ^9\CYGR-C/YMC]BII?[J==_UFO'O2>"W
MFV/V*FE_NIUW_6:\>])3KI;Z4VA],R?M9%WNAWHG9OT+&^RB  <\=(
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M\M+RJV^Z-L?)?<I;DGYNAJMP4*\W6,8].Q'L:]$]7,U';?$B_F*Y;5,INF
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M-9-ER5LZWO2=7T2O[6XM#U+>B[OIEGV5( !%1+X
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MJR=<OE0DXO\ K1?3#R8W4U70\VVN%D?DSBI+EJN3  /.>@
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M3CU,])G"^S9=LO>[5*[&3?FVQ6];6O59!.Q)<$ZY-+6;,E0'"') !8\
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M7CY0"Y1J36.+?&I,8O8 3F+VE=%[OA(K5[E)*+W@$A%[2HG>ORE!J]A6W[E
M*A712@BE5BF&#N #(
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M=I6MVV*]<J]V:7A5)GNR " 2Q@
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MZ23]:::9>*FZ-D(V0DI0G&,X27%2C))QDO4TTUZ@ #\S]
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MW0[T3LWZ%C?91  .>.D
M !_"<4OX,:C_ )"R_P!'V#^[/X3BE_!C4?\ (67^C[!^E/GQ^5']:/SM\R7R
M9?J9IWL=^]X/XF+^@TF$/'?O>#^)B_H-)A>*/?[64"7-^U@ 'T9(M[]PF_BI
M/Z"FWVZ.GUOM"?<;ICZ$HFH)O?N$W\5)_04V^W1T^M]H3[C=,?0E$A/KG^];
M/^<R?V:2>.HW[[M'YO&_:N/V0 $!EB
M             8MOG67UG.'WWQ6_U?RIE)&+;YUE]9SA]]\5O]7\J==T#],8
M'SW]R9Q/6/Z#VC\POM(&"" "W*Y(IG#D  9/H]E_(!?94\._XG4/T-9-ER:T
M;R 7V5/#O^)U#]#639<E;.M[TG5]$K^UN+0]2WHN[Z99]E2  142^
M                    #^ XK_P6U+_(&9^CK)_?G\!Q7_@MJ7^0,S]'63]*
M?/C\J/ZT?G;YDODR_4S3YS_NDG\9)_3<4BK/^Z2?QDG]-Q2+R% 8<E[%^H
M'T1;W[A-_%2?T%-P!P"_@)HK[DM.?0],T_\ >_<)OXJ3^@IN . 7\!-%?<EI
MSZ'ID(]='WO9WR\K]G')\ZC//VG\G$_7DGZT "!2P@              !^><
M7.'-+6&E-3:2R/9C]4:?S.G;JHB*J5,UCK&.L.:B[;N;%9>YO:G:B=J=Z:@O
M4>EK^"R61P>6@6ME<)D+V&RE9V_-7R6*M2T+]=VZ-5%@MUYHE16M7=G:B+NB
M;C94-:!Y>CHYKP[Z2NMG5ZR08K6WN77.-ZMBLA63,L5N8:USD3GD^K->Y9L.
M3=$DM[<SE)FZG=IJ&1E8LG]^KA=#7XU+<9)>N4;-7ZJ^[O@[KMV7OXV)F17W
MBV=-C\(7).+?J4Z]U:=\^3[O&\ %@BN .%0Y!AH-&=AYK/TEV9OAGK#AA;FW
MOZ'SJ9C'1/=N]V"U,CY-V\R[\E?*U+L?)&U61I(QSG-69K3*?136 >1CZ7W]
MQGI!:,SMVVZKIC4<LNBM7(KG)#]2-0*R*I<E:B.1/J1GHL1DW2(QTB5:]RO&
MK$M/5=GZR1KD1S51R.1'-5%14<U>U%14[%14[45.]"KG6=L9XNTYVI>]Y<5?
M%]W:>;='V[ZWVNY61+:=5&W%E[*KJD];<)^YYK7CV:\JB6G/3LWN:]\JY'<
M$=DF
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M*#E%\.39M^@4H94>QCTV5'M:Y-N[9R(J;>SM*I2PO4
M                        4GE-4W*ST*0!27N3Y"BO>GR>/E*WH^<I._
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M 544 K-7L.[5[2EZ?8I4 ) .K5[#L87@  #(
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M:\.*?%,NUL+;5.T,2G+H?D6P3<==77-<)UR_&A+6+\=-5P:  -4;<
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MQ(Q:\]I5EZWNEBRLB.S:):TXLMZ]KE/)W=%%-<U3&4HO_62DM-8)G( )>(9
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MDGCJ-^^[1^;QOVKC]D ! 98@
M      &+;YUE]9SA]]\5O]7\J921BV^=9?6<X???%;_5_*G7= _3&!\]_<F<
M3UC^@]H_,+[2!@@@ MRN2*9PY  &3Z/9?R 7V5/#O^)U#]#639<FM&\@%]E3
MP[_B=0_0UDV7)6SK>])U?1*_M;BT/4MZ+N^F6?94@ $5$O@
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M<6$U)*46I1DDXR33336J::X--<4UP:  ,'T
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MK$<K-7<PS!V !D
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MSQ# [\U2^N_Q$^X*M]-0F>(59ZT/3%WS6/\ 91+;=4OH3'^=R?MY@ $>DE
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M])3KI;Z4VA],R?M9%WNAWHG9OT+&^RB  <\=(
M                   #^$XI?P8U'_(67^C[!_=G\)Q2_@QJ/^0LO]'V#]*?
M/C\J/ZT?G;YDODR_4S3O8[][P?Q,7]!I,(>._>\'\3%_0:3"\4>_VLH$N;]K
M  /HR1;W[A-_%2?T%-OMT=/K?:$^XW3'T)1-03>_<)OXJ3^@IM]NCI];[0GW
M&Z8^A*)"?7/]ZV?\YD_LTD\=1OWW:/S>-^U<?L@ (#+$
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M?T%-P!P"_@)HK[DM.?0],A'KH^][.^7E?LXY/G49Y^T_DXGZ\D_6@ 0*6$
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M6L1LF@L02,F@GAD:CXY898U<R2-[%1S'L<K7-5%151=R80&6+3
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MQWH*AA   R
M                     ='N]!\OP!T<IT5=CDZ.[?QGT#K[?64G+L=U4I*O
M;OZ$ .KNSL(SG;E1ZD=Z^@ HO<0Y%*[W?,1'N[ "/([QX]I D7O)$K_'CU$&
M5WCV@$65Q >[O)$KB!*X B2N+;(XE2N+=*[Y_'X "),_QX^-2!(XD/=W^P@R
M.^< H/=WF"QYPKTF/U7\:(M$T;'68?AGBH,;,C%_8I-3YJ*#*9I_,U=I/<51
M^*QFSF\]>W7R4;5Y9%,T+I"<9L;P\T3JG6^6>UE#3&$OY:5'=O6OJP/?7KM;
MNBO?9L=5 R-J\[WO1C-W*B+K ^(>NLAJG/YO4V5E=+D]09;(9J_(YZR*ZWDK
M4MJ;W[O?.Y7RJU'.[51J+V*3!U1;&[3*NS91\G'AV=;_ -=;YS7R:DXOYQ$)
M]=6V^RPZ,"#\O*L[6U)_Q%/%)^J=KBUKS[*6G)G\B@ +$%:P   ?87D_.!#N
M)?&GASHSE<^OD]1U[61Y6H]68C"1S9S*O<BM<WD;0QTZ*CTY7;HS=.=%/CTR
MDO-HNC<MK4&N>*]V%%AQ-"/1> >Y-_\ #,F^#)9VS&CF^]?%4JXZG%-&Y55M
MO(0/1J*J.YOI=M586SLJ_722JE"KQ[6WWNMKY,I*;7A%G3]#-CO.VIAX^FL'
M=&RWAP[&GWVQ/PWHQW$_C27-Z)Y@E:!D;61QL;''&QK(XV)LQC&)RL8Q$[$:
MQJ(UJ)V(B(B)V%QB;^3Q\Y%C3T_(7*%O=[/PE.R[),C0N4+>[QW$*%/RETA;
MX_" 3(T[OE)\:=Q$C3\A<86]P!+C;W$^-/'CVD6).TG1H 2H^XFL3YB-&G<2
MV %=B=I(1.Y/C*+$["NWO^#L *K>]#NWO53JWTE1G< =C&&\ZF^LQH?[X$/T
M/D#)[:G:8PGG4WUF-#_? A^A\@=9T%]+X'SZ_9D<;UA>A-I?1I?KB8&  +>%
M,0  #*,\U2^N_P 1/N"K?34)GB&!WYJE]=_B)]P5;Z:A,\0JSUH>F+OFL?[*
M);;JE]"8_P [D_;S  (])*                  ,3_S@/R/":OIY'CIPQQ;
MOU68NFZ;7NG*$"O74V,IL54U!CZM>)9%U!CX&N;D(XT>F5H1Q2\D=NI)+<P;
M6N14W3M1>U/@-RAML8)?E_?(^+H*_D>-_#3%(FB,M<6QK? X^#:/265N2[OS
MM6M$FT6GLE9>JW6Q,;#B;TJ/5L=.PBPSGU:=./,V;ES_ !<2V3_)CR;_ /A;
M?^J^(BOW6GT!\_:F%#\;,IA'B]>>3!+\MR2\;?CLQ90$4$ZZD :@      R9
M_-8OKZ:Q^]Q:^G<28S!DS^:Q?7TUC][BU].XDY#IYZ(SOF?[\#LNKSTWL[YZ
M7V4S/I !48N<                  #^:UCI#&:@Q.2P>:I09+$9>E9QV2H6
M6\\%NE<B?!9KRMW1>62)[F\S7->U51S'-<B.3^E!E-IIK@TTTUP::XII]S7<
M8:3332::T:?%-/FFO U=7E7_ "=.6Z.?$^]@&Q6;.AL[)/E= YJ3FD2SB7/1
MTN'MS*B)]5\%)(E*TBKO:KI5R#$:VT^.'S#W-KUT_>@YI7I \.,OH+4K6UII
MV.N:=ST<#9KNFM00QO2AEJK5=&LD;'NZJ_2ZV)F0HR3U7R1K(V6/6#=*+HPZ
MQX.:VR^@-=8Y,?GL0]%YX5DDQ^4HRN>E/+XBS+%"^UC+S8W/K3.BBD39\,T4
M4\4L3+1=7_3%;1H5-TDLRB*5B;XW06B5\?%O@K4O-GY7",TE4CK&Z$RV7D]M
M1!O R)-UM+A18]6\>6BX+OI;\Z&L>+A)OY_!PBG)(I&X  !^K<$..>K^&VI<
M=K'0N?OZ;U)BW.6ID\>]J/ZM^W6U;4$K9*UZC81$;9HW(IZL[41)(G;(J9V/
MDR/.&-"\3Z^.TGQ;GQ7#[B$Y(:D>1EF]Q:,U/9<K(HY*-VW*YN$O6Y'?]%9&
MPZ))')%3OV5<V--?P=7L1R;*B*GI14WW^4Y7I-T0Q-J02OBXVQ6E=]>BMA^*
MVUI.&O'<EP7'=<6]3K.BO3/-V1-O'DITS:=F-9JZI^+BD]:YZ<-^/%Z14U*,
M4C<H(Y-D5.U-MT5.WL]';XW.QK/N@+Y<+C-P(CJ8-MYFN]"U6Q0Q:2U/9G>N
M-K1JY$AP&;:V:]BHT8[EBJR-NX^'JX6Q4V1L<Q^8ET,_+X< N+K:>/M9N7AU
MJRPL,+M-ZW=7HQSVY5:SJ\1GXI9,-E(GRJK:Z/GHY)\:)+9Q53F1A7KI!U?;
M0P'*2K>30N5U"<M%XV5K6=?K>DH)\%8RR?1OK*V;M%1B[%BY#T3HR&H^5X5V
M\*[5X:.,VN=<7P/:\$2E>@LQ1V*TT5B"9C9(9X)&2PRQN3=KXI(U<Q[')VM<
MURHJ=J=A*13AB04SD            '&Y^,<:ND7H3ASC),QKO5N TICHV+)[
MHS>3JT>L:BJG[!%-(V:PY7)R-;!'(YSU1B(KE1%^ZZY3DHPC*4I/11BG*3?@
MDM6W[#\[;8PBY3E&$8K64I-1BDN;;>B2];/V?<_*.-''/1_#K 6]4ZYU'B=+
MX"BB>Z,GF+<=6#G=^YUX4<O6VK<R[M@IU8YK5A_O(8GN[#%^Z:_G1^EL4V[A
M.!NFK6J,BU7P-UGJB"7%:;B=LK5GQ6%5S<WEE8O[1^1CPM?G:U[8[L#MS$8Z
M4/2\XC<9\_\ JDXD:HR&H\A%UK,?!.](<5AH)G(Z2OAL3#RTL=')RQMEDAB2
MS:;##[KGG6*-6R;T>ZKLW*<9Y>N'2^+4DGD27A&O7WO7EK;HX\^SER(IZ3=;
MF#B*5>%IG9'%)Q;6-%^,K?XS3GI4I*6FZ[(<UL>_)^>5DX:](W,ZVPNBF9*G
M:T?-6EABS4<52WG<'97J6:@H4T>^:*DRXGN2:*?ELUGR55LQPI<KI)ZBFIFZ
M"O2XS' WBII7B3A^MF^HMMT&9QT3D3ZLZ<R"-KYK%2,5S&2=?6VGJMD<C(\C
M6I6&N9+!'(S:L<*N*&%UKIK!:MTY=BR."U'BZ>7Q5V%S7LGIWH63PNW8YS4>
MUKN25B.58Y6/C7M:IK^G_1&.R[ZY4*3Q;HK<<GO.%L$E9"4N&K?"R+T2TDXI
M>0V;+JXZ:RVOCV1R-Q9F/-]HH1W(SKFVZYQBW+1+C7);SXQ4F_+2/T$ $?DD
M               'SCTM.B]I?C+P^U)PZU?66;$:BH25VV8>5+V(R+$ZS&9O
M&2.1S8LCB;K8;E57M?!*Z):UN&Q3GL5Y=6STP^B=JG@EQ!SO#S5T'+D,1,KZ
M5^.-T=3.8>=SUQN;H<RNWK7H6<SH^9ZUK#9JLCE?$JKMLU/(CRO?DNL/TD=#
M(RDVKCN)&EX;5G1>>E:UB2NE1LEG3F4G:B.=B,J^*-$63G3'W$9=A1J+8;+(
MO5]TR>S;W3?)^X[Y+?\ ]39P2N7JY1M2YQ2EQ<$G&/63T(6U*%?CQ7N['B]S
MN[>K5R=$GXIMRJ;Y2;CP4VUK)T4']AQ#X?9O26>S&E]2XRUAM08#(6<5F,7=
MC6*U2O5'K'-#(U?VS5[)()F*Z&S!)%8@D?!+'([^/+0PFI)2BU*+2::>J::U
M337!IKBFN#7(J?*+BW&2<91;C*,DXRC)<&FGQ33X-/BGP  /H^0>@/0 \I3Q
M*Z.FHERVC+S+N!OV(7ZDT7E'ROP.?AC5&O=RL57XS+-AW94S%)$FA<D;;4-Z
MHU]23S^!Y<W"JR*ITWUQMJFM)0FM8M=WL:?%-:.+2:::/5A9MV-;"^BR=-U;
MUA9!Z2B^3]J:X.+UC)-J2:;1M+O)_>5)X5](C$METGEH\=JFM62?,:&S$\$&
MH\:UO*V6Q#6Y_P#RIC62.:WZI8_KJ[%?$VQ[GDECC=Z1;FG0TCJ[+:?RE#.8
M')W\-FL78;;QN5Q=J:ED*%EB*C9JMJN^.:%^RJUW(]$>QSHWHZ-SFKE0] [S
MGK4FG(Z.GN.N"LZPQD?)7_5OIME2#4\#-F1MGRV%FDIXS,M9LLEFQ1LXZZC.
ML?%4OS=76= ?2;JHOJ<K=G:WU<6\>;BKH>J$FU&V/J\FSNTF^)8GHGUP47*-
M.TTL>[A%9$(MT6=VMD5JZ9:\WQJ[]Z"X&<<#Y<Z,_34X6\8<8S*\.=:874L+
MF-?-4K64ARU)7,;(L60P]I(,G1GC8YJRQ6JL;X]T1R)NA]1;D17T3JFZ[(3K
MG%Z2A.+A*+\'&233]J)GQ\FNV$;*IPLKDM8SKE&<)+QC*+::]C.0 ?D?L
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MLYP^^^*W^K^5,I(Q;?.LOK.</OOBM_J_E3KN@?IC ^>_N3.)ZQ_0>T?F%]I
MP00 6Y7)%,X<@ #)]'LOY +[*GAW_$ZA^AK)LN36C>0"^RIX=_Q.H?H:R;+D
MK9UO>DZOHE?VMQ:'J6]%W?3+/LJ0 "*B7P
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MUW4^9W_5GL669M?&\G6K%?NJU]R[+C4N6FLKG7HN#T4FN,3(A0Y.$.2J)<$
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MNQA@K@X13D)_E  !D
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M\1/N"K?34)GB%6>M#TQ=\UC_ &42VW5+Z$Q_G<G[>8 !'I)0
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M;FV1TMO2X03T;IIUXJM->5+12L:3DDE&,0 .&)
M!JY?+-_93\;ONOB^@<,;1HU<OEF_LI^-WW7Q?0.&)>ZF_P"'Y7T-_;TD,]=G
MH[%^F+[&T\R0 6**R@X53D;&&M3#1FC^1)\K5P$X0< ,#HCB!K;ZAZEI9_5E
MVSCOJ)GKW5ULGG+5RE)[HH8VS6<DU>1DFS95<S?E>C7(J'K7^N!^B?\ ;._^
MF-5_\&-::B C3:/5;@9.1=D3MRE.^V=LE&=2BI62<FHITMI:OAJV].\E39G6
MYM'%QZ,:%&'*%%4*HN4;MYQKBHIRTM2UT7'1)>HV67ZX'Z)_VSO_ *8U7_P8
M?K@?HG_;._\ IC5?_!C6F@\7W']G?ALO])5_D'N^[7M/^3X7YM_^<;++]<#]
M$_[9W_TQJO\ X,/UP/T3_MG?_3&J_P#@QK30/N/[._#9?Z2K_('W:]I_R?"_
M-O\ \XV67ZX'Z)_VSO\ Z8U7_P &'ZX'Z)_VSO\ Z8U7_P &-::!]Q_9WX;+
M_25?Y ^[7M/^3X7YM_\ G&RR_7 _1/\ MG?_ $QJO_@P_7 _1/\ MG?_ $QJ
MO_@QK30/N/[._#9?Z2K_ "!]VO:?\GPOS;_\XV67ZX'Z)_VSO_IC5?\ P8?K
M@?HG_;._^F-5_P#!C6F@?<?V=^&R_P!)5_D#[M>T_P"3X7YM_P#G&RR_7 _1
M/^V=_P#3&J_^##]<#]$_[9W_ -,:K_X,:TT#[C^SOPV7^DJ_R!]VO:?\GPOS
M;_\ .-EE^N!^B?\ ;._^F-5_\&'ZX'Z)_P!L[_Z8U7_P8UIH'W']G?ALO])5
M_D#[M>T_Y/A?FW_YQLLOUP/T3_MG?_3&J_\ @P_7 _1/^V=_],:K_P"#&M-
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MT%-OMT=/K?:$^XW3'T)1(3ZY_O6S_G,G]FDGCJ-^^[1^;QOVKC]D ! 98@
M                                        &+;YUE]9SA]]\5O]7\J9
M21BV^=9?6<X???%;_5_*G7= _3&!\]_<F<3UC^@]H_,+[2!@@@ MRN2*9PY
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M%5QCJE)R+>]7'1']RL).U:9>3NV9&NC<-%[W3JOP:;WM-=;)2T;2B  <(2$
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M)HJOKXUW5PLA\F<5):^M:Z/P::*,[0PK,:^['M6EE%LZI_*A)K5>I\UZFF
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ML1SLUQA@K  )@  R
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ML>G&+7?&24EWI$$Y^SK\2QTY--E%L><+(N+T\5KPE%]THMQ?<SN #VGB
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M?GF!Y%[[%S@M]QE'_:3'I^4MV]_#LSZ5D?:R+T]'_P" 87T7'^R@  :DVX
M             /X3BE_!C4?\A9?Z/L']V?PG%+^#&H_Y"R_T?8/TI\^/RH_K
M1^=OF2^3+]3-.]COWO!_$Q?T&DPAX[][P?Q,7]!I,+Q1[_:R@2YOVL  ^C)%
MO?N$W\5)_04V^W1T^M]H3[C=,?0E$U!-[]PF_BI/Z"FWVZ.GUOM"?<;ICZ$H
MD)]<_P!ZV?\ .9/[-)/'4;]]VC\WC?M7'[( " RQ
M                       ,6WSK+ZSG#[[XK?ZOY4RDC%M\ZR^LYP^^^*W^
MK^5.NZ!^F,#Y[^Y,XGK']![1^87VD#!! !;E<D4SAR  ,GT>R_D OLJ>'?\
M$ZA^AK)LN36C>0"^RIX=_P 3J'Z&LFRY*V=;WI.KZ)7]K<6AZEO1=WTRS[*D
M  BHE\                           '\!Q7_@MJ7^0,S]'63^_/X#BO\
MP6U+_(&9^CK)^E/GQ^5']:/SM\R7R9?J9I\Y_P!TD_C)/Z;BD59_W23^,D_I
MN*1>0H##DO8OU   ^B+>_<)OXJ3^@IN . 7\!-%?<EISZ'IFG_O?N$W\5)_0
M4W ' +^ FBON2TY]#TR$>NC[WL[Y>5^SCD^=1GG[3^3B?KR3]: ! I80
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MAL]QS,U1LS=-:Z^$J\77P?%3NTX.:\F'%0U\]D.0"*R70
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M_ 1T[?Q?D*C7>A>\ KHNW8IW*2+Z%.R+MV+\0!6:_8JD<[-=L8:!6 W!G4
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M#_6-Q-_YP'ZW:Z(GVL<A_K&XF_\ . ^Z_LW\%G?H<?\ ZD?<3VI_*<'\^_\
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M?H_R-:HU?_@/;/%?N=E<'IYGZFGHUZUJC'^!D",\V<Z4"N:BU>'S6JYJ*_\
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M=&XG+LU$V1-UUANNR)Z5*OZW:Z(GVL<A_K&XF_\ .!8[[K^S./O.=S_!8_\
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MM-23.KCH-E;'GERR;:+.WC5&'8RL>G9N;>]OUPY[ZTTUY,O@ (R)4
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M[6.0_P!8W$W_ )P'W7]F_@L[]#C_ /4F?N)[4_E.#^??_P!.:U>ZJ]3-V?\
MHI/3_P"XIN N 7\!-%?<EISZ'IGE%)YNOT0W-<UW#'(*CD5JI_=&XG=J*FR]
MVL?4>SVG<!5Q6/HXNC&L-+&TZM"G$LDDJQ5:<#*]>-99GR2R*R&-C5DE>^1Z
MIS/>YRJJQUU@],L7:L<2./"^/82N<^VA7'7M%4H[NY;9KIN/773NTU[I.ZM^
M@^5L=YCR;:+/="H4.Q<WIV3MUWM^NOGVBTTUY/4O( (T)2
M             !PIR #\)X]]&'A[Q2Q"8/B)H[3^L,8QSI*\.;QT%N6C,Y$:
MZQC;JM2[B[2LWC6UC[-:RL;G1K+U;G-7&RZ5GFLFB<RZUD>$6L[^C;;T=)%@
M-21R9_ .>C7*D,5YCXLQ19)(J-ZU[LBRO'MRU9E39<L,X-YLCI+G8+_>N397
M'FZ]5.I^.M4U*&K\=W7UG/[9Z*[/V@OWWBU6R[K--RY<-%I;#=LX>&]IZC6&
M]([R)'26X9OL29/AU;U+B8.=4U!H2S%JC&R1QHU7S+4KI!J"E$WF3WV4PE%'
M+OU2R(URIY9YS#7<9:?1R=.WC;L?[I3R%:>C;9WI[^M:CBF;VHJ>^C3M0W'V
MQ^'<6>C)PZUY7DJZTT/I75$$W[JS.8+'9%9-TV]\^Q7?(O9ZW>A/4A)NSNN.
MZ*4<K$KLX:.=$G6_:X3[2+?J4H+PT(JVIU(T2UEAYME6NK4,B$;8KGP4X=G)
M+EQ<9O1<=7Q-1!N$4V._&/S<?HNZKZV6AIK4&AK<SU>^WHO4UVJU-TV1L6+S
MS-0X&NQO>C:^(B15_;\R=AYU:]\TUTK)UCM*<8]2TT[>IKZCTYB,NY>WWJ27
M<5/@FHB)WN;CUYE3L:U%[.UP^M79-FF_.ZA]ZLI;_KI=JT];TX<TCA,OJ@VS
M4_(ACY"\:KU%M>RY5<?%+7B]$WS,)X&5#JOS4OBG7YW8?B9H?)M3FY([6/S6
M.F<B-D5O,K6VH4YE;&Q=GKLKU=MRM/G[,^;&=)*!7I3GX>WVM5B,7]4MJHLB
M+MS+M+B9.7D7=-E7WVW8O:;VKIWLB?+/I7R]^O\ ;C$T-W5]MJ&F]LZ]Z_$[
M.S3V]G.>G_#O,=\&0%^MGNE#_P!CX??Z92?\%"^;/=*'_L?#[_3*3_@I^O\
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MS_G2:7):(  U!N@
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M^<GQ/ +O&_Q[/R$ICO'CU%KC?M\!,8_Y%\?-^  N;'$ECO06UCB2QP!<&O\
M65T[?A]!":[UE9K@"4UWH7O*J.]"D;?YBJUWH7O *Z+MV>CT*=RBB^A>X[;[
M>U "LCMBJBD=%.R+L8:!7!U1Z'8)^(  ,@
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M                                       '&QR  #C8Y
M                                !QL-CD     XV.0 <;(-CD
M                                         XV.0 <;'(
M
M
M
M
M       .-CD       '&QR
M<;#8Y
M                  !2>GI.A7<FY0,)@I;=BIZBDY.PKN[%W*:F04'>OY2,
MY/02U3T>ON^$CO0 A/;Z"'(GI0N+T])$>WYP"W.;X\>H@2-]!=7H0I6^/'K
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M[;L4J P2-P4$4J(_UF =P -0  9
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MX1/0=N]=O0@!4:FR'=B=IU*K$[##8.X "0  ,@
M
M
M
M
M
M
M
M
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M%'??O^4Y3L^  K([8J(\H(]#L8T!(W!013LCP"J#JCD.QD  #4
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MFQ"H8  !D
M
M
M
M
M
M
M
M
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M;(=T3<X*C$](9@J
M
M
M
M
M
M
M
M
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M+9/'CN+.R0E,D]0!=6O]16:_XBV,D^+QX[B0U_S^/C +DU_K*S7EM:_8K-D
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MN+UPJY)^7-?^9:?#<B_O//>DNT6BC!RE,;Z?1X[2=#'Z3I%'NJ>K\9<&,]!
M98L[L9\A<(F>/:4HV=WCXRXQ1@%2-A.C9^<IL;^8G1L\>L J1,\>PGQM])28
MST?*36-]'J[_ !X[0"I&WQ\Y,8TIL82V-]/R %1C?026IZ#HUNQ(8WYP#NU-
MOB*K4^<Z(WM^ K-3< [)V)OZ5[CNU-CJG:OL0J '*)N5SHQ#N8  !D
M
M
M
M
M
M
M
M
M                                                     &&"D]#H
M5U3<H*$_Z@4O8OQ'14]!5<AU7M[?E,@C[>CTIW>TH/3TDIR>E.]"FY-TW^4
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MA58GI^0 [(FQ4]&WI4-3TKW'9J>GU@'9$V.S4W."LU-D#!V
M
M
M
M
M
M
M
M
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M#JQ/22$[/A ")OV>@JHGH.$38J=WPK\P!SW]GH0J'#4V.R)N =F(53A$V.3
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MH_6HJE_[WU&XPNN[-BU[HP\:Y=_92LID_9O.Y?[IN3!N:S?HE^73Z0W"F:I
MNK9=>:>KJQDF UR^;+\]=B*BQU\XY_U;K2+[U>NDMVME8B+&K'/:[,J\F]Y;
MKA9T@U@P*I+H3B(K$231V<MPS1Y%R-1SI=,YMC*]?-P[JYON>2O0RT;F.63&
MI"L-B>,ND'5]M#9\96RA&^B/%W4-RW5XV5M*</7)*4%WS)6Z-]9.S=I2C5&<
M\?(GPC1>E%S?A79%RKD_".]&;^)ST]G@<(IR<,2             #R;\H;Y7
MWA[T;\]I[3^L\-J7)6M1XBSF:4N#KU)X8Z]6XM*2.=9[,#FR]8B.:C6N:K5[
MT5-CUD,&#SL#ZYW"?[A,S_6!#J^A.R*<[:-.-D*3JG&YR4);LM853G'26CTX
MI:^HX_IYMJ_9^R\C+QG%75NE1WX[\?+NA"6L=5KY,GW\STV_73/ S_)7B!_-
M^-_X@/UTSP,_R5X@?S?C?^(& NG<AR3I]RG9'Q+_ -._^17]=<&V?CXW]'7^
M,SY7^=-\"T1572O$'9$55_\ )^-[D3?_ -8&17PIXAU-7:9T_JFA%/#1U%A\
M=FJ<-E&ML15\E5BMPQSM8Y[4E8R5J/1KG-YD7953M-/38_<W_P#<=_14VV?0
MA^LYPM^X'2GT)3(VZQNB.'LRO%EBQL3MLLC/?L<^$8P:TU2TXR9*'5CTTSMJ
MVYD,MU-40IE#LZU#C.4T]>+UX16GUGU& "*28              <;@')QN?@
M72.Z4>@>$NG;&J>(6IL=IK#0H_DFNR*MB[*QO-[EQM"%LEW)6W(K495I033.
M<]B(S=R&'+TXO.?]6Z@?>P/ [3Z:.Q'/) S66HV5[^I[T2<[/=%#"LZS&8-D
MB+UD*VI\K=5J1R2,HRK+6;TFP.B>=M)_O:KWM/25]CW*8^*WFM9-=\:U.2YN
M.G$Y;I'TRV?LN/[ZN2L:UA16NTOGX:07FQ>CTG8X0U6F]KP,T[BGQDTCH?%R
MYO6>J-/Z3P\/9)D]19>AAJ*.V56QI9R%BO$^5^RI'"QSI)'>]8QSE1%\7>./
MG'?1JTFLT.&SF:UY<C[&LTMAK7N)[D[VIDLJW'U^Q>Q'1I)&_O8]S??&ODXN
M<9-6Z_S,FH=;ZDS.J\U+S(N1SM^QD)XHW.5ZPU4F<L5*LCW*YE2G'7K,<JJR
M)JJI^;(2_LOJ>QHI/+R+;I\W&E*JM>K5J<Y+U^1K\5/E"NUNNS+G)QPL6JB'
M)3O;NL]N[%PA%^I]HM>]KGF3\1_.RFMD>W1_!F2>%4>D<^IM5QT96+W1O?5Q
M.,R;)/6Z-+<?<C4E3]LGREG/.JN-LLG-CM <,Z<.[_V*W'J7(R;*Y59^S19K
M&M]ZS9KEZCW[D5Z(Q%Y$QA0=A1U=[&K2TPH2>G.RRZ;?K:E8XZ^Q(XS)ZRMM
MVZZYTX)O5*JNFO3U)QKWM/:V_69-%;SJ3CRDD:S:*X621(]BRQLQ^J(GOC1R
M*]C)5U/,D3W-W:V18I48Y4<L;T3E7]VT7YV/JZ)6,U%P<T_<9V=98PVJLA1D
M3;FYE94NXFZQ_-NW9'78^5&NW5_,B-Q(0?I;U?['FM'@UKY$K8/\L+(GY4=8
MNVZWJMH72^<C38OR3KE_WZS/OX/>=&\#<T]D.J].ZVT6]W*Q;$M*IG:2/79%
M<LF*LOG9"G:JO?7YTV[8]EW/:;H[=/C@SQ81&</>).E-2W$CZU^(JY2"OGX8
MT1%66? 7EJYF&)%7EZZ2BV%7HYK9%5KD34TKX\>/QI7J69:\\-JM++7M5I&S
M5K->1\%FO,Q=V303Q.9+#*Q>ULD;V/:O:CD.6VCU18%B;Q[;\>7<FXW5^K6,
MMV?_ ,GZCK-F==&T:FEDT8^3#O<5*BQ_SH[T/_B[O$W).YSN:W;H;><"<>N%
M3ZE'-95O%#2]?D8_#ZPLROR[8&HB<E+5;8Y\G%*B<RMER,>5:Z1W--'*UJ,,
MT+R?_E=>$/2%J1P:;RDF U?&Q77]#:D?6J9V%S4_9)<<Z.:2IG*'^/';QLLC
MTC5/==:G8;+7BB7I%T#S]G)V605U"?W^G644N[M(Z*=?MDMS7@IMDR]&NL/9
MVTVJZ[)4Y#7\'O2A*7CV<TW79[(RW].+@D>HX .+.Z            //KRAG
ME&-']&[3VG]2:RQN;R5+46<=@*D>#AKSSQ6VXZWDN>9MB>!$A6&E*U'-5RH]
M6HK=E54\F_UTSP,_R5X@?S?C?^('\!YU_P#6GX6_?,E_JCGS!7)PZ#= MGY^
MSZ\G(C:[966Q>Y:XQTA-J/DZ>! O6!UA;2V=M&>-C2I52JJFE.I3EK..K\K>
M7#7D9\_ZZ9X&?Y*\0/YOQO\ Q ?KIG@9_DKQ _F_&_\ $# 8!U_W*=D?$O\
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MV=ET"ZQ-I;0VG3BY,J75.%TI;E*A+6%<I1\K>?>D9=( (,)^
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MM5PL=&0__+WZ0E)^%<TW79ZE&6_IQ<$CU=!QN<G%'=@
M
M
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MHUKZNXRGHTUP:>J:X--<FGW-/BO7Q,T;R1'G#WU3L8KAIT@<E!#=E;%C]/\
M$ZQU=>O=G3DBJT-9*U(X*UJ=/V.+4+6LKV)D;]5&Q2S/NNS!8)V2L9)&YLD<
MC6OCD8Y'L>QZ(YKV.:JM<US516N151R*BIV&FQ<U%394147?=%[45%[TV[OB
M[C+U\@=Y:2;&6L/P*XLY9TN,N2PXWAYJW)6.9^/M2O2.KI/,6YE5SZEF1S8L
M%>GDWK2JW&3O6.2HL<%=/NKN,8SS=GU[NZG._&@N&[SE93%<E'G*M<--7#33
M=+ =776;*4J]G[2LU<FH8^5-K5M\(U7R>FK?*%CXMZ1FVWO&:\#A%.2#2P
M       !BK^=?_6GX6_?,E_JCGS!7-@+YRYP UQQ#X:<.,=H72F;U9?H<09;
M]VG@Z,MZ>K2_4QFJWNJ9D:>\A]T3Q0\[NQ9)&M[U,-S^]F=(;[3/$'^8+/Y"
MRW5GM+'JV35"R^FN7:WO=G;7"6CL>G"4D^/=P*M]:^S<FW;%DZL:^V'84+>K
MILG'51>JWHQ:U7>CX=!]Q?WLSI#?:9X@_P P6?R#^]F=(;[3/$'^8+/Y#O\
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M[?\  ?#H/N+^]F=(;[3/$'^8+/Y!_>S.D-]IGB#_ #!9_(/W:P_Y5C_IZ?\
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M]#9'R\?[:!)/5-Z<QOFLG[&1ET@ JP6X
M  /*SRVWV+/&/[EW_P"^536!&S]\MM]BSQC^Y=_^^536!%BNIW^ Y/TI_95%
M9NNWTAB?1']M,'"]RG)PO<I+KY,A=\F9NGFFG\"^,OW6:9^AKIENF)%YII_
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ML/DL6K#T:CI[,\DDT\BNEE>Y[G.6Y %1V]2YR6G!=P !@R
M
M
M
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M.-G[426/<H7:>5C7:0O7CI'5JQ+XU<II=^G(^PFR+\7CXBJU_J7;QZBV-?\
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M:LN6FB??"O=33W9.:YO2JKVJJJJJO:KE7O5RKVJJ^E5W5?2 "22,
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M4^"WW,6/IS+&L"-G[Y$3[%/@M]S%CZ<RQ$/7'_ <7Z6OL;2:>I'^'Y?T3_\
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M@?LFKWWJ=7_3VC386E8NM?TL_H]/Z["UO4]Z&C])R/UQ  (T)3
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MQ&X;?RGQ%_\ $G5A[=E-^E/I/:/T[+^WL+Q]%O1FSOH.)]A6  :$WP
M/*#RX?V+/%[[GXOI*D>KYY0>7#^Q9XO?<_%])4C;]'_X?A?2L?[6!IND7H_.
M^B9/V,S6&IW(<G"=R')=!<D477)'*=Z&;-YIA_!+C3]TND?HC*F$RG>AFS>:
M8?P2XT_=+I'Z(RI'_6AZ&R/EX_VT"2>J;TYC?-9/V,C+I !5@MP
M                     >5GEMOL6>,?W+O_ -\JFL"-G[Y;;[%GC']R[_\
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M%1DX+A5#1-\(1U;X\9RDUHFD@ .3.R
M
M
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M'^^!#]#Y R@3%^\ZF^LQH?[X$/T/D#K.@OI? ^?7[,CC>L+T)M+Z-+]<3 P
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MZ$/UG.%OW Z4^A*9"G7-]YP?G;OV*R=>HW[_ +1^:Q_VK3ZC ! 18P
M   ^6^FMTC:G"7A3KKB';<B?J9T]>NTXUY%6?*.B6#%5F,?[R1]C(2UHFQNV
M217<FZ;[FIHS^?N9;(7\KD9G6,AE+MO)7[#U5SY[MZQ):M3/<Y5<YTD\LCU5
M5555W:J]YG6>=1\>GX3A'H?A_5F=%8U]K&3(WF)OM8P.BZ<=RQ"Y$V1%^KV6
MTU.U7=BI6D;RJOOF8'R%C^J/92JP;,IKRLJUI/\ U5.L(_\ R=KKIX+PX5@Z
MYMKN[:-6)%^1B4IR7A=>E-Z^RI5:>U^/$ "62'C]3X'\%]1<1M7Z=T+I.HEW
M46J<I7Q.*@D<Z.!L\ZJLEJW*QDCX:-"NR:[?G;'(Z&G7FD9'(YK8W;4CH2=#
M[3' SASI_A[I>)'08NLQV4RCXF16\_FY6-7)YJZC>;::[81SV0\[FUH$BK1J
MK(45<4WS5SHE09/-:[XT9.JV6/3SX]#:7ED:JM9E[E2MEM1V8O?(U):N+M8:
MNURL<G+DY>1S',<9LR%<NM;I'*[*6!7+WG&TE8E\.^<=[CXJJ$E%+NFYZZ\-
M+-=3W1F-&&]HV13OR]Z-3:XUXT)./#P=LXN;??!5^O7D $2$S         %A
MU/IC'YK&W\/EJ=?(XO*T[./R-"W$R>K<I7(7U[56Q#(US)89X9'QR,>BM<QR
MHJ;&L#\K7T!K/1ZXP972U>.9^D,Y"NI-"WY$<YDV"MV)8Y<6Z==VNNX"['+C
M[,3G+/[F^I]V1C8LA7<_:-'@7YQ3T1X.(O /(ZHJUNLU%PML+JG'2L;O,_$/
M1E745+WK'/?%)16.YU?,UB34(9G;]4B$@=7/2*6%GPKDW[GRY1IL6O",V]*K
M$O&,WNM_$G+O2(WZSNC,<_9T[8Q7NG#4KZI:+64(K6ZK7PE!;R7QX1]9KHP<
M(Y%V5.Y>U/'QG):C4J.F<*AL/?-LNE#)KCH_P:1R%N2SF.%N6LZ91TSG/E73
MMM79/3;.9RJJQ4*L\V'K1L3JZ]+&TX4[MDUX9DM^:[<=),%QOU%HB69&4=<Z
M/M3PL>[='9C3%B*Y R)G<DDV-MY)\CD[593:UVZ(G+P'65LM9.RKY):SQG'(
MAZMQZ6?5V4IM^.B\"1.JW:KQ=L8\6](92GC3XO36:4J^')OM802\%)Z<S/U
M!58MX               >07E[/L2>,7\GZ8_KUI<UEALT_+V?8D\8OY/TQ_7
MK2YK+"R'4]Z-O^G6?V?&*N]=?I;'_P#3JO[3E@ $KODR('R9G&^:=?6XXM?=
M[C?ZMTC+#,3SS3KZW'%K[O<;_5ND9894CI]Z8SOG(?95ER^KGT)L[YF7VM@
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M/_2W;/6VI>W]TF<B=B;'[:4\Z4[>GM'-NR)-[FNY3#NA3%M07M?GS\9RD^7
MNST1Z.U[+P:<6*6^EOWS7\9?-)V2]B?DP7=",5Q>K8 '.G3
M           &*WYU]]:3A=]\]W]3]1F"F9UGG7WUI.%WWSW?U/U&8*9:+JL]
M$5?.W_:2*F=;OIJWYC'_ &&#A?1X]"G)PI(DN1&+Y&R6\W4^Q&X;?RGQ%_\
M$G5A[=GB)YNI]B-PV_E3B+_XDZL/;LIOTI])[1^G9?V]A>/HKZ,V=]!Q/L*P
M #0F^      !Y0>7#^Q9XO?<_%])4CU?/)_RXB[=%CB]]S\7TE2-OT?_ (?A
M?2L?[6!IND?H_.^B9/V,S6')W(<G"=QR707)%%UR1RG>AFS>:8?P2XT_=+I'
MZ(RIA,IWH9LWFF'\$N-/W2Z1^B,J1_UH>ALCY>/]M DGJF].8WS63]C(RZ0
M58+<                              'E9Y;;[%GC']R[_P#?*IK C9^^
M6V^Q9XQ_<N__ 'RJ:P(L5U._P')^E/[*HK-UV^D,3Z(_MI@X7N4Y.%[E)=?)
MD+ODS-T\TT_@7QE^ZS3/T-=,MTQ(O--/X%\9?NLTS]#73+=*E]87IC-^55]A
M47'ZM/0>S_F[/M[0 #C#N@        #Q0\XB^Q"XI?Y[PW_\4]%&M<3O7XC9
M1^<1?8A<4O\ />&__BGHHUKB=Z_$6/ZG_1MWTZW^SXI6#KM]*8OT&'V^0=@
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M26L*V]-=*8RW=.6]OR7G,  XL[H
M
M
M
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MPARDA 1_9OLNWK]!RC_::TV9<$D3QN=^L3U_/^4M_.ISS@%PY_4J_,=N=?\
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MTI)/P(MVQTMVEGZK+R[;(-Z]DFJZ?5[U6HUO3N<HMKQ.J-1.S;L.P!T!SN@
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M?I)4<149$3(XO'CN .D<7C\A-9'L=V1^/426,_. =6,^7\!+9'X_(=F1DQC
M#JQA+9'Z0R,EM9\OCY_8 <,9X\?-ZR2UH:STJ26M]( :TD-;Z0UGK*[6[]H
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M*X1BN27>]67#V1LC'P<>O%QJU756M$N;DWQE.;YRG)ZN4GQ;]6B  ->;(
M      &#!YV!]<[A/]PF9_K AG/F#!YV!]<[A/\ <)F?ZP(=_P!6/IC'^1D?
M86$<]:_H++^5C?VFHQ34[D.3A.Y#DM25$7)%&Q^YO_[COZ*FVSZ$/UG.%OW
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M[;'K^/.4OZM="]^R,-8^+C416BIHJJ7/X%<8]^KXZ:\7JWQ?$  \!L0
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M!3KG&4)PDM5*,EI)/U-<#1X^1.JR%M4G"RN49USCPE"<6G&2?BFE_P 3; ]
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MG07]+5!AUF8IYI9^_..7\3H+^EJ@X7K)]"YG_L?VBHD'JN].87^T?V6XS/
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M]B$H I07N0
M
M
M                                                    *+F[%8&&
M".4U3;M0K.;L=3(**IZ4[OP%-S=RLJ;=J=QU5OI0 C[;_"4G-)*MW*;OG_"
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M+FLL-FGY>S[$GC%_)^F/Z]:7-9860ZGO1M_TZS^SXQ5WKK]+8_\ Z=5_:<L
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MTUTY]N//_P"CF-_M(^Z?L?\ E$OT-W^6/N4;<_DU?](I_P 1Y2^;0_914?N
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M3TBLNJ+?#@K'V;;UX)+?U?J7#CP-G<BG(!3LNT
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ML'7;Z4Q?H,/M\@[  EDAXV$'FP7V-UC[X.I_]GC3(P,<_P V"^QNL??!U/\
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M*H[GJY"G6O5G]GOZ]N%D\+NQ53WT<C5[%5/4I>"D[6G#P+WIZ\5R8 !@R
M
M
M
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MBW+PKL>;KOIMIL7.%M<JY?DFDSN #TGF
M                  .'+LFZ]B)WKV?CV/WS@CT6.)'$FVRGH/1&HM42O_\
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M #6_*5$3TKW!$]*G9$W[?0 $3?X$[BH#LUNX!PB;E9$V")L<F&@  9
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MGW\^8 !^1^H      ,&#SL#ZYW"?[A,S_6!#.?,&#SL#ZYW"?[A,S_6!#O\
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MTWD1EUI=*(X.SYT0E^^<V,J813\J%4EI=:US2W6X1?QY)KS7I\!HAR 6C*F
MR??-9^!;\QQ@UAKV:-5J:-TB[%U7NC58URFIKD+7*R3;9)Z]#&S)R[[]5==O
MWH8P*KMW]QL</-VNBM+PZZ.^&SF2J.JYWB=;EUO<9(U6S,PUG_!M*,?VKNVQ
M@HJ^6C[&N8W*]2]$=&I'O69M58^RKH)Z3R91QX>R7E6</#LXRBWW.4>]HD?J
MJV4\K;%,VM88D9Y,WH]$XK<J6O+5V34DN]0EP>C/>$ %62W(
M  !Y!>7L^Q)XQ?R?IC^O6ES66&S3\O9]B3QB_D_3']>M+FLL+(=3WHV_Z=9_
M9\8J[UU^EL?_ -.J_M.6  2N^3(@?)F<;YIU];CBU]WN-_JW2,L,Q//-.OK<
M<6ON]QO]6Z1EAE2.GWIC.^<A]E67+ZN?0FSOF9?:V  ''G;
M  '\WK+_ *'RO\FWO]UE-.)BOWK6_B(?]FTW'>LO^A\K_)M[_=933B8K]ZUO
MXB'_ &;2=^I;S=I>W#_5E$ =>?+9G^V?_C$\ $XE?C(C\V!^R:O?>IU?]/:-
M-A::]+S8'[)J]]ZG5_T]HTV%I6+K7]+/Z/3^NPM;U/>AH_2<C]<0 "-"4P
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M>DT-J8%5Z:[:"563#OC=%:2>GQ;/OD'\66C\J,DNP .6.N
M          ,5OSK[ZTG"[[Y[OZGZC,%,SK/.OOK2<+OOGN_J?J,P4RT759Z(
MJ^=O^TD5,ZW?35OS&/\ L,'"^CQZ%.3A?1X]"DB3Y$8ODS9+>;J?8C<-OY3X
MB_\ B3JP]NSQ$\W4^Q&X;?RGQ%_\2=6'MV4WZ4^D]H_3LO[>PO'T6]&;.^@X
MGV%8 !H3?       \H/+A_8L\7ON?B^DJ1ZOGE!Y</[%GB]]S\7TE2-OT?\
MX?A?2L?[6!IND7H_.^B9/V,S6&IW(<G"=R')=!<D477)'*=Z&;-YIA_!+C3]
MTND?HC*F$RG>AFS>:8?P2XT_=+I'Z(RI'_6AZ&R/EX_VT"2>J;TYC?-9/V,C
M+I !5@MP                              >5GEMOL6>,?W+O_P!\JFL"
M-G[Y;;[%GC']R[_]\JFL"+%=3O\  <GZ4_LJBLW7;Z0Q/HC^VF#A>Y3DX7N4
MEU\F0N^3,W3S33^!?&7[K-,_0UTRW3$B\TT_@7QE^ZS3/T-=,MTJ7UA>F,WY
M57V%1<?JT]![/^;L^WM  .,.Z         /%#SB+[$+BE_GO#?\ \4]%&M<3
MO7XC91^<1?8A<4O\]X;_ /BGHHUKB=Z_$6/ZG_1MWTZW^SXI6#KM]*8OT&'V
M^0=@ 2R0\;"#S8+[&ZQ]\'4_^SQID8&.?YL%]C=8^^#J?_9XTR,"GW33TMM#
MZ39^LNIT$]#;-^B5?L@ ','6'\3Q%X<X/5N"RNF=2XRIF<#G*4^.RN+O1)-5
MNT[+%9+#*Q?6B[M>U6OC>C9(W,>UKDUK/E<O)59SHV:Q:^FZUE^&>I+EA='Y
M^6-5EJ.V?873.:E;S1_5:A UZ0656/ZKTZ[[T<,4D=J"'9N'X7TD>CCI'BQH
MO-Z"UOB8,OI[.UNJL02M3K:UB)R34LE0G_=*>2QUID5NC<A<R6O/$QS7;;HO
M8]#>EMFRLC7RIXUKBLBI/FEP5D->"LAS7)37D2:U4H\1TXZ%U;8QMWR:\JI-
MXUS7)\W59IQ=4VEKS<'I.*;3C+41(IR>@?E(/)Y:MZ.?$"WI3.Q6+VGKRR7=
M&:K;"J4=0X=SW<K72L:D,&:QZI[GS&,7DFKR)';CC?CKE&U8\_"UN%FU9%5=
M],U959%2A./)I_UIKDT]'%III--%/\S"NQK;*+X2KNJDX3A):-23_(T^<9+5
M2333:9PJ'O!Y/_RO-_1_";B'P(X@VI[VC\YHO4-'068?UDUK2V9M49F18&=$
M1RR:=R;WN=6DYD?A[J*Q&RTKJ^X/" XV\>/'Q'FVKLBC,J[*Z"DE.-D'RE"R
M#UC.$M.$D^'A*+<9:Q;1Z=D[7OP;NVQY[LG&=<T]=RRN:W9USCKY46N*7P9*
M,HM2BF=(4V8U%[T:U%^1"H ;,UJ!F*>:6?OSCE_$Z"_I:H,.LS%/-+/WYQR_
MB=!?TM4'"]9/H7,_]C^T5$@=5WIS"_VC^RW&9X "J)<       UU'G)7 Q=)
M])&YG(H.JHZ_TUB-1PO1/>RWJB283*;O3L65):$+W-_;,CFA5?>O8J^ QGU^
M<[=$=^LN$6#XEXRJLV8X692P^^L356232&I?<=7,.<C4_9$QV1HX7(H^55;5
MJ19)8D1UA_/@*%L.KO:BRME8SUUG1'W-8N].KA#\M3KEX<>!3OK*V0\3;&5Y
M.E>0UE5/31-6\;/R7*Q?D?>#JYB*BHJ=BILOP+W_ #'8'<'!FR7\@)TPX^*W
M1]P-"[/UFI^&TB:%U Q[T=-/7Q\$<VG<LJ*YTKX\C@Y:L4L\B-ZW*T,LQF[8
M4<[VY-8+Y('RBTW1TXJ5LWDY+<F@M21PX37-*LV2=T./69'5<_!4B:^6Q;P,
MKY+'4UV+9LTY+E:%LDLD43MF_IO4N/S./HY;$W:N2Q>2JU[V/R%&>*S3NTK4
M;9JUJK9A<^*>">)[)(I8W.8]CD<U512JO6'T<E@9]DXQTQLJ4KJ9+S5*3UMJ
M]3A-MI?$E'UEO.K7I1#:&SZZY2_?.)&--\6_*<8K2JWQ:G!)-_A(S7@W>P <
M"2(
M
M
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MFZ*BIZT7L.AC)-)III\FGJG[&CG)Q<7NR3BUS36C7U/B<@ ^CYU &X
M         W  &X U &Y-Q&-LY"9*V/K6;]E>U*]&O-<G5-T3=(:S))%3=43L
M;WJB>DPVDM7P2YM\C*6K22U;X)+BWKRT1"!]I<,O)Q\=]9-9)IWA3K&Y ]41
MMJUC?J1217)[WGN9F3'UH]T[4ZR5O8BJNR(JIZ4<(_-Q^.N;=!)JC):+T-5>
MB+/%9RLFI,Q7W3M1*6!ADQ$SF_XW+J-C57;D<Y.TT.=TIV=C:]MFXT6N<5;&
M<^6OWN#E-_F^HZ# Z)[4R6E1@94T]&IRIG77H^"]\L4*_7YW+CRXG@*='RM:
MF[G-:GK<J(GSF:=P<\VFX98Q(9M;:RU1JRPU/V>MCFU=-XR14VV6)L'NS)1;
MKONU]^5.79$5%W5?6S@CY-G@9P]=#-IGAEI6*_ B=7ELGC8L[EF/3;]EBOYA
MMV:K,O:G64_<R\JN8FS7O1>*VAUN;.JU5$+\F2Y-155;_G6>6OT3_7IWFS>I
MG:=NCR+,?%B]-4YNZQ+O\FM=FVN7WW3U^.OLX$="/BWQ,6)VB.'^I<W4FV5F
M5;CY*6$5NZ<SFYG()5QLO5I[Y[*]B:5&[*D:JK4=[5<!O-K>(F86&QQ!UE@M
M'57;.DHX:O)J7+\J[+RH]TF.QL+E3WJN=8F6-_=%*B;.S2FQ;(C41$:B;(B=
MB(B=R(B=B;>A-MMMMO45NJ(^VGUM;0MU6/"K%CW-+MK?SK%V?Y*D2-LCJ:V9
M1H\F=^9-::J4G35KZH5-3T]4K9(\<NCKY"[H_: 6"U8T]=UWEX%Y_JGKJW%E
M&-D3M18<-2K8[!0I&_WT#W8Z6U$C6<]N5[>=WKC@=.4,75BHXRC4QU&!$;#4
MHUX:E:)$1$3D@@9'$WL1$549NNW:JE_:Q/05&Q^OQX^(CS:&ULG+EOY-]M\N
M[M)RDEKW1BWNQ7JBDO429L[9&+APW,7'IHCWJJN,7+3ODTM9/UR;?K(Z1>LJ
MM9ZD_%X^$EL@]:?E*[8D^'QZ$3])KS8D1L._CL\=I(;"GP? 2D85VQ>/2 1F
ML]A7;%X7\A);%X[R4R'QZ?S $5L?CTDED)*;%X0K-C^( HMC3]!(;'^CL*S8
MO'I)#(O'I *#(R4R+Q^4K-CV)#(_D *38_C*[(_65V1IZ$*S6>/'X #HQOQ>
M/G^(KMC]7C\Q4:PD-9\@!38PD-9\9V8SU%9K=@#AK/654;N=FL]96VV[_D .
MK6_I*B)O\ 1N_?\ (540 ZHFQ4VV[^_U'/=V)WG*-]8,A&^E3N#NUH,'#6[E
M8 QS]@  ,@                        &+]YU-]9C0_P!\"'Z'R!E F+]Y
MU-]9C0_WP(?H?('6=!?2^!\^OV9'&]87H3:7T:7ZXF!@ "WA3$&S]\B)]BGP
M6^YBQ].98U@1L_?(B?8I\%ON8L?3F6(AZX_X#B_2U]C:33U(_P /R_HG_P#-
M6>J8 *ZEEP   #^,UQQ%P&F:,^4U'F\3@<=5B=/8O9?(5<=4AA9^WDDGMRQ1
ML8W_ !G*[9#%O\IKYR'I/"8S)Z.X VOU4:FLLL4K6OO<\L6FL&CTZF23 K8;
M#-G\BU%>ZO?@C;AH',BG@M9+G5L6ZV+T>R]H6*O&IE/BE*S1JJM/OLL?DQ27
M'37>?**;X&BVYTDPMG5.W*OA#1-QK33ML?Q:ZUY4FWPUTW5SDTN)Y*><K=*;
M':[XZU-(8>Q#;H\+<+)@;UB%>9OZI<K89?S=/K$562+C(X<?3FY5W@NI>J2(
MV6N]#'=)5_(6+=BQ;MSSVK=N>:W;M697SV+5JS*^:Q9L32*Z2:>>:1\LTLCG
M/DD>Y[U<Y>98I;C86RX86)1BP>]&F"CO/AO2?E3GIW;\W*6G=KH4RV[M>>?F
M9&98MV618Y[J^!%)1KAKW[E<8QU[]-01K2[1R+Z$8Y5^)J^/623]_P"BCP#M
M\4^)NA.'=..21^K]48G$6EB<C7U\3+99+G;R*JILF.PL.0O.1%YE2ORL1SW-
M0V&1=&N$K)M1A7%SG)\E&"<I/ZDFS6TT2MG"J"<IVSA7"*YRE.2C%+Q;;2T-
MJ-T0-.R8CA-POQ4T;8IL=P\T72GC:U&(V>MIS&PSIRIW+UK'J[TJ[=555[3Z
M+*<,+(V,CC8V..-K6,8QJ-8QC41K6,:U$:UK6HB-:B(B(B(B;%0I#=9OSG/X
MTI2_.;?_ !+[TU[D(0^+&,?S4E_P  /S/U      !@P>=@?7.X3_ '"9G^L"
M&<^8,'G8'USN$_W"9G^L"'?]6/IC'^1D?86$<]:_H++^5C?VFHQ34[D.3A.Y
M#DM25$7)%&Q^YO\ ^X[^BIML^A#]9SA;]P.E/H2F:DRQ^YO_ .X[^BIML^A#
M]9SA;]P.E/H2F0IUS?><'YV[]BLG7J-^_P"T?FL?]JT^HP 0$6,
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M2=D-7X0G."BWX;^XO6B.<3KKV=.W<MQ\JFMO17-5S2X\YPA)R2\=SM'ZC8_
M^-^@UTY]"=(#0];7&AKDJP),M#-86^UD.9TYF8XXY9\5E:S'R-;(D<D<U6U"
M^6I?J216JLSV.5&?9!%N3C64V3JMA*NRN3C.$EI*,ES33_[:XK@2]BY5=U<+
M:IQLJLBIPG%ZQE%\4T_^VN3X@ 'X'[@
M
M
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MORG*(5-MN_Y #AK=SGO39#E$W^#T;'=$ ")L<A$*S6[?"&P=6L]94 ,   R
M                           8OWG4WUF-#_? A^A\@90)B_>=3?68T/\
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M\^Y*OP</S5_R/KW5;^%L_23_ .9^D_W9]9_Y8:K_ -(\S_;1_=GUG_EAJO\
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M=J55I2E3FN-%U<8N3U>O96I+5ZU2;<M$_>W9PUT:V0 .$4Y*KEO@
M#%;\Z^^M)PN^^>[^I^HS!3,ZSSK[ZTG"[[Y[OZGZC,%,M%U6>B*OG;_M)%3.
MMWTU;\QC_L,'"^CQZ%.3A?1X]"DB3Y$8ODS9+>;J?8C<-OY3XB_^).K#V[/$
M3S=3[$;AM_*?$7_Q)U8>W93?I3Z3VC].R_M["\?1;T9L[Z#B?85@ &A-\
M   #R@\N']BSQ>^Y^+Z2I'J^>4'EP_L6>+WW/Q?25(V_1_\ A^%]*Q_M8&FZ
M1>C\[Z)D_8S-8:G<AR<)W(<ET%R11=<D<IWH9LWFF'\$N-/W2Z1^B,J83*=Z
M&;-YIA_!+C3]TND?HC*D?]:'H;(^7C_;0))ZIO3F-\UD_8R,ND %6"W
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MMN%.4U5KKY*G7"<HQ?+3>UEHN3E)OF  1(3*
M
M
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MB1>Q"?U7L^<[I#[/FW ("1J5$A\?H)Z1>PJ)![ " D7A$*B1>%+@D)42- "
MV%2LV$FI'["HD?Z$ (C82JD9*;%["LD0!$2,JMB\*3&Q>$*K8@"(V(D,B\>@
MDMC]GC\!6;& 1FQE=L?L)#6>S?Q\JE9&>/S?E ([8T\>-BNV,K)'ZBLD8!1:
MWV?!X[BJC"NV/XBJUGL *36?(5FL]151A41 "FUFQ51NY41GQE1$3T_(@!T:
MS])43V=OM]!V1-_8GJ.Z)Z@#JC?2O>=T3<[<J)W_ "'/?\ !U^ J(TY1-CD
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MO"U&105Z\+610Q1L1&LCC:UK6HB(B(74 CMO7B^9):6G!+1+@DNX  P9
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MD=7/07*V/;ESR+*+%?"J,>QE-M.N4V][?A#GO+334_J@ 1D2L
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MN:)BZ.]"MG;,XXU"=NFCR+7VES7>E)K2"??&N,(OO3.$0Y .7.L
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MDWP)^Z)[)LP-G8N);*$K**W"4JVW!MSE+R7)1>FC7-(  T)T(
M   !_-ZR_P"A\K_)M[_=933B8K]ZUOXB'_9M-RM=J1V(9:\K>:*>*2&1NZIS
M1R,5CTW394W:Y4W3M3T'CK%Y ?HJL:UC>&4"-8U&M3ZL9E=D:FR)NM[?N0DG
MJ^Z98VR5EK(KNGV[H<.R4'IV2NWM[>G#GVBTTUY/70C'K'Z%9.V/<?N>RFOW
M/V^_VTIK7M>QW=W<A/EV;UUT[C6A V8/]X+Z*WVLX/YXS/\ ;1_>"^BM]K.#
M^>,S_;21ONP[._ 9?YE7^<1?]Q3:?\HPOS[O\@UGP-F#_>"^BM]K.#^>,S_;
M1_>"^BM]K.#^>,S_ &T?=AV=^ R_S*O\X?<4VG_*,+\^[_(-9\#9@_W@OHK?
M:S@_GC,_VT?W@OHK?:S@_GC,_P!M'W8=G?@,O\RK_.'W%-I_RC"_/N_R#6?
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ME?AN-.13;)1G;O.-=L9M+6E+5J/#5I:GJ@#A%.2OI8\            '&QR
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M=&UKR;+&;%PY8V'B8\VG.C&HIFXZN+E77&$G%M)Z-IZ:I/3N0 !K#9@
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MGH^6A+W1SH+LW9FDL>C>NTXY%S5EW+1[LM%&O5-IJJ,$TVGKJ=>5#L <J=@
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M&,=7NPC&.KTU8 &A.B
M
M
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M^KO]8!PC?7V'*+Z$.R-]9VV .J,.X*B,]?R '5K=RJB;'(,   R
M
M
M
M
M
M
M
M
M
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M)L<G9&[@'4[M:=T:B'8QJ#A$V.0#(
M
M
M
M
M
M
M
M
M
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MLB;')V1J@'4[(W<J(W8[&-0=4:AV &GB  #(
M
M
M
M
M
M
M
M
M
M
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M R
M
M
M
M
M
M
M
M
M
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M4ZOVG9&H8U!21J^H[(PJ@<?^_P#M?\0=.1#ML<@R
M
M
M
M
M
M
M
M
M
M
M                                              #C8XY4]1V !TY$
M..K*@,+4%'E4XV7U%<&01P2#C8 H K\J>HXY$]1C7_O_ /P%$%7D0<B#7_O1
M@I'&R>HK<B''5^T:_P#>C!2V3U#8J]7[3GD&O_>C!2!5Y$'(@U_[T8*0*W(G
MJ'*GJ&H*(*^WL.0"ALOJ.>5?45@9!2Y#GD*@,/4'7D0YV3U'("  !D
M
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MN6LX16B<HKGKQ/N( '/G2@
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MA5.Z=M:UH483A#=C8]-^3<TTX*4-$_+UT3]F@ <L=8
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M$56EJE9RL;U6G9J4.?E<-'[T  Y0[
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M>U<?-ICD8MJNIDY*,XJ23<6XR6DE%\&FN1R #PFP
M
M
M
M
M
M
M
M             !B_>=3?68T/]\"'Z'R!E F+]YU-]9C0_P!\"'Z'R!UG07TO
M@?/K]F1QO6%Z$VE]&E^N)@8&Q#\V6^Q@I?=WK+_>:AKO#8A^;+?8P4ON[UE_
MO-0FKK<]%P^ET_9WD%=3'IBSZ#=]MCF0: "M):<
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M4[ZN?36S_GG]E,V H *AES@                                 <'(
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M7]!,S9EN1E9FY"=M2IKIA)3:CO1G*<Y1\E/6,5%1<N<FVN!4 !$Q,@
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M1],7_-T?91)3ZIO0F/\ .9'VTP "/"20
M
M
M
M
M
M
M
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MXN<M$ZUJ]$]%KQ)TQ.MO95UM5,%E;]UM=4-ZE);]DXPCJ]_@MZ2U?<N)G.
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MYS(^VF  1X22
M
M
M
M
M
M
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M*TWWN,)*+?#5K4MMT/VT]H;-Q,N>G:65Z6Z+1=K7)UV-+N3G!R2XZ)Z:O0
MYXZ4Q+?.L. MW(:*X=\1JLMM]33F<LZ<RU1)I5HLCST*SXZ^^HCEB6RRW3DJ
M,M.8CHV65A21.N1C\(#?M1.]7*C6M1%5SG+V(UJ=[E5>Q$1%W7L0VSG3KZ*]
M/C7PEUSPRN6(:+M4866MC<E/ MF+$YVI+%D,%E)(&NCDFBH9>K3L6(8I89+%
M9DU=DL?6\Z?(OD_O(R<'^ 5:I>H8N/5VN(VQOLZXU'5KV,C'9:O,YV#IN26M
M@*Z/VZIE/FM(UC%GNSR\\KIEZ(]8F/L_9:HMA.V^JVQ4U06ZI53TL4I6-.,4
MIRFGHI2Y>2^:@[IGU9Y.TMK^Z*9UTX]U-;ONFW)PMAK6XPJ33GK7&$EY48Z[
MVLH\%+!MZ-7D5NDCQ2KU[^&X>7<!A;3$DK9O7$JZ5I3QN3F9-!4O1/S=BO*W
M9\%J#$25)V.:Z&=Z.:IZC:6\U-XM6JZ297B3H3$V%1-ZT5#-9-J.W<BIU[/<
MC5V1K5WZM-^=6[>]55SNMCDT^=UK[3LD^Q5&/'7A&%:LEI^-*W?3?K4(KP2-
MWL_J=V15%=LK\J??*=LJXZZ+7=C3N.*\$Y2?'FS7Z<8/-?\ CU@:T]K36<T5
MK;J&/D2G6MW,%?L(UO,D=6/)Q/JOG<OO&LGNU8U[W3IV&/[Q7X1ZHT)G[VEM
M::?RVE]18UZ-NX?-4I:-V)'HJQ3M9*U&V*EAB=;4NUG34[<*MFJSS1.;([<&
M*AXN^7)Z!N&XQ<%M29B/'P+KGA]A\CJC2V4CB;[O=!BX'W\M@EE:G6S5,I2K
MSI'57F3W>VM)$ULF[C>=%^M3(>173GQKLKMG&OMH15<ZW)J*E*,?(E#73>24
M'%>4F]-U\_TKZH,6./;?LUV56U0E9V$Y.VNV,5O.$)2]\A/1/=UE-2>D6EKO
M+6YZ1U?E=/Y7'9W!9"UB<SB+E?(8O)TI%AMT;U61LL%F!Z;[/B>U%V<BL>F\
M<C7,<K5VA/DH.G&G2 X+Z;UO;;7KZFJNL:>UE2KKM%!J/$.;#9LP1N<Y\53,
M575,U4B<Z1:\5]*CI99*SY%U:;'HYJ.3N5$5/@5-S+L\U!XPS0:CXK:"EF1*
MM_%8355.!=MUN4K$^,NO;OVM1*T]1'(U-G+MS[<K3L.M/8T+]G2R=U=MB2C-
M2TX]G.2A9#A\'649\>3APTUEKQ/5%MR>/M..+O/L<V,X2@WY*MA!V5S2;\[2
M,J^'-3[](F;,6C4$+Y:%V.-JODDJ68V-3O<]\+VM:GM<Y41/:I=SA2LR9:PU
M;F-\BWTJF5X&.X(ZN1S(8VN3K]/=CFL1%3_IOT+V'X9TA>@3QCX3XREF>(_#
M[-Z0Q>1N_4ZE=R<F+?%8O=2^?W,Q*.0MR(_J8WR;O8UFS5]]OLAMES%M\ZO^
ML_P^^^#_ /J2^3QT;ZS\S-SL;%LQ\6,+K-V4H*[?2W9/R=ZV4=>'>F5\Z5]5
M6#@[/R\RJ_*E916[(QG*IP;WDM&E4I:<>Z6OK,$$^UN!/DX^.?$[3\6J] <-
M,_JG3LUNW1BRV.EQ+:S[=&1(K<"-N9*K/S02+R/5848J_M'.1%4^*38I>;1?
M8MX?[M-;?2B'?]..D=NR\..33"NR<KX5;MJFX[LH62;\B4'KK!:<=-&^!'70
M#HQ3M;-GC7SMKA'&G<G4XJ6]&RJ"3WXS6[I8^[75+B8<W]Y@Z5'VD=6__'T_
M_P :/O7R7/DKND1HOI!\*M5:JX3:EP>G<'J:.YELM;EPKJU&JE.W$LTS:V5G
MG5B/D8U>KB>OOM]MD54V$1P0WF];.=?3;3+&Q%&ZNRJ3BKMY1L@X-K6YK5)Z
MK5-:]SY$VX74[L^BZF^.1F.5%M5T5*5.ZY53C9%/2E/1N*UT:>G>CG< $6$M
MG\#Q3XGX+1>F\YJW4V1@Q6G].8NYF,OD;+D;#5HT873SO]<DBM9R0P1HZ6Q,
MZ."%CY9&,=K,/*F>4\U7TD=;SWK,]O&: PUF6+16D>M5M:G6;S1_5G)PLVCL
MY_),WDL6)4>M*%[:%160QN63()\Z2Z:LM+'Z7X$X:TK'YJ.#66LVQ2.:JXNK
M;DBTYC9VHB(^.WDJEK(NC<]R([&5WOC15A>F%>J;)Z-O;X^7T%@^JWHK"NA;
M2N@G==O+'WE]ZIUW78EW3L>]Y7=7IIPG+6M76_TNLMO>RZ)M44;KR7%Z=K<U
MOJN6G.%47%M<G:WJM:XG*.^=41.]5555$1$[]U5>Y$W7M/87HN^0IZ1W%.C7
MS%/2$>D,%:;#-5RFNK3\!)<K2]O7TL.L%G,O8D?+)&^W1HP6&2,=6FE8KW,R
M"/(!>1VPF%TW@>._$G%0974VHJ<&8T%A,C DM/3>#ML;-CL_-4GCZN7.Y:NK
M+M&:1)&X['3UGUTCN32NCRQ40_'I;UI/'NGBX$*YRJDX69%B<H;Z>DHU03BI
M;KX.<FXMI[L&M)OT=#.J*.317E;2G9"-L5.K&JTC/<DM8SNFU+=<D]Y5P2DE
MHY3U;@L"Z[YJSQFCJ.E@UYH&Q;2)KFU'1YF%CI5Y>:);*P/:U&JKOV7JG(O+
MV-]]V>.O3(\F5QHX#R-DX@Z0LP821[8X-685SLSI265[DCC@ER]>)J8ZS(Y>
M6&MEX<?/9[5JQSM:YR;5P_GM5:4QF<QMW#YG'T\KBLC7DJ7\=D*\5NE<K2IR
MR06:T[7Q31O3O:]JIW+WHBG*[-ZV=HUV)Y,:LFK7RHJ"JGI^)."T3^5&2?JY
MKK]J]36S+:FL5W8MR7D3<Y75Z_CUV/5KY$X-<^/)Z<Y>TR4_(,>5[R'"_4V*
MX1\0<O)/PSU+=AQ^ OY"PBQZ%S=V1(JB-GF=M6TUDK,C(+D3GI5Q5F2.^QL-
M9UUR?._ERO)?5>CWKNAF-)02,X:Z[=;FP-=SY)ET]EZB,DR.GG2RJZ1];JY&
M7<4Z1SW^Y5FKJY4J=GAD]$<BHOI14_1W]O;V=A-EM6'MS9Z;\NC(AK!Z+M*;
M%JM5SW;:III\=):.+UA)ZP-7?F]']IRT>YD8T]V<=7V=];TEH^"WJK8--/35
M:IK=G%;NY30Y/*3R+G2[FXQ]'_1V=R5GW5J+!1RZ0U+(Z1KYI,I@.2M';L;=
MK9,ACEI7_?J^1Z6$ED<KI%/5LJ9M#"GC7W8]B\NFR=<O6X-K5>IZ:KU-%RMG
M9]>5CTY-3UKOJA;#Y,XJ23]:UT:[FF@8ZGG/_P!C55^^7I+_ ''/F168ZGG/
M_P!C55^^7I+_ ''/FYZ&^E=G_2J?VT:3IMZ(VE]"R/LY&O:,^OS6CZQ6I_O@
M9+Z/H& H9]?FM'UBM3_? R7T?0)ZZU_1$OI%']\KQU/^F8_1LC^X9,H *P%K
MS$U\Z;Z)K<OHW1G&/'UM\AI"ZNE-031M;SRZ=SDSK&-?.J-61[,9FD>D&ZMB
M@9E[SW+O(W?!X5-_'CX#;F=++@!0XJ<--;\.\BYD=?5VG,EAV6'HJMI79X'.
MQF0V:BJJX_(LJW6M1KN9T"-5KD5474HZITIDL#E<I@<S5?1S&#R-[#Y:E(J+
M)4R>,M2T;]9ZM56N=!:@EC5S55KN7F:JM5%6Q_5+MGML&S$E+R\2SR?'L;MZ
M4?;NV*Q>I."X<"KW7+L/L,^K+A'2O-K\M]W;TZ1E[-ZMUOUM3?/4V+7F[_2D
M=Q$Z.>!PM^W[HSW#.U8T1?YEWE7$U'+9TK*]J[\K68":KBVN5RK-)BII51J2
M(B>[)KW?-I.E4W1?'*?0>0L+%B>*.(EQU5'N7JF:GPD4^4Q?8JI'&Z[1CR=3
MK%7FDL)2K,1SYFH;"%")>L'9'N/:F1%+2N]^Z:^&BW;6W-+NTC:IQ2[DD3-U
M;[:]V[)QI-ZV8Z]RV\=7O4I*#?KE4ZY-^+9R #BCNS^.XAZXQVF,#FM29BQ%
M4Q. Q.0S.2M3/2.&O1QE26Y;FED7=&1QP0O<]RHJ-:BJJ;(:D_I+<=,AQ-X@
M:QX@91TBV]6Z@R.9Y)4:DE>K9G=]3ZCD9[Q%J4&UJRHS9BNB56HB*9X7G*G2
MD_45P!ET71L.AS/%++U-/KU3N62/3F.FARVH7;HN_5WHJ];#2L<WDFJ9*XWF
MYF<KM>8BE@^J#8ZKQ[\Z:\J^?8UM\U55HYM>J=CT?KJ16SKJVYVF5CX$7Y&/
M#M[5_K;=5!/UPJ6J]5K/2;R1G1<7B]TA.'NE9J[[&&I9%VJ]2JU'<D.!TPC<
MC-USFH[D9=R"8[$QN<U6+9R-=C_>N4VE,<;6-:UK4:UJ(UK6HB-:U$V1K439
M$1$39$1$1$[$,37S6+HH?4C1^M.,61KHEW5]UFE-/R/8WGBT_@Y4L9*6)RHD
MC&Y/-.8V=J<T<K,11D:[=KD3+-.$ZT-L^Z=I2IB]:\2/8K3D[6]ZY^U2:K?S
M9(75)L/W)LJ-TUI;FS>0]=-55YE"]C@G:M==.U[N0 !&Y*(       &X!CF^
M<O=*7]17 R#1%*RD68XHY=F'6-CV)+^IW$]5DL[*L;O?+ ]WU/H22,_<Y+T*
M.14D-? A[M><3=*!W$/I&9;"U+#I,'PRQ531="-LBN@=E5>_*ZEO-9S.8RQ-
M?MP8J9\>R35L'15R(YJHGB/H[2.0U!EL5@<3#U^4S>1I8C'0[*J2WLC9CJ5F
MNY4<J,ZZ5BR.Y5Y6<SMMD+6]7VRE@[*I<](SO3RK6^&G:14H:ONW:5#75\'O
M%/>LC;+SML7J#<H426)2EQU=;<9Z+O<KW/1]ZW5W(SEO-9^C(F$X6ZJXIW:_
M)=U[GYL/AYG,5'.T[I61]*:2)_8CXK&H'92!R;+RR8U=E]\IDR\1]"8_5.G\
MUIO+0LL8S/8N_B+T,C&R-?5R%:2K-NQZ*URHR57-W[G(B]Z(?FG16X%8[ACP
MWT3P^Q;>6GI+3>+PS7*C$?//5K,2[<F6-$8^Q>NNL7+,C41))YY).]Q^_*5O
MZ0[7EF9^1EIM;]S=7C&N&D:5ZFH1C]9:+HSL6.#L[%PVD^SI4;?"5DTY7/UJ
M5DI?4:@OC[P?O\/=<ZPT+E(WQ7](ZDS&GYVO7F5R8V[+7AF1Z=DD=BNV*Q%*
MU59-%*R5CG,>UR^CWD,^E$O"[I&Z+L6;*5L+K)\FA,VLCG-A6+/20MQ;I$:J
M<RQYR#'=4B^]ZQZ*J+L?;OG.W1:32G&C%<2:-=8\9Q.PD"9-[&/ZMFJ=+UZ^
M)G>]W*D,;K^"9AWQQ-7GEEH7[+]W2.4QK8+,\,D<]::2M8@DCGKV(7NCFKV(
M7I)#/#(Q4<R6&5K)(WM5%8]K7(NZ(6AP;:]K[)AO::9F*X6=^Y8XN%C7KKM3
M<?'=3*E;0ILV+MF2AYV%F*RI:^?2I*=:;TY64R2EIRWFD;DO<Y/BWR>'2:BX
MP\%.'/$'=GN[.::I-SD4:LY:VI,<Q<9J*NUK7O<R%,Q4N/J))RRR4GUIGQL6
M3E3[2*D96/.FVRFQ:3JG*N:\)0DXR7U-,N;B9,+JJ[JWK7;7"R#\83BI1?UI
MH  _ ] .-SD\1_+[],:7A-P!S=3%V5K:DXB2.T/AY8W]7/7K9*M,[/787-]^
MR2##MM1Q2-1%CFL1O9)'(C')[]E[/GEY%.-7Y]UD:T^:CO/C)^J*UE+U)FNV
MOM.O#Q;\JWS**IV27)RW5JHK\:;TC'UM&+?Y=7RL]OC9JVSP]T3EW_W)M*7Y
M(N>C,J5=;YVH]8Y<U8EC=RWL-2D:^/!1;K4FW?E$;,LM26/'W.C&(U$1.Q&H
MB(GL1.Q/@]2'LWY%_P EY-TC=?23YY9ZO#31DM2[JVQ KXI\U8D<LM'2U&PW
M;W.[()&Z7)VV.Z^KC6O96Y+5J"S6MK5##V+L]K[WCXT-7)I.=DN";>FF_;;/
M1+EJVEPBEI32=F=MW:.OWW*RIZ1CJU"N"3:BM==RFJ";[^"<O*FVW\/=%KH'
M\7>-5F:#AIH7,ZCK596PW\RR..AIZA(J(Y8K6>R,E7%I9;&J2K1ALSY!T6SX
MZCVJF_K+CO-B^DK-6;-+/PZJS/9SI4DU/?DD8JL1R1RRQ8)T39$<JLDZM96-
M<BJU\C=E78!:!X>X/2N&Q^GM-XFA@\'B:T=3&XK&5HJE*G7C[&QPP1-:Q-^U
MSW+N^21SI)'.>YSE_L4(5VCUNYT[&\:FBFI/R5.+ML:\9RWHQU]48+3EK+@R
M=MF]2NSX5I95V1?<TMZ5<E36GWJ$=V4M.[6<WKHFE'BC5U=*+R.'2)X1T[.7
MU-P_MY/ 4V<]O4.D;$>I\74C1'.?+<CHL;EJ-6)C>>:]=Q=>A$BM22RUWO4\
MPD5')V;*B_&GA%^?VFY2,2+R\_D6<+D-/9SC?PEPT&,U#A&2Y?76E<9 V"GJ
M'$(Y9,EJ'&58T;#7S>*8K[^1@C;%'E,='<E;S9.O7@O=-T4ZT_=%L,;.KKJE
M9)0KR*]8UN3X15L)-[F\^&^I;J;6L8QUDN4Z8]4/N6BS*V=99;"N,IVXUJ4K
M%6M7*54XJ._N+5]G*.^XKA.4M(O"+1#)-\U@^R0U3]Y+5G]>^&!C9M<BHBIW
M*FZ? 9)GFL'V2&J?O):L_KWPP.[Z;K_Z1G_,2_7$X/JZ]-;/^>?V4S8"@ J(
M7-!B5^=8='[)9'17#CB71FN2X[2^<NZ:S]!LTSZ,46HX63X7-/J\WN:&2KD,
M?8Q+[7)U\CLY3@YT8WE7+4/E'IP=%ZGQGX4ZUX:7)X*7ZJ,/)4IY"Q7=:BQF
M4ADCMXK)K7;)$Z9V/R$%>TUC9&.5T2<KFN1%3?\ 1;:RP=H8N2_,KM2LX:^]
M33KL>G'5J$I27?O):<3G.EVQWG[-R\5+6=E3=2UTUMK:LJ3?#12G&,9:\-UM
M/@:ESF3=$]+E1K43M5SE[$:U$[7.5>Q$1%55[-CU-Z-7D6^DAQ3AAO87AUD,
M!A[#$?!F]<.72=&=CFM>R2M5R$7U;MP2L=SPVZV)EIRM3WEE55$7.1\G]Y&'
M@]P$J4+U/$Q:OUW UDMG7&HZM>Q?CMHJ/<[!TU:^I@:\3T1*J5&NNLC8Q9[U
MF=99I/7+8E7;O6_HY5[/HC))M=OD:Z2]<*8N+2[TYSU??6N1$.P.I76,9[2R
M))M1;Q\;1;O>XSNDI)^#5<$E\&Q\&8(FE?-3>+5JLV3+<2="8BPK&*ZM#0S6
M31CUWYF).SW&UR,V39Z1MYM^Y-C\RXO^:^\>L#6FLZ9SFBM;+"QS_<E:W;P%
MZ=&HY4CK,R<3ZCYG*B(UL]VM%N[WTS6M538$@Y"OK2VNI[SMIE'\'*BM1]FL
M5&S3^>=K9U1[$E#<5-T):??(Y%KGKXZ3E*O7^9IZC3Z<6.#VJ]!9ZYI?6NG<
MQI;4./=M;Q&;I34K;&*Y[8YXFR)U=NE.K'.JWZ<EBE<C1):MF:)4<O\ ,:5U
M7D\%DZ&:PF1N8C,8JW#?QF3Q\\E6]0NUW))!:JV(G-DBEC>B*BM7M3=KD5JN
M:NR9\N#T!L3QIX+:AO5J$*Z^T'CK>I]'Y..%/=DOU,C=;R>G'R-V?+2SE"*Q
M6CAD?U-?)K1O]GN=Z/UH4;D<U')LK7(CD^!4W3V>DG'H?THAM?%E/LXUV0EV
M=].N]%-K52CJN-=BU24N*:G%[R2<J^]->B5FQ<N-2LE959%6X]^FY-[LM)1E
MIP5M32;<>#4H36C;BMIGY*/IQLX_<&=.ZTMNKMU-51^!UC6KMCC9#J3&MC9;
MG9!'[V"')Q/@R<$36L9'%;1D;$C:T](S"%\U XVSUM:<5N&\LSG5LOIG&:YH
MP*Y>2"S@,I7T]EYV,VY5?<AU%@HY7*J*U*,*-14<[;-Y0KETTV/'!VEDT06E
M6\K*EW*NV*FHKU0;=:^26@Z"[;EM#9>+D6/6W==5S[W93)UN3]<TE9_.[N1R
M6W,_O.W_ )M/_LG%R+;F?WG;_P VG_V3CEUS1UKY,TY^4_?=S_/+?^\2E"O;
ME@>LD$LL+UCGA5\,CXGK#9@DK685?&YKEBL5IIJ\\:JK)H)989&NB>]JU\I^
M^[G^>6_]XE/T'@KP;U#Q#U=IW0^DZ*Y'4>J,I7Q.)J;\K'3S<SY)YY-G=33I
M5HYKUZPJ*VM2K3SO][&JEX;9QC"4IM1A&+E*4M%&,4M9-M\$DM6]>[4H%57*
M;A""E*<G&,(Q3<I2DTHJ*7%MMI)+CKR/Y#2.D,OG\E3PNG\3E,[F+\G4T,/A
M,=<RV4NS;*[JJ>.Q\%BW9DY45>2&%[D:BJJ;(JGM-PD\W8Z4.JJ<5ZSI?!:/
MBE1KV0:MU%7J9'JGM1S7NHXF#,/A<K7)S5[4E:S$J.9/%%(BL7-5\FGY+W0G
M1QTG!0Q%6KEM:WZ\3M5ZVL5F?5+*6^7FDJ4)'M67'8*O(KF4\="YB/:B6+G7
M6G.>GIHB$$;>ZW;>TE7L^JM51;2OO4I2LTX;T:TXJ$7W*>])K1M0>L587HYU
M+T]C&>T[;';*.O842C&%6J\V=CC-V3CWN&Y!/5+?7E/7,<2_-N>D]@*,EZEA
M])ZKZIG,M#3VIHTR;U]\KFPP9FIB:TFS6HJ?X<USU=R-CYMN;Q%U[P]S^E,O
M<P&J,)E].9W'OZN]A\YCK>*R=5_^+UU*[##.UCT]]#*D?53QJV2%\D;FN7<1
M'F=Y37R9FC>D=HFUB<I7JXW6F-K32:-UDRNQU_#WT3K(ZEJ1O)+=P5V1$BR&
M/D>K>1[K-7J;D<<R8V!UMW=K&&T*JW5)I.ZF+A*K7X4H:R4X)\6H[LDM6MYI
M1?UTBZF*.QE9LVVU7PCJJ+Y1G"[1>;&>D779)<$Y.4&]$U!-R6KCAF?&^.6*
M1\4L,C)8I8GNCEBEB>DD4L4C%:^.6.1K7QR,5'L>UKV*CD13/^\@'Y66WQBP
M=CA9Q!R"3\1](XUEO%Y6PYJ3:RTQ7?'6?:E5R_LN<PSY*\641J(^Y6F@R+&N
M5E_J,#WBMPMSFA]39[1^I:3L?G]-92WA\M3=O^Q7*<BQ2+&YS6.?!*B-FKR*
MUO6P21RHU$>B'][T6ND3F.$W$/27$3!/D2_I7,5LBZ&-W(MZ@CEBRF-?VHUT
M>0Q\EBHYLF\>\J*]JHFRR?TLZ.U;5PI12C*U0=F):M.$]-Z.DOP=J2C+BXZ-
M3TUC%J)NAW2:[8^?&;<XTNQ59E+X)P4G&3<>ZREZRB^#UBX-[LI)[=0'\-PR
MXA8W5FF\!JG#3LM8C4F%QF=Q=F)>:.>AEJ4-ZI*QW9NV2">-R+LFZ+W>@_N2
MI$XN+<9)IQ;33X--<&FNYI\RYT)J24HM.,DFFN*::U33\&N*,3+SD'H.<7.+
MFJN%5WAIH/,ZQJX/3^JJN6GQ;\<QE&Q>R.$FJ13>[KU-5=/'6G>WJDD1$C7G
M5N[=\;7^\P=*C[26K?\ X^GO^-FT61#DD78?69F8&+3B548TZZ5-1E8K=][]
MD['KNVQCP<VEI%<-._B1KM_JMP=HY=N9=?E0LNW-Z-<JE!;E<:UHI52?*"UX
M\S3EZGTU?PN3R6%RM62CE</D;V)RE*;D6:EDL;:EI7ZDJQN?&LM6W!+!(L;W
MLYXW<CW-V5;[PSX:9_66?Q6EM+8NQF]0YRU[BQ.)J+"VS>M=5)-U$*V)884?
MU44C]Y)6-V8OOM]D7]7Z9?UY.+_WUN)']=,V?2_D=4__ !H>"GMUBWZ(RJ?C
M^8L9E9\J\*S)2BYPQ9WJ+UW=Z-+L2?'7=U6CXZZ=_>5CQMG0GM"O$;DJYYD,
M9R6F^H2N5>J>CCO:<==UK7NT+E_>8.E1]I'5O_Q]/_\ &POD8.E1]I'5O_Q]
M/_\ &S:+@@A]<>?_ "7#_-O_ ,\L)]Q/9O\ *<W\ZC_)/'7R$O +67#/H[:?
MTGKW3U[2^I*FH=76K.(R#JSK,5>_G;5JG,YU2Q9@5EBO(R5G+,Y41VSD:Y%:
MGL4<(AR1AM+.EDY%^1-1C.^VRZ48Z[JE9)R:CJV]$WPU;>G-LE?9N#'%QZ,:
M#E*%%5=,'+3><:XJ"<M$EJTN.B2U[@:U3SA/[+;B;_F6A/ZB:?-E6:U3SA/[
M+;B;_F>A/ZB:?))ZG_2=WT&W[?&(KZ[/16/_ .H5?V;+/$K+?O6S_F\W^S<;
ME+&?O:O_ !$7^S:::W+?O6S_ )O-_LW&Y2QG[VK_ ,1%_LVF_P"NGELW_;/_
M ,4T749RVI[</]643BV9G$5[]2U1MQI+5NUYZEF)W[66"Q$Z&9B^Q\;W-7V*
M7,$%)D^M:\#4O].WHWS\(N,'$#AW+&^.'3FH;46,YF*WK,%?1F3P4S$<KG+'
M)B;E-T;G=KV;/5$YD1/T7R8'28DX1<=^'.M%F=#CH<Y#AL[LYC6R8'4'_DG)
M)*K]V)%%'99;<]R+U:UFRM3K(V*GOMYU-T4%IZAT'QHQT")!F*+M":H6-NR)
M?QC[63TYD)$9&N[[-.SE,;9L32I[RAAZT;7=O+B(2QH]KF.3=KD5JIZT5-E3
MY"W6P,RO:NR:Y6/>[?'E1D>/:*+JM]C<DYKEPDGWE+ND6!/8^V;HU)Q]SY,<
MC'TX>]N2NI2[FDFH/CIY+3TTT6Y-K3LE8R6-S7QR,;)&]J[M>QZ(YCVJG>US
M5147THOQK7/*SR+?2IDXN]'706?O6/=&H,)4GT7J9SG\\JYC2TGU/9:F=RM3
MK<OB$Q6;>UJ<L?U32+?>-3U3*H[0PIXU]V/9Y]-LZI>#<).+:]3TU3[TTRXN
MS<^&5CT9-;UKOJKMA\FR*DD_!K71KN:: !^2<>N+^.T!HK56MLLYK,=I; Y/
M.6N=W(U[<?5DG;#SKV-=/(QD#7+V(Z1%543M/-76YRC&*;E)J,4N;;>B2];?
M ]5ED81E.348QBY2;X)1BM6WZDEJS 5\Y)Z4B:ZX_P NCZ,[9<-PLQ5? ?L;
MD=')J+*10Y;//YF.5KUJ-FQ^,>U6I)7MT[T+E[VM\%-):1R>H,MBL!A:SKF9
MSN3H87$4VJC76LIE;<5#'UVN=[UJS6[$,?,[9K4=S.5$15+CQ%UYD-5:BU!J
MG+2OGRFILYE]19*:1RNDER&;R-G)W)'N55W<^Q:D<Y=U[5[/;[F^;A]%I-?<
M?X-47:_6X;A?BY=22N<W>)<Y?ZW&8*)V[71N>QS[MUD;O?;U.MCV="CDMU'L
M]C;([FL/%Y<E.W3_ /ENE]3EWE+I=IMS;36K3SLOAWN%&O=K^"QX</D&>QT6
M^ F-X6\.=%</,2J/I:0TYC,(VPC5:MVS4K,2_DI&JJ\LV3OK9R$[6[,;-9>C
M&M8C6I^]'"')4:ZV5DY3FW*<Y2G*3YN4FW)OUMMLN?13&N$*X1485QC"$5RC
M&*48Q7J222!X1^6]\K$SH]Z2@TSI&>M+Q7UE1GDP39&0VFZ8PZR/J3:JNU9$
M=$][9F3U\%7M,?7N9&":26*U5Q]R!WMKK35]#3^'RF=RDS:V-P^/N9._.]6M
M;%4HUY+,[U5[FM3:*)RINY$5=DW3<U/?3:Z4>4XS\4]9<2<J^57:CRTC\;6>
MY[FX[ TVI3P>-A8]?V*.IC(:Z.8B)O8?/-)S32R2.D#JXZ+PVAERLOCO8V+N
MSG'NMLDWV=<OQ?)E.:XZJ*B^$M5&_6ATMGLS#C7CRW<K+<H0GKY5545[[;'\
M=:QA!]SEOK7<T/G74^J,EFLE>S&9R%S*Y;)V9;F1R>1LRV[UZW.Y7RV+5F9S
MY9I9'+NKGN7T-:B(B(?HG [H^ZXXFYV'3/#_ $KFM79R9$>M'#4WV/<T*JC?
M=60MN6.EBZ37*C77LG9J4V/5K7SM<YJ+^H="+HA:CXZ\2M/<.-,JVO8RTS[&
M3RDK'25L'@J:L?E<Q88Q%5Z587-97A[$LW9JM97L297MV>_0^Z&N@^!^CJ6C
M-!8>''TH&L?D<@]C7Y7.Y!&[39++W53KK=J5RN5B/>L5:-R05V1Q-1I,73/I
MQ5LF,*:ZXW9,X;T*M=V%<.49V;O'=;34*XZ.23\J*2;A'H-T!NVS*=UMDJ<2
MN>[9;IO6W6/24H5[W#71ZSLEO*.\O)DVTL)GAEYK]Q_S%5EG/9G0VDWR1-D;
M2GR%W,6XE<B+U5GW!596CE;VH](;%F-%3LE>B]EBXR>;*](73E*:]IZSH_7/
M41=8_'XK)RXG*S+NG[%3@S,4-*9Z;[_LV1JILGO5<O8;"T$1+K5VLI[VN.XZ
M_>^Q6YIX:J2L^O?U)HEU/;&=>XH9*EI]]5[WT_'1IU?_ !Z&G@XA</,_I+-7
M].:IPN4T[G\7,L&0PV:HV,=D:DJ;*B35;4<<B,D:J20RM1T,\3F2P221/:]:
MO#7B7G]'9_$ZJTKEKF"U%@KD=_$Y?'R=5:I6H]T1[%V<U\;V*Z*Q7E:^"Q ^
M2"Q')%(]CMFEY4;R8&D.D=HNS2MUJF-U[B*=B31FKV0M9;I748^2+%Y*9C5E
MMZ?O3;1W*DBR)661UVHUMEB]9K%]8Z1R6G\QE\!F:DE',8+*9#"Y:C+[V6EE
M,5;FHWZDB>A]>W!+$[VLW3L5":NB72ZG;%$_>U"ZM*.11+247&::4HZK2=<]
M&FI+6/&,DTU*4$]->AN1L7(KTF[*+&Y8V1'R)J4&FXRT?D6UZJ2E%Z26DXZ-
M2C#9B>1[\I=3Z2'#;ZI9%M2AQ TM+!B=<8BJBQP/M/A1]/4&-A<KG1XK.1ME
MDCAYY%HW8+M%SWM@BFG];#6->1)Z7MCA#T@='69K+H=.:VN5="ZFCYMHEK9Z
MU%6Q-R5%<QB)CLV^C,^61>2&J^W(O[5-MG(A G3_ *-QV=G2C5'3'O7;4KN@
MF])U?S)>;WJ$H:MO4L5U;]*);3V=&5SWLG'EV%[Y.;23A:UXV0:WN"3FIZ)+
M0Y !PYWX-9UY?+[*GB3_ /H#Z%J&S%-9UY?+[*GB3_\ H#Z%J$K=4'I*WZ)/
M[2HB#KI]%T_3*_LKCTG\U"^N5Q7^XO _3-PSGC!A\U"^N5Q7^XO _3-PSGC5
M=:'IG(^1C_80-QU3^@\7Y>3_ &BP&&]YVO\ N/ C_..(G^PT>9D)AO>=K_N/
M C_..(G^PT>?AU:^FL/_ &C^RW'[=:?H'._V7^VXQCX^1^^R?X(_=S1_W:V>
MV_G2/0J7&:ETQQTPM-R4]1P0:1UJL3%6-F9QT4CM.YB=6QKR.OXM),-8EDE9
M'OBL3%%'ULTSG^)'D?OLG^"7W<4?]WM&QXZ=717QW&GA1K3AQ?ZB-^H,1/'B
M;D[$>S&YZLGNG"9%?>2.:VID8H'S+&U95KK,R-4<Y%)*Z:[;>S]N[.R-?>_<
MO9WKQILOMC/ESW>%B7QH(BSH+L!;2Z/;4QDD[?=?:X[?=?7CTRAIX;_&MONC
M-FLN\GSTH+O!SC'H/B!5F6*OB<W7K9IO-RQSZ=RKDQV<AF]Z[>)*%B6?L3FY
MX(W,<QS6N;]'^6>Z:*<;^/.IL[C,@E[1VG65])Z(6%[EK/PV-8C[N3B17(QS
M\UFILA?2?JV2+1=CJDR.]Q,<OF#J;3.1PF3R.$S%27'YC#7[N)RV/G1J34<E
MC;,M._3EY7.;UE:W!+"_E<YJN9NURMV5;&NZ=S57N1&M3=57N1$3TJJ[(B>E
M>PDI[)HEEPSM$[HX\J(RX-=G.:FI+3O7E)27P9R7)HBA;:R(85FSMYJB63'(
MG!ZJ2LA!P<&OBOR92C\>$7S,AKS;[H:_W1N-DVN,I5673?"BE7S*ODCWKV=5
MY5UBMIVGNYJQR+6AKY/*S-17K$M.HDC6>Z87K^'><+)_^-OQ,_S'0?\ 4/3I
MFF>1?Z&*<$^ ^EL+=K-@U/J5GZL-6.5G+-]5\U!"^*G,NS7*N*QL=+&M1[6/
M9[G5KVI)SJ["U\X7^RWXF?YCH/\ J%IPCGHUMWW?TDS+(O6FK!MHHX\-RO(Q
M]9+U63<IK\5Q7<2ETJZ/?N;T7P*I+2^[:%61D>*LLQ,IJ#^;@H5OUQ;7,^__
M #4/ZZG%/[W^-_K' 9U)@K>:A_74XI_>_P ;_6. SJ2.NM'TQ?\ -T?91)0Z
MIO0F/\YD?;3  (\))
M
M
M
M
M
M
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MS<EKRJ::ZH:]W;RE*37=JE2ERU2EP>C9_9  KZ60!\W],1/_ #2\3ON!U=]
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MS32?]1R #@"1@
M
M
M
M
M
M
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M,;7_  0?KL[/?:4Q?^F-K_@AB,_4:[_V&[_\G9__ '0^HUW_ +#=_P#D[/\
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M;%(C+K;]*Q^BT_MVDL=3?H=_2[_U5@MN9_>=O_-I_P#9.+D6W,_O.W_FT_\
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MI;&/UPKA!_D::)XZNJG#8FSTTTW2Y\?"=DYI_7%I_6  <>=J:C_IE_7CXO\
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MD5  1\20            <;'5C&M1&M:C6M1$:U$1$1$[D1$[$1/1L=P
M
M
M
M
M
M
M
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MTECU3?"$++4]W>F^'D[R@]%-QUX9JH.$7?X/0OK.3C3N
M
M
M
M
M
M
M
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MWX[LO(IKA+6/'3RHOOY'?=!MCW8&S,;$R%%75=KOJ$M^/EW636DM%KY,EW(
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MV?=#-S+NTR:VW553*2IK<EHY3FU&5LM&UNZ1K6KU5G!KA#D B<F0&.IYS_\
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M0WJ7&+;:?%[STY>!L>B'5GM7"VEB95\<?LJ;'*;A?O2TW)1X1W%KQ:UX^)[
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M#:CQ=S":@Q6/S>'R$+ZU[&96G!>H6X)&JU\5BK9CDAE8YJJBH]B]_9LICO\
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M7R227))(L?35&N$*X+2,(QA%-N348I12;DVWP2XMMOFVV  ?F?H
M
M
M
M
M
M
M
M
M
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M^T^NI78G9XV1GSCI+)FJ:6UQ[*EO?DO5.U[K7C5X:'( (<)O
M                                                   !;<S^\[?^
M;3_[)Q<BVYG]YV_\VG_V3C*YHP^3-.?E/WW<_P \M_[Q*>NGD!_LO^#'^<Z_
M_P#";7QY%Y3]]W/\\M_[Q*>NGD!_LO\ @Q_G.O\ _P )M?%R>D_HO:'T#+_L
M]A2+H=Z5V9].Q/MH&S. !34N\
M
M
M
M
M
M
M
M
M
M
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M*\N?=QG/>D_6P #6FT
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M##LHRLW(=N13.NV%5'DTPL@U*+E.2W[=))/@JH]S4D=@ 1"34
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
3                      ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
